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Abstract: Alle Zellen besitzen Mechanismen, um ihr Erbmaterial vor Schäden, die durch Substanzen endo-
genen oder exogenen Ursprungs verursacht werden zu schützen. Wenn Schäden in der DNA nicht adäquat
repariert werden, können sie zum Zelltod oder sogar zu Mutationen und damit zur Entstehung von Krebs
führen. Um dies zu verhindern, sind die Zellen mit einem komplexen System ausgestattet, welches DNA-
Schäden erkennt und repariert, dem „DNA damage response”-System. Der zellulären Reaktion auf DNA-
Schäden durch das DDR-System liegt ein komplexes Netzwerk von Signalkaskaden zugrunde, welches
die Läsionen erkennt und durch posttranslationale Modifikationen, wie Phosphorylierung und Ubiqui-
tinierung, verschiedene Reparaturmechanismen aktiviert. Dabei ist die DDR auch für die Aktivierung
der Zellzyklus-Kontrollpunkte verantwortlich, wodurch ein genügend grosses Zeitfenster zur Reparatur
des Schadens gewährleistet und gleichzeitig die Replikation der fehlerhaften DNA gestoppt wird. DNA-
Doppelstrangbrüche (DSBs) zählen zu den gefährlichsten Schäden, die entweder durch Fehler während der
DNA-Replikation oder durch Exposition der Zellen gegenüber mutagenen Substanzen entstehen können.
Zur Reparatur von DSBs hat die Zelle hauptsächlich zwei Mechanismen entwickelt: nicht-homologes
Verknüpfen von DNA-Enden (NHEJ) und homologe Rekombination (HR). NHEJ ist der vorrangige
Reparaturmechanismus für DSBs in menschlichen Zellen und findet während des gesamten Zellzyklus
statt. Im Gegensatz dazu ist für HR die homologe Sequenz des intakten Schwesterchromatids als Ma-
trize erforderlich. Deshalb ist die Reparatur durch HR zwar fehlerfrei, aber auf die S/G2-Phase des
Zellzyklus beschränkt. Während der S/G2-Phase sind NHEJ und HR konkurrierende Reparaturwege
und die Wahl des richtigen Mechanismus ist entscheidend für die Erhaltung der genomischen Stabilität
der Zelle. Werden die DSBs in dieser Phase nicht richtig prozessiert, können chromosomale Transloka-
tionen und Krebs die Folge sein. HR wird durch die Resektion der DNA-Enden des Strangbruches
eingeleitet und bestimmt somit den Reparaturweg, welcher wiederum streng durch den Zellzyklus reg-
uliert wird. Das humane CtIP-Protein ist ein Schlüsselfaktor für die Initiierung der Resektion, dessen
Aktivität durch verschiedene post-translationale Modifikationen kontrolliert wird. Zusätzlich wird die
Proteinmenge von CtIP während der G1-Phase 1 reduziert und während der S/G2-Phase des Zellzyklus
erhöht. Im ersten Teil meiner Dissertation charakterisiere ich einen neuen Mechanismus zur Regulierung
der Proteinstabilität von CtIP während des Zellzyklus. Ich zeige, dass die APC/CCdh1 E3 Ubiquitin Lig-
ase für den Proteasom-abhängigen Abbau von CtIP während der G1 verantwortlich ist. CtIP interagiert
mit Hilfe eines hochkonservierten KEN Box-Motivs mit dem APC/C Co-Aktivator Cdh1. Die Mutation
der KEN Box (CtIP-K467A) verhindert die Interaktion und beeinträchtigt die Poly-ubiquitinierung von
CtIP. Dementsprechend ist die CtIP-K467A-Mutante nach dem Austreten aus der Mitose stabiler als
die wildtyp-Form des Proteins. Wenn Zellen DNA-schädigenden Substanzen ausgesetzt werden, kann
APC/CCdh1 auch in der S/G2-Phase aktiviert werden und ist an der Aufrechterhaltung des G2/M
Zellzyklus-Kontrollpunkts beteiligt. Im zweiten Teil der Studie zeige ich, dass CtIP nicht nur in der G1-
Phase, sondern nach DNA-Schäden auch in der S/G2-Phase durch APC/CCdh1 poly-ubiquitiniert und
somit für den proteasomalen Abbau markiert wird. Überexpression der CtIP-KEN Box Mutante führt,
genauso wie die Inhibierung des APC/C Komplex nach DNA-Schäden in S/G2, zu einer verstärkten Re-
sektion von DNA-Enden bei einer gleichzeitigen Verringerung von HR. Möglicherweise ist in diesen Zellen
der darauffolgende Schritt, nämlich die Rekrutierung der Rad51 Rekombinase beeinträchtigt, weil die
CtIP-KEN Box Mutante nicht von den prozessierten DNA Enden beseitigt werden kann. Interessanter-
weise haben wir eine ähnliche Beeinträchtigung in der Rekrutierung von Rad51 und in HR auch in Cdh1-
defizienten Zellen beobachtet. Zusammengefasst deuten diese Ergebnisse darauf hin, dass APC/CCdh1
den Abbau von CtIP während der G1-Phase sowie nach DNA-Schäden in der G2-Phase des Zellzyklus
kontrolliert und dadurch entscheidend an der Wahl des geeigneten DSB-Reparaturwegs beteiligt ist. Diese
Studie beschreibt eine neue Rolle für die APC/C Ubiquitin Ligase bei dem Erhalt der genomischen Sta-
bilität, unter anderem durch die Kontrolle der Stabilität des DNA-Reparatur Faktors CtIP. 2 Summary
Summary Our genome is constantly exposed to endogenous and exogenous agents causing DNA damage.
Unrepaired lesions can lead to cell death or, even more hazardous for an organism, misrepaired DNA dam-
age can result in genomic instability and promote tumorigenesis. To counteract genomic instability, cells
are equipped with a multifaceted system to efficiently signal and repair defects in DNA: the DNA damage
response (DDR). Upon detection of genomic lesions, the DDR activates DNA repair pathways through
a cascade of post-translational modifications including phosphorylation and ubiquitiylation. Moreover,
the DDR is responsible for the activation of cell cycle checkpoints thereby allowing time for DNA repair
to occur. DNA double-strand breaks (DSBs) are particularly cytotoxic lesions, which can arise either
during replicative stress or from exposure to DNA damaging agents. Cells can deal with DSBs through
two major repair pathways: non-homologous end joining (NHEJ) and homologous recombination (HR).
NHEJ is the predominant pathway in human cells and acts throughout the cell cycle, while HR only
takes place in S/G2 phase when the intact sister chromatid is available as a template to allow homology-
directed repair. Thus, during S and G2 phases of the cell cycle, NHEJ and HR compete for DSB repair.
Choosing the suitable mechanism is pivotal for genome stability maintenance, because inappropriately re-
paired DSBs have the potential to trigger chromosomal translocations that may result in various diseases
including cancer. HR is initiated through the resection of broken DNA ends, a process determining DSB
repair pathway choice and, thus, tightly regulated during the cell cycle. The activity of the key DNA-end
resection factor CtIP for instance is controlled by various post-translational modifications. Moreover,
CtIP protein levels are low during G1 and increase in S/G2 phases of the cell cycle. In the first part of
my PhD thesis, I characterized a novel regulatory mechanism responsible for the cell cycle fluctuations of
CtIP, by showing that the APC/CCdh1 ubiquitin ligase targets CtIP for proteasome- dependent degra-
dation following mitotic exit. In addition, I discovered that the APC/C co-activator Cdh1 interacts with
CtIP through an evolutionary conserved KEN box motif, mutation of which (CtIP-K467A) abrogates
CtIP-Cdh1 interaction and impairs CtIP polyubiquitylation. Consequently, we found that the CtIP-
K467A mutant is more stable throughout G1 compared to the wild-type CtIP protein. 3 Summary Upon
treatment with genotoxic agents, APC/CCdh1 is transiently activated during G2 phase and is involved in
the maintenance of the G2/M checkpoint. In the second part of my study, I demonstrated that, besides
in unperturbed G1 cells, CtIP is polyubiquitylated and targeted for degradation by the APC/CCdh1
after DNA damage in G2. In irradiated G2 cells, we observed that CtIP-K467A causes disproportionate
DNA-end resection, resulting in reduced HR efficiency. As a possible mechanistic explanation for these
phenotypes, CtIP-K467A is defective in being cleared from sites of DSBs. Hence the loading of the Rad51
recombinase, an event occurring downstream of DNA-end resection, is impaired in the CtIP-K467A mu-
tant cells. Interestingly, I observed a similar defect in Rad51 recruitment to DSBs and, thus, a decrease
in HR in Cdh1-depleted cells. Taken together, we hypothesize that APC/CCdh1-mediated degradation
of CtIP, both during G1 and after DNA damage in G2, contributes in limiting DNA-end resection and
therefore choosing the appropriate DSB repair pathway. In summary, this study describes a novel role
for the APC/C ubiquitin ligase in the maintenance of genome stability, at least partially, by controlling
the stability of the DNA-end resection factor CtIP. 4
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Zusammenfassung 
 
Alle Zellen besitzen Mechanismen, um ihr Erbmaterial vor Schäden, die durch 
Substanzen endogenen oder exogenen Ursprungs verursacht werden zu schützen. 
Wenn Schäden in der DNA nicht adäquat repariert werden, können sie zum Zelltod 
oder sogar zu Mutationen und damit zur Entstehung von Krebs führen. Um dies zu 
verhindern, sind die Zellen mit einem komplexen System ausgestattet, welches DNA-
Schäden erkennt und repariert, dem „DNA damage response”-System. Der zellulären 
Reaktion auf DNA-Schäden durch das DDR-System liegt ein komplexes Netzwerk 
von Signalkaskaden zugrunde, welches die Läsionen erkennt und durch 
posttranslationale Modifikationen, wie Phosphorylierung und Ubiquitinierung, 
verschiedene Reparaturmechanismen aktiviert. Dabei ist die DDR auch für  die 
Aktivierung der Zellzyklus-Kontrollpunkte verantwortlich, wodurch ein genügend 
grosses Zeitfenster zur Reparatur des Schadens gewährleistet und gleichzeitig die 
Replikation der fehlerhaften DNA gestoppt wird.  
DNA-Doppelstrangbrüche (DSBs) zählen zu den gefährlichsten Schäden, die  
entweder durch Fehler während der DNA-Replikation oder durch Exposition der 
Zellen gegenüber mutagenen Substanzen entstehen können. Zur Reparatur von 
DSBs hat die Zelle hauptsächlich zwei Mechanismen entwickelt: nicht-homologes 
Verknüpfen von DNA-Enden (NHEJ) und homologe Rekombination (HR). NHEJ ist 
der vorrangige Reparaturmechanismus für DSBs in menschlichen Zellen und findet  
während des gesamten Zellzyklus statt. Im Gegensatz dazu ist für HR die homologe 
Sequenz des intakten Schwesterchromatids als Matrize erforderlich. Deshalb ist die 
Reparatur durch HR zwar fehlerfrei, aber auf die S/G2-Phase des Zellzyklus 
beschränkt. Während der S/G2-Phase sind NHEJ und HR konkurrierende 
Reparaturwege und die Wahl des richtigen Mechanismus ist entscheidend für die 
Erhaltung der genomischen Stabilität der Zelle. Werden die DSBs in dieser Phase 
nicht richtig prozessiert, können chromosomale Translokationen und Krebs die Folge 
sein. 
HR wird durch die Resektion der DNA-Enden des Strangbruches eingeleitet und 
bestimmt somit den Reparaturweg, welcher wiederum streng durch den Zellzyklus 
reguliert wird. Das humane CtIP-Protein ist ein Schlüsselfaktor für die Initiierung der 
Resektion, dessen Aktivität durch verschiedene post-translationale Modifikationen 
kontrolliert wird. Zusätzlich wird die Proteinmenge von CtIP während der G1-Phase 
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reduziert und während der S/G2-Phase des Zellzyklus erhöht. Im ersten Teil meiner 
Dissertation charakterisiere ich einen neuen Mechanismus zur Regulierung der 
Proteinstabilität von CtIP während des Zellzyklus. Ich zeige, dass die APC/CCdh1 E3 
Ubiquitin Ligase für den Proteasom-abhängigen Abbau von CtIP während der G1 
verantwortlich ist. CtIP interagiert mit Hilfe eines hochkonservierten KEN Box-Motivs 
mit dem APC/C Co-Aktivator Cdh1. Die Mutation der KEN Box (CtIP-K467A) 
verhindert die Interaktion und beeinträchtigt die Poly-ubiquitinierung von CtIP. 
Dementsprechend ist die CtIP-K467A-Mutante nach dem Austreten aus der Mitose 
stabiler als die wildtyp-Form des Proteins. 
Wenn Zellen DNA-schädigenden Substanzen ausgesetzt werden, kann APC/CCdh1 
auch in der S/G2-Phase aktiviert werden und ist an der Aufrechterhaltung des G2/M 
Zellzyklus-Kontrollpunkts beteiligt. Im zweiten Teil der Studie zeige ich, dass CtIP 
nicht nur in der G1-Phase, sondern nach DNA-Schäden auch in der S/G2-Phase 
durch APC/CCdh1 poly-ubiquitiniert und somit für den proteasomalen Abbau markiert 
wird. Überexpression der CtIP-KEN Box Mutante führt, genauso wie die Inhibierung 
des APC/C Komplex nach DNA-Schäden in S/G2, zu einer verstärkten Resektion von 
DNA-Enden bei einer gleichzeitigen Verringerung von HR. Möglicherweise ist in 
diesen Zellen der darauffolgende Schritt, nämlich die Rekrutierung der Rad51 
Rekombinase beeinträchtigt, weil die CtIP-KEN Box Mutante nicht von den 
prozessierten DNA Enden beseitigt werden kann. Interessanterweise haben wir eine 
ähnliche Beeinträchtigung in der Rekrutierung von Rad51 und in HR auch in Cdh1-
defizienten Zellen beobachtet.  
Zusammengefasst deuten diese Ergebnisse darauf hin, dass APC/CCdh1 den 
Abbau von CtIP während der G1-Phase sowie nach DNA-Schäden in der G2-Phase 
des Zellzyklus kontrolliert und dadurch entscheidend an der Wahl des geeigneten 
DSB-Reparaturwegs beteiligt ist. Diese Studie beschreibt eine neue Rolle für die 
APC/C Ubiquitin Ligase bei dem Erhalt der genomischen Stabilität, unter anderem 
durch die Kontrolle der Stabilität des DNA-Reparatur Faktors CtIP. 
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Summary 
 
Our genome is constantly exposed to endogenous and exogenous agents causing 
DNA damage. Unrepaired lesions can lead to cell death or, even more hazardous for 
an organism, misrepaired DNA damage can result in genomic instability and promote 
tumorigenesis. To counteract genomic instability, cells are equipped with a 
multifaceted system to efficiently signal and repair defects in DNA: the DNA damage 
response (DDR). Upon detection of genomic lesions, the DDR activates DNA repair 
pathways through a cascade of post-translational modifications including 
phosphorylation and ubiquitiylation. Moreover, the DDR is responsible for the 
activation of cell cycle checkpoints thereby allowing time for DNA repair to occur. 
DNA double-strand breaks (DSBs) are particularly cytotoxic lesions, which can 
arise either during replicative stress or from exposure to DNA damaging agents. Cells 
can deal with DSBs through two major repair pathways: non-homologous end joining 
(NHEJ) and homologous recombination (HR). NHEJ is the predominant pathway in 
human cells and acts throughout the cell cycle, while HR only takes place in S/G2 
phase when the intact sister chromatid is available as a template to allow homology-
directed repair. Thus, during S and G2 phases of the cell cycle, NHEJ and HR 
compete for DSB repair. Choosing the suitable mechanism is pivotal for genome 
stability maintenance, because inappropriately repaired DSBs have the potential to 
trigger chromosomal translocations that may result in various diseases including 
cancer. 
HR is initiated through the resection of broken DNA ends, a process determining 
DSB repair pathway choice and, thus, tightly regulated during the cell cycle. The 
activity of the key DNA-end resection factor CtIP for instance is controlled by various 
post-translational modifications. Moreover, CtIP protein levels are low during G1 and 
increase in S/G2 phases of the cell cycle. In the first part of my PhD thesis, I 
characterized a novel regulatory mechanism responsible for the cell cycle fluctuations 
of CtIP, by showing that the APC/CCdh1 ubiquitin ligase targets CtIP for proteasome-
dependent degradation following mitotic exit. In addition, I discovered that the APC/C 
co-activator Cdh1 interacts with CtIP through an evolutionary conserved KEN box 
motif, mutation of which (CtIP-K467A) abrogates CtIP-Cdh1 interaction and impairs 
CtIP polyubiquitylation. Consequently, we found that the CtIP-K467A mutant is more 
stable throughout G1 compared to the wild-type CtIP protein. 
Summary 
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Upon treatment with genotoxic agents, APC/CCdh1 is transiently activated during G2 
phase and is involved in the maintenance of the G2/M checkpoint. In the second part 
of my study, I demonstrated that, besides in unperturbed G1 cells, CtIP is 
polyubiquitylated and targeted for degradation by the APC/CCdh1 after DNA damage in 
G2. In irradiated G2 cells, we observed that CtIP-K467A causes disproportionate 
DNA-end resection, resulting in reduced HR efficiency. As a possible mechanistic 
explanation for these phenotypes, CtIP-K467A is defective in being cleared from 
sites of DSBs. Hence the loading of the Rad51 recombinase, an event occurring 
downstream of DNA-end resection, is impaired in the CtIP-K467A mutant cells. 
Interestingly, I observed a similar defect in Rad51 recruitment to DSBs and, thus, a 
decrease in HR in Cdh1-depleted cells.  
Taken together, we hypothesize that APC/CCdh1-mediated degradation of CtIP, 
both during G1 and after DNA damage in G2, contributes in limiting DNA-end 
resection and therefore choosing the appropriate DSB repair pathway. In summary, 
this study describes a novel role for the APC/C ubiquitin ligase in the maintenance of 
genome stability, at least partially, by controlling the stability of the DNA-end 
resection factor CtIP. 
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1 Introduction 
1.1 Cancer and genome instability 
Cancer is a widely used term, which can be employed to indicate an evil or 
destructive phenomenon that is hard to contain or eradicate [1]. The word originated 
in the medical field, in which cancer indicates a heterogeneous disease arising from 
abnormal cells, which acquired the capacity to divide without control and ultimately 
invade other tissues. Cancer is not just one disease but many diseases that can 
originate from cells belonging to any tissue of the body. There are more than 100 
different types of cancer [2] and with 8.2 million deaths in 2012 they account for the 
leading causes of death worldwide. Despite the huge efforts to understand and 
restrict cancer incidence, 14.1 million new cancer cases were diagnosed in 2012 [3]. 
The “war on cancer” was initiated in the seventies to improve the understanding of 
cancer biology and to develop more effective cancer treatments [4]. Over the years, 
cancer research generated a huge amount of data, which help the treatment of some 
forms of cancer, but mainly demonstrate the complexity of this disease. The main 
challenge in treating cancer is that it arises from inside the body making a targeted 
approach extremely challenging.  
In the year 2000, Hanahan and Weinberg, tried to identify underlying principles, 
which are common to all cancer cells [5]. Accordingly to the authors, the acquired 
capabilities of cancer cells are self-sufficiency in growth signals, insensitivity to 
antigrowth signals, evading apoptosis, limitless replicative potential, sustained 
angiogenesis and tissue invasion or metastasis. Virtually, all cancers must acquire 
these six capabilities, but they can arise in different ways, both mechanistically and 
chronologically. The work is based on the observations that cancer is enabled by 
dynamic changes occurring in the human genome, eventually leading to mutations. 
The genes that, if mutated, play a role in tumorigenesis are categorized as 
oncogenes, which acquire a dominant gain-of-function or tumor suppressors, which 
result in a recessive loss-of-function. Accumulation of mutations enables the cells to 
acquire the above-mentioned hallmarks that allow them to overcome intrinsic and 
extrinsic control mechanisms, which in healthy tissues restrict cellular proliferation. 
Therefore, genome instability and mutations are defined as main enabling 
characteristics of cancer. In a more recent review, the same authors refine their 
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model by suggesting tumor-promoting inflammation to be a second enabling 
characteristic, which fosters multiple hallmarks [6].  
Genome instability is observed in almost all human cancers, whereas “normal” 
human cells are equipped with complex genome maintenance systems, which allow 
them to deal with DNA lesions and avoid mutations. In fact, despite cells experience 
tens of thousands of DNA lesions per day, the rate of spontaneous-arising mutations 
is extremely low [7, 8]. There are different types of DNA lesions and they can arise 
following exogenous or endogenous challenges. For example, various environmental 
agents, such as the ultraviolet (UV) component of sunlight, ionizing radiation (IR) and 
genotoxic chemicals are able to disrupt the DNA integrity. Moreover, normal 
metabolic processes, such as cellular respiration, can indirectly damage the DNA 
through the production of reactive oxygen species [9]. Finally, the chemical structure 
of DNA can degenerate over time, affecting the original information [10]. Even if they 
are highly different, all lesions affect the integrity of the DNA structure, thereby 
interfering with vital cellular processes like DNA transcription and replication. 
Therefore, the majority of lesions are in principle able to kill a cell. Therefore, cells 
must be capable of detecting, signaling and repairing DNA lesions though a complex 
network of interconnected pathways, named the DNA damage response (DDR). 
Errors occurring during the detection and the repair process can easily lead to the 
introduction of mutations in the genomic information. As discussed above, for a 
multicellular organism, mutations can have consequences that are even more 
detrimental than those of cellular death, namely causing various disorders including 
cancer. Generally, acquisition or genetic predisposition to mutations in genome 
caretaker genes, such as DDR factors, increase the overall rate of mutations, thereby 
causing genome instability and paving the way for carcinogenesis [11, 12].  
 
1.1.1 DNA repair pathways 
Cells evolved different repair pathways to deal with the wide variety of lesions that 
can arise in their DNA. For example, the nucleotide excision repair (NER) pathway is 
responsible for repairing UV-induced cyclobutane-pyrimidine dimers (CPDs) and 6-4 
photoproducts (6-4PPs). Two sub-pathways of NER, with partly different substrate 
specificity, are responsible for detecting the lesions either using a global genome 
approach (GG-NER) or focusing on damages that block elongating RNA 
polymerases (TCR, transcription coupled repair). Base excision repair (BER) is the 
main actor in dealing with metabolic-induced damages, such as 8-oxoguanine or 
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DNA methylation, hydroxylation and deamination. Different damage-specific 
glycosylases are involved in the recognition and removal of the modified bases, 
leaving an abasic side that is addressed by the APE1 endonuclease. The following 
repair process overlaps with single-strand DNA break (SSB) repair and requires the 
combined action of nucleases, polymerases and ligases. A central player in SSB 
repair is the poly-adenosine-diphosphate-ribose (PAR) polymerase (PARP). After 
damage detection, PARP catalyzes the formation of PAR chains, which enable the 
recruitment of proteins required for repair. Mismatch repair (MMR) recognizes and 
repair insertion/deletion loops and nucleotide mis-pairing occurring during DNA 
replication. After detection of a lesion, the DNA is incised in close proximity and then 
repaired by various downstream factors. Homologous recombination (HR) and non-
homologous end joining (NHEJ) are the two principal mechanisms used to repair 
DNA double-strand breaks (DSBs).  
 
 
Figure 1 DNA damage and repair mechanisms. Different DNA damaging agents (top) 
induce a variety of DNA lesions (middle), which are addressed by dedicated repair 
mechanisms (bottom). Adapted from [8]. 
 
Cells are not able to directly repair all DNA damages. Translesion synthesis (TLS) 
is a repair tolerance system that permits to bypass DNA lesions. TLS is achieved by 
the use of dedicated DNA polymerases with a less stringent base-pair requirement 
than replicative polymerases. Interestingly, the different repair pathways are tightly 
interconnected and some lesions (e.g. a SSB) can be introduced to the DNA by the 
repair process and then be addressed by the specific repair pathway. The Fanconi 
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anemia (FA) pathway is a well-established example where different DNA repair 
pathways co-operate to repair cross-linked DNA (interstrand cross-link, ICL). The FA 
pathway is composed by a set of genes (15 so far) that have been identified to be 
mutated in patients, which display hypersensitivity towards cross-linking chemicals, 
such as mitomycin C (MMC) or cisplatin. Apart of the core components of the FA 
pathway, ICL repair requires the action of proteins belonging to the NER, HR and 
TLS pathways. 
 
1.1.2 The DNA damage response 
The DNA damage response is a multifaceted system that permits to properly 
signal and deal with damaged DNA. Although the repair processes per-se differ 
between the various classes of lesions, they are usually controlled by a common 
signaling program. Detection of DNA damage leads to the activation of one of the 
three apical kinases, belonging to the family of phosphatidylinositol 3‐kinase‐like 
protein kinases (PIKKs) [13]. ATM (ataxia telangiectasia mutated) and DNA-PK 
(DNA-dependent protein kinase) become activated following detection of DSBs by 
the Mre11-Rad50-Nbs1 (MRN) complex or the Ku70-Ku80 heterodimer, respectively 
[14-16]. ATR (ataxia telangiectasia and Rad3-related) is activated by the presence of 
ssDNA coated by the Replication Protein A (RPA) complex and requires the 
presence of the ATR-interacting protein (ATRIP), Rad17 and the 9-1-1 (Rad9, Rad1, 
Hus1) complex [17, 18]. Proteomics analysis showed that DNA-PK activity is 
restricted to few proteins, whereas ATM and ATR target more than 700 substrates 
[19, 20]. Active ATM/ATR/DNA-PK phosphorylate serine 139 of the histone variant 
H2AX at chromatin regions surrounding DSB sites [7]. Phosphorylated H2AX, called 
γH2AX, can now be recognized by phosphopeptide-binding BRCT (BRCA1 C 
terminus) domains, which are present in many proteins involved in the DDR. One of 
these proteins, MDC1, is a large adaptor protein, which directly binds γH2AX and 
serves as a docking site for the recruitment of different factors amplifying the DDR 
[21, 22]. Importantly, MDC1 recruits RNF8, a RING-domain E3 ubiquitin ligase that 
initiates a ubiquitylation cascade by forming K63-linked ubiquitin chains on different 
histone protein variants [23-25]. RNF168 then binds to ubiquitylated histones and 
amplifies RNF8-dependent ubiquitylation events, which is necessary for the 
recruitment of different chromatin-associated repair mediators such as 53BP1, 
BRCA1 and TopBP1 [26-28]. Generally, DNA repair mediators help sustaining 
damage-induced signaling. For example, TopBP1 binds phosphorylated 9-1-1 
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complex and thereby boosts the activity of ATR [29]. Other examples of mediator 
proteins are 53BP1 and BRCA1, which play an antagonistic role during the initial 
stages of DSB repair. Two well-studied targets of the ATR and ATM signaling 
cascade are the checkpoint kinases 1 and 2 (Chk1 and Chk2), respectively [30]. 
Claspin, another mediator protein, is required for Chk1 stability and mediating its 
association and activation by ATR [31, 32]. In turn, Chk1 and Chk2 inhibit main 
components of the cell cycle machinery to delay cell cycle progression, allowing time 
for repair (see below). Besides activating DNA damage checkpoints, ATM/ATR 
directly phosphorylate repair proteins leading to their activation and recruitment to the 
site of damage (see chapter 1.6).  
 
 
Figure 2 The DNA damage response. Detection of DNA lesions by specialized sensor 
proteins results in the activation of one of the three apical kinases (ATM, ATR or DNA-PK). 
Mediator proteins are involved in the activation or in the amplification of the signaling 
cascade, which finally result in the activation of the two diffusible transducer kinases (Chk1 
and Chk2). Effector proteins modulate the activity of cell cycle regulators, transiently blocking 
cell cycle progression, allowing time for the repair to occur. In case of severe DNA damage, 
DDR activation results in senescence or apoptosis. Adapted from [33]. 
 
Mutations in various proteins involved at different steps of the DDR cause a 
predisposition to tumor development. For example, ATM mutations observed in 
patients suffering from ataxia telangiectasia (A-T), result in an increased risk of 
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developing thymic lymphoma and other cancers [34]. A-T cells are impaired in 
checkpoint activation upon DNA damage, a condition that contributes to genome 
instability and favors tumorigenesis. Similar phenotypes are also observed in patients 
suffering from the Nijmegen breakage syndrome, which is caused by mutations in the 
gene encoding for the Nbs1 protein [35]. These patients also suffer of 
immunodeficiency, due to inefficient V(D)J recombination and class switch 
recombination (CSR). Moreover, mutations in genes encoding for NHEJ proteins can 
facilitate lymphomagenesis due to the increased rate of transpositions that is caused 
by unrestrained alt-NHEJ [36]. Finally, germline mutations in the BRCA1, BRCA2 or 
PALB2 genes predispose the carrier to develop breast and ovarian cancer [37, 38].  
 
1.2 The cell cycle 
The cell cycle is an ordered sequence of events, which result in the duplication of 
a cell. Indeed, proliferating cells are constantly cycling through a growth or gap phase 
(G1), a phase in which the DNA is replicated (S phase), a second growth phase (G2) 
and, finally, the division into two daughter cells (M phase or mitosis).  
 
 
Figure 3 The cell cycle. The various phases of the cell cycle –G1, S, G2 and mitosis– are 
depicted. Dedicated cyclin-CDK complexes control each phase. Passage through the 
restriction point in G1 phase commits cells to enter S phase and complete the cell cycle. An 
expanded view of mitosis is shown at the top of the figure. In prophase, the chromosomes 
condense and the nuclear envelope breaks down. In prometaphase, the chromosomes attach 
to the mitotic spindle, and any unattached chromosomes generate a “wait” signal. In 
metaphase, all the chromosomes attach, and the “wait” signal is turned off. In anaphase, the 
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sister chromatids separate, and in telophase the DNA decondenses, the nuclear envelope 
reforms and the two daughter cells form by cytokinesis. Adapted from [41]. 
 
Transitions between the different phases are orchestrated by cyclin-dependent 
kinases (CDKs), which are controlled by dedicated activating subunits, called cyclins 
[39]. The human genome encodes for 11 CDKs and 9 CDK-like proteins, but the 
main cell cycle transitions are regulated by a few, highly conserved CDKs [40]. 
Moreover, higher eukaryotes express different isoforms of the various cyclins (e.g. 
cyclin B1-3), which perform slightly different cellular functions.  
In case of growth stimuli, D-type cyclins are synthesized. D-type cyclins activate 
CDK4/6 allowing progression through G1 phase, by phosphorylating different 
members of the retinoblastoma (Rb) protein family and therefore suppressing their 
anti-proliferative activity. Hyperphosphorylation of Rb releases inhibition of E2F, 
which results in transcription of E-, A- and B-type cyclins and of E2F itself. The fast 
increase in E-type cyclins, ensure a positive feedback loop, which generates a rapid 
rise in E2F-dependent transcription, which is now sustained alone by CDK2-cyclin E 
complexes. This point is known as “restriction point” and the cells can afterwards 
undergo cell division, independently of mitogen stimulation. In addition to maintain Rb 
phosphorylation, the activity of CDK2-cyclin E complexes is essential for initiating 
DNA replication through loading of the mini chromosome maintenance (MCM) 
complex to origins of replication. Right after origin firing, E-type cyclins are rapidly 
degraded to avoid re-replication of DNA and the slow accumulating A-type cyclins 
ensure the maintenance of high CDK2 activity. CDK2-cyclin A complexes 
phosphorylate numerous proteins that are required for proper completion and exit 
from S phase [40]. During G2, A-type cyclins are degraded in a ubiquitin-dependent 
manner, whereas B-type cyclins are actively synthesized to sustain CDK1 activation. 
CDK1-cyclin B complexes are the main drivers of the extensive reorganization 
required for mitosis. Indeed, activity of CDK1-cyclin B complexes permit Golgi 
fragmentation, nuclear envelope breakdown, chromosome condensation and 
formation of the mitotic spindle [42]. Other important kinases orchestrating mitotic 
progression belong to the Aurora and Polo-like kinase (Plk) families. Finally, 
inactivation of CDK1-cyclin B complexes and mitotic kinases is required for proper 
completion of mitosis and re-establishment of G1 phase. Inactivation of the various 
mitotic regulators is accomplished by ubiquitylation and proteosomal degradation 
supported by the anaphase-promoting complex, also known as cyclosome (APC/C). 
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1.2.1 Cell cycle checkpoints 
To ensure that the various processes belonging to a cell cycle phase are 
completed before proceeding into the next one, the cells evolved different control 
mechanisms. These mechanisms are called cell cycle checkpoints and permit to 
temporarily arrest cell cycle progression at different critical transitions. The G1/S 
checkpoint, or restriction point, is an important commitment point for the cells, 
because they have to decide whether initiate a further round of cell division or stop 
proliferating and enter a quiescence state (G0). The next checkpoint is placed during 
DNA replication (intra-S checkpoint) and, in case of DNA damage or other problems, 
it can decrease the speed of the replication machinery to ensure faithful completion 
of DNA synthesis. If the problems persist, cells can activate the G2/M checkpoint, 
which blocks cells from entering mitosis with damaged DNA. If the previous 
checkpoint has been satisfied and cells enter mitosis, the last control is performed by 
the spindle assembly checkpoint SAC (see chapter 1.4.2), which prevents 
chromosome separation until each chromosome is properly attached to the mitotic 
spindle and aligned on the metaphase plate. 
In order to block cell cycle progression, the checkpoint inhibits CDK activity in 
different ways [40]. CDKs can be inactivated by phosphorylation of two amino acids 
located in the ATP binding loop by Wee1 and Myt1 kinases. These inhibitory 
phosphorylations are reverted by the activity of the Cdc25 family of phosphatases 
(Cdc25A-C) [43]. Additionally, two families of CDK inhibitors (CKI) have been 
described: the Cip/Kip family (p21Cip1, p27Kip1, p57Kip2) and the INK4 family (p16INK4a, 
p15INK4b, p18INK4c, p19INK4d) [44, 45]. These two families differ in their way of action; in 
fact Cip/Kip binds and inhibits CDK-cyclin complexes, whereas INK4 acts on 
monomeric CDK4/6.  
 
1.2.1.1 DNA damage checkpoints 
As mentioned above, Chk1 and Chk2 are responsible for the fast activation of a 
checkpoint following DNA damage. This rapid response mainly relies on the 
transmission of the signal by phosphorylation of multiple substrates. The role of Chk1 
is conserved from yeast to human and both homologues operate by the same 
molecular mechanisms. Chk1 is essential for induction of the checkpoint response 
and needs to be in complex with Claspin in order to be efficiently activated by ATR 
[32, 46]. Blocking Cdc25 phosphatase activity is a fast mean to arrest the cell cycle in 
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response to DNA damage. In brief, following DNA damage, Chk1-dependent 
phosphorylation of Cdc25A enables its recognition and polyubiquitylation by the 
SCFβTrCP E3 ligase [47]. The resulting rapid degradation of Cdc25A results in 
increased phosphorylation and, thus, inhibition of CDK2 or CDK1 activity, ultimately 
triggering cell cycle arrest [48]. Moreover, also Cdc25B and Cdc25C are 
phosphorylated by Chk1/2 which promotes the binding of 14-3-3 proteins to block 
Cdc25B/C activity [49, 50]. Chk2 is the human homolog of yeast proteins Cds1 and 
Rad53. These two kinases are structurally different, but they share some overlapping 
substrates [51]. In higher eukaryotes, Chk2 is functionally redundant with ATM in 
checkpoint activation, but it plays a major role in regulating proapoptotic pathways 
[52, 53]. Indeed, ATM and Chk2 phosphorylate and activate the tumor suppressor 
p53, which is involved in the long-term damage response that can trigger 
senescence or apoptosis [54, 55]. Interestingly, Cdc25B- and Cdc25C-deficient mice 
are able to activate the G2/M checkpoint, indicating that damage checkpoints are 
regulated by redundant pathways [56]. For example, after becoming activated in 
response to DNA damage, Chk1 phosphorylates and activates Wee1, which, in turn, 
directly phosphorylates CDK1 and CDK2 [57]. Moreover, in case of exposure to IR 
occurring during G1 phase, rapid degradation of cyclin D1 ensures arrest at the G1/S 
transition [58, 59].  
The checkpoint response not only has to be fast, but it also has to last long 
enough to give time to the cells to efficiently repair the damage. Pathways ensuring 
checkpoint maintenance rely on transcriptional changes in many target genes [51]. 
For example, after genotoxic stress, p53 becomes highly modified by different 
posttranslational modifications, including phosphorylation by ATM/ATR/DNA-PK and 
by Chk1/Chk2. Modified p53 is no longer bound by its inhibitor Mdm2 and, after 
tetramerization, p53 activates the promoters of multiple target genes [60, 61]. One of 
these target genes is the CDK-inhibitor p21, which is able to bind and inhibit CDK2-
cyclin E and CDK4-cyclin A complexes, blocking the G1/S transition [62, 63]. In a 
similar fashion, p21 inhibits CDK1-cyclin B complexes, retaining cells from entering 
mitosis [64]. p53 is involved in the G2/M checkpoint also in a p21-independent 
manner, by transcriptionally repressing different mitotic inducers, such as cyclin B 
and Plk1 [65] [66].  
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Figure 4 DNA damage checkpoint activation. Detection of DNA lesions leads to the 
activation of ATM and ATR kinases and a downstream signaling cascade, resulting in the 
inactivation of cell cycle progression. ATM signaling stabilizes p53, which, in cooperation with 
its transcriptional target p21, enables the inhibition of CDK-cyclin complexes (depicted as red 
box). Similarly, ATR activates Chk1, which, by inhibiting the Cdc25 phosphatases and 
activating the Wee1 kinase, inhibits CDK activity. ATM is also involved in the activation of p38 
and Chk2, which are responsible for checkpoint maintenance and apoptosis. Chk1 and p53, 
in green, are key players in DNA damage checkpoint signaling. Yellow dots indicate 
phosphorylation, whereas orange and blue dots indicate other posttranslational modification. 
Adapted from [51]. 
 
Interestingly, p53 levels oscillate in response to DNA damage and the oscillatory 
pattern highly depend on the type and the extent of damage [67, 68]. During G1, the 
DNA damage-induced response is mainly dependent on the activity of p53 and 
cancer cells that are compromised in p53 activation fail to establish a G1 arrest. 
Nevertheless, these cells are proficient for the G2/M checkpoint, indicating that 
alternative pathways ensure the maintenance of checkpoint signaling [69]. In this 
line, the p38/MK2 pathway has been shown to play a primary role to ensure survival 
of p53-deficient cells after induction of DNA damage [70]. In fact, after checkpoint 
initiation through the Chk1 pathway, p38/MK2 is needed for maintaining its activation 
[71] and deficiency in MK2 and p53 results in synthetic lethality [72]. Since 
checkpoints need to remain active until the damage is fully repaired, DNA repair 
factors are directly involved in checkpoint maintenance. For example, CtIP-driven 
DNA-end resection plays a critical role in sustaining ATR signaling and maintenance 
of the G2/M checkpoint [73]. Moreover, depletion of BRCA2 or its interaction partner 
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PALB2 results in premature checkpoint termination, which allows damage-bearing 
cells to enter mitosis [74, 75].  
 
1.2.1.2 Checkpoint recovery 
Once the DNA lesions are successfully repaired, cells need to re-enter the cell 
cycle in a process called checkpoint recovery. Since checkpoint activation causes the 
inactivation or degradation of many cell cycle regulators, they need to be re-
established for re-entering the cell cycle. Nevertheless, during checkpoint recovery, 
the cell cycle machinery works differently than during unperturbed cell cycle 
progression and some proteins acquire different roles [76]. For example, Plk1 
depletion does not affect mitotic entrance in cycling cells but it completely blocks 
checkpoint recovery [77]. Phosphorylation of Plk1 by Aurora A, sustained by its 
cofactor Bora, is required to fully activate the kinase in late G2 [78-80]. In response to 
DNA damage, Plk1 phosphorylation is inhibited and, at a later timepoint, the protein 
is targeted for degradation by APC/CCdh1 [81, 82]. Following the repair of the lesion, 
Plk1 promotes recovery by inducing nuclear import of Cdc25B/C and inhibiting Chk2 
activity [83-85]. Moreover, Plk1-induced phosphorylation of Wee1 and claspin cause 
their SCFβTrCP-dependent degradation [86-88].  
 
 
Figure 5 DNA damage checkpoint recovery. After DNA repair, Plk1 phosphorylates Wee1 
and claspin enabling their degradation. Plk1 activity is also required for the re-activation of the 
Cdc25 phosphatases. Multiple proteins are also dephosphorylated by the activity of Wip1, 
which leads to the silencing of the checkpoint. Green indicates active proteins, whereas red 
indicates the inactivation of the main players of the checkpoint signaling. Adapted from [51]. 
 
Plk1 activity is essential but not sufficient for checkpoint recovery and different 
phosphatases are reverting checkpoint-induced phosphorylation events [89]. One of 
these phosphatases, Wip1, plays a central role during checkpoint recovery and its 
depletion results in prolonged checkpoint activation [90]. Interestingly, Wip1 activity is 
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directed towards pS/T-Q sites in target proteins, which are specifically 
phosphorylated by ATM/ATR, and it has been shown that Wip1 dephosphorylates 
several proteins involved in the DDR [51]. After a genotoxic insult, Wip1 levels are 
increased in a p53-dependent manner and they hence limit the amplitude of the 
checkpoint [91]. Moreover, Wip1 dephosphorylates p53 and Mdm2, facilitating the 
interaction between the two proteins and therefore promoting p53 proteolysis [92, 
93]. Noteworthy, p53 inactivation is critical for checkpoint recovery. Indeed, inhibition 
of ATM/ATR, Chk1/Chk2 and p38 is not sufficient to promote recovery in Wip1-
depleted cells, whereas cells lacking p53 and Wip1 recover normally. Importantly, 
Wip1 activity is necessary throughout the checkpoint response to maintain the levels 
of cell cycle regulators above a critical threshold and therefore enable cells to recover 
from the arrest even after long periods of activation [90]. 
 
1.2.1.3 Cellular senescence 
In case the DNA damage is particularly severe, cells may undergo programmed 
cell death (apoptosis) or initiate a different program, which leads to an irreversible 
cell cycle arrest. This state is called senescence and, in contrast to quiescence, 
cannot be reverted by altering the cellular environment in vitro, for example by 
removing cell contact inhibition or adding nutrients [94]. The factors determining the 
outcome of the DDR activation are still unclear, but the cell type and the kind of 
damage, as well as the intensity and the duration of the signal seem to be major 
determinants [95]. Senescence was observed for the first time in vitro, due to the 
exhaustion of the replicative capacity of human fibroblasts. Indeed, cultured 
fibroblasts do not duplicate infinitely, but they arrest after a limited and reproducible 
number of populations doublings (the so called Hayflick limit) [96]. This replicative 
senescence is mainly due to telomere attrition, which occurs at every DNA replication 
and that, once telomeres reach a critical length, triggers DDR activation [94]. As 
discussed in the previous chapter, checkpoint maintenance is dependent on the 
activity of p53 and its downstream effector p21. p21 expression has been suggested 
to negatively regulate p53-dependent apoptosis: high p21 levels often result in 
senescence, whereas a response involving low p21 expression results most likely in 
apoptosis [97]. Prolonged checkpoint activation leads to the upregulation of p16, 
which, beside acting as a CDK inhibitor, activates the transcriptional regulator Rb [98, 
99]. Rb, cooperating with heterochromatin proteins, drives heterochromatization and 
stable repression of E2F-responsive genes, causing the appearance of peculiar 
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heterochromatic regions called senescence-associated heterochromatic foci (SAHF) 
[100]. However, SAHF is not a common feature of senescent cells [101] and since 
not all the senescent cells display all the phenotypes so far associated to this state, 
they are mainly identified through a combination of characteristics [102]. 
Histochemical staining for senescence-associated β-galactosidase (SA-βgal) is 
commonly used as a marker, because this enzyme is highly expressed in lysosomes 
accumulating in senescent cells [103, 104]. Interestingly, apoptosis leads to the rapid 
elimination of cells by phagocytes in an inflammation-independent manner, whereas 
senescent cells release growth factors and different cytokines [105, 106]. This 
senescence-associated secretory phenotype (SASP) can establish a prolonged 
paracrine signaling, which influences in both beneficial and detrimental manner the 
surrounding tissue. For example, SASP can result in maintaining the senescence 
state, clearing the senescence cells, or promoting a pro-tumorigenic phenotype [97].  
 
1.3 The ubiquitin-proteasome system  
Targeted proteolysis through the ubiquitin-proteasome system (UPS) is a highly 
regulated process that allows the removal of proteins, thereby restricting their activity. 
The UPS is involved in virtually any cellular process, which depends on regulation of 
intracellular proteins by degradation [107]. For example, the periodic degradation of 
cyclins and CKIs by the UPS system allows the strict control of CDKs, permitting tight 
regulation of cell cycle progression. In fact, in contrast to phosphorylation, ubiquitin-
mediated degradation is an irreversible mechanism that ensures the unidirectionality 
of the cell cycle [108]. Ubiquitin is a small, 76 amino acids long protein that is 
covalently linked to substrates through the sequential activity of three enzymes. 
Modified substrates can then be bound by the 26S proteasome complex, which is 
responsible for the lysis of the proteins [109]. Ubiquitin is first bound by a specific E1 
activating enzyme, which activates the C-terminal residue of ubiquitin in an ATP-
dependent manner. Activated ubiquitin is next transferred to an E2 ubiquitin-
conjugating enzyme and, finally, a E3 ubiquitin ligase is mediating the binding of 
ubiquitin to the target protein. In this last step, the carboxyl group of the C-terminal 
glycine of ubiquitin, is covalently linked to the ε-amino group of a lysine present in the 
substrate protein [110]. Several rounds of this sequential reaction, lead to the 
formation of long ubiquitin chains in which each ubiquitin is bound to a specific lysine, 
or the N-terminal residue, of the previous ubiquitin. Totally, there are 7 lysine 
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residues in ubiquitin (K6, K11, K27, K29, K33, K48 and K63) and specific linkages 
through all of them have been reported to occur in cells [111]. The synthesis of 
particular ubiquitin chain linkages appears to be a function of the specific E2s and the 
E2-E3 combinations involved in the process [112]. Structural characterization of 
various chain types revealed that the different linkages results in distinct chain 
conformations, which can be more open or compact [113]. Moreover, the type of 
linkage between ubiquitins within a chain determines the functional outcome of the 
modification. For example, if polyubiquitylation occurs through lysine 11 or 48 (K11 
and K48, respectively) the substrate is recognized and subsequently degraded by the 
26S proteasome. Differently, monoubiquitylation or K63-linked polyubiquitylation of a 
substrate specifies non-proteolytic fates, while the precise outcome of other chain 
linkages is less understood [114]. Finally, ubiquitylation can be reverted by the 
activity of deubiquitinating enzymes (DUBs), which can remove ubiquitin molecules 
from a chain, or directly from the substrate [115].  
 
 
Figure 6 The ubiquitin-proteasome system. Ubiquitin is attached to the substrate protein in 
a three-step reaction. Firstly, the E1 ubiquitin-activating enzyme binds ubiquitin in an ATP-
dependent manner. Secondly, ubiquitin is transferred to the E2 ubiquitin-conjugating enzyme 
and, finally, attached to the substrate by the E3 ubiquitin ligase. Repetition of this cycle leads 
to the formation of a polyubiquitin chain. The 26S proteasome recognizes and lyses 
polyubiquitylated proteins in an ATP-dependent manner. At the top of the scheme, the 
different families of E3 ligases are shown. Adapted from [116]. 
 
Mammalian cells express two E1, at least 38 different E2 and 600-1000 E3 
enzymes. E2 enzymes play a central role during ubiquitylation of substrates, because 
they determine the linkage specificity and length of ubiquitin chains. Moreover, they 
can strongly influence the processivity of chain formation [117]. Nevertheless, the E3 
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ligases are pivotal in directing the activity of E2 enzymes toward the right substrate. 
Depending on their homology domains, the E3 ubiquitin ligases can be subdivided in 
to two major families: HECT (homologous to E6-AP C-terminus) and RING (really 
interesting new gene) E3 ligases [118]. Other than possessing different functional 
domains, these enzymes perform their function in distinct manners. HECT ligases 
form a transient linkage to ubiquitin before transferring it to the substrate, whereas 
RING ligases mainly act as scaffolds and mediate the passage of ubiquitin from the 
E2 to the substrate by bringing them in close proximity [119, 120]. To date, more than 
600 RING proteins are annotated for human cells [121]. A canonical RING domain is 
composed by spaced cysteine and histidine residues, coordinated to a specific 
conformation by Zinc atoms [120]. RING domain-containing proteins can act as 
monomers, dimers or multi-subunit complexes and one of the best-studied multi-
subunit RING ligases belong to the cullin-RING ligase (CRL) superfamily. In their 
minimal conformation, CRLs are composed of a backbone, consisting of one out of 
several cullin isoforms, which binds through its C-terminus to a RING-containing 
protein, whereas the N-terminus is linked to a substrate-recognizing module. Two 
prominent examples are the SCF and the APC/C E3 ligases, which play a central role 
during cell cycle progression. SCF complexes are cullin 1-based and contain the 
small RING protein Rbx1. The linker protein Skp1 and a F-box motif adaptor protein 
form their substrate recognition modules. The majority of F-box proteins contain 
protein–protein interaction motifs, such as WD-40 and leucine-rich repeats, which are 
involved in substrate binding [122].  
 
1.4 The anaphase-promoting complex 
The anaphase-promoting complex or cyclosome (APC/C) is an evolutionary-
conserved multisubunit E3 ligase [123]. In mammals it comprises 15 subunits, 
however the basic organization resembles the one of the SCF complex. Apc2 is the 
cullin-like scaffold subunit and it is connected to the Apc11 RING protein, which is 
responsible for recruiting specific E2 enzymes. Cell cycle-dependent and mutually 
exclusive association with two co-activators, Cdc20 and Cdh1, is a prerequisite for 
APC/C capability of binding to its substrates [124]. Both proteins are characterized by 
the presence of an N-terminal “IR-tail”, which is important for their binding to Apc3, 
and a WD40 domain, which mediates the interaction with the substrates [125, 126]. 
Apc3, similarly to other structural subunits of APC/C, contains different 
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tetratricopeptide repeats (TPRs), which are involved in intra- and inter-molecular 
interactions [127, 128]. Substrate-binding capacity of the complex, also requires the 
Apc10 subunit, which is positioned close to the co-activators [129-131]. The 
presence of Apc10 is also important for stimulating the processivity of the complex 
[132].  
 
 
Figure 7 Structure of the APC/C. Electron microscopy based reconstruction of human 
APC/C, in complex with its co-activator Cdh1 and a substrate protein. The different subunits 
are color-coded. The “platform”, in the lower part of the complex, comprises subunits Apc1, 4, 
5 and 15, whereas the “arc lamp” is form by Apc3, 6, 7, 8, 12, 13 and 16. In the central cavity 
is possible to identify the substrate recognition module (Cdh1 and Apc10) and the substrate 
protein (in orange). Adapted from [123]. 
 
Electron microscopy studies showed that the complex is organized in an 
asymmetrical triangular shape, composed of an outer wall surrounding a central 
cavity. The complex can be conceptually divided in two large domains, known as 
“platform” and “arc lamp” (also called “TPR lobe”). The catalytic subunits (Apc2 and 
Apc11) are positioned at one end of the platform, whereas at the other end the arc 
lamp is mounted, which bears the substrate-recognizing module (Apc10 and 
Cdc20/Cdh1). The two domains possess a high degree of conformational flexibility 
bringing the catalytic and substrate-recognition motifs in close proximity upon binding 
of the co-activators [123, 133, 134]. This conformational change enhances the 
catalytic activity of the APC/C and depends on the N-terminal region of the co-
activators [135]. In human cells, APC/C assembles atypical K11-linked conjugates to 
drive proteasomal degradation and mitotic exit. Indeed, APC/C activation during 
mitosis correlates with and increased abundance of K11 linkages and this boost is 
dependent on the E2 Ube2S [136, 137]. APC/C initiates chain formation by using the 
E2 Ube2C (also known as UbcH10), which synthesizes K11, K48 or K63 linkages 
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[138, 139]. However, chain extension by Ube2C is inefficient and elongation is taken 
over by Ube2S, which specifically catalyzes K11 linkages [140-142]. Interestingly, it 
has been recently shown that the combined activity of these two E2 enzymes 
generates branched ubiquitin chains, which enhance substrate recognition by the 
proteasome [143].  
 
1.4.1 Two co-activators provide specificity to the APC/C 
The two co-activators, Cdc20 and Cdh1, are responsible for directing the APC/C 
towards specific substrates. Structural insights into the mechanisms of degron 
recognition showed that the co-activators collaborate with the Apc10 subunit to 
properly bind substrates [130, 144]. Through their WD40 domains, which folds in a 
propeller-like structure, the co-activators have the capacity of recognizing two 
conserved degrons present in most of the APC/C substrates: the destruction box (D-
box) and the KEN box. The D-box was initially identified as a nine amino acid-long 
motif present in the N-terminal region of cyclin B, mediating its degradation [145]. 
However, RxxL seems to be the minimal consensus motif required for the recognition 
of a substrate [146]. The second degron is simply formed by the three amino acids K-
E-N, but a more extended consensus motif is facilitating substrate recognition [147, 
148]. Despite the identification of different non-canonical destruction signals, such as 
the A-box present in Aurora A, KEN and D-boxes are regarded as the major APC/C 
recognition motifs [146, 149]. No particular structural organization is required for the 
region surrounding the degron, but the presence of additional binding motifs in the 
substrates facilitates their recruitment [41].  
 
1.4.2 APC/C function and regulation during the cell cycle 
The APC/C, in conjunction with its co-activators, controls the degradation of 
various cell cycle regulators. Therefore, periodic activation and inactivation of the 
APC/C is required to organize cell cycle progression. This becomes particularly 
important during mitosis to ensure that the daughter cells inherit an equal set of 
chromosomes. During unperturbed cell cycle progression, the APC/C is inactive from 
late G1 phase until mitosis and this allows the accumulation of its substrates, many of 
which are needed to enable DNA replication and mitosis. Both co-activators are 
already transcribed and translated during S/G2 but their interaction with the APC/C is 
prevented by several mechanisms [150]. For example, in vertebrate cells, E2F 
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activation at the G1/S transition drives the expression of the early mitotic inhibitor 1 
(Emi1), which blocks APC/C activity [151, 152]. Another, more conserved 
mechanism, exploits in an ingenious fashion the activity of the different CDKs. In fact, 
Cdc20 only interacts with APC/C when several subunits are phosphorylated at 
various sites, which is mediated by the mitotic CDK1-cyclin B complexes and Plk1 
[153]. Activity of CDK1-cyclin B complexes is particularly important to enable Cdc20 
binding and APC/C activation [154]. Noteworthy, phosphorylation of the APC/C 
subunits is not required for Cdh1 binding [155]. Nevertheless, in S/G2 and early 
mitotic phases Cdh1 is phosphorylated by CDK2-cyclin A complexes and this blocks 
the association of Cdh1 with APC/C [155, 156]. In budding yeast, mutating the CDK 
sites enables Cdh1 to activate the APC/C during mitosis and renders Cdc20 
dispensable [157]. Whether phosphorylation is the principal mechanism of APC/C 
activation in mitosis is unclear. Some studies proposed that Plk1-dependent 
phosphorylation of Emi1 and its subsequent SCFβTrCP-dependent degradation is also 
needed to enable APC/C activation [158, 159]. However, overexpression of a non-
degradable form of Emi1 or inhibiting Plk1 activity does not block APC/C activation 
[153, 160, 161].  
APC/C activation occurs early in mitosis and has to be coordinated with 
chromosome attachment to the mitotic spindle and their alignment on the metaphase 
plate. In fact, one prominent target of the APC/C is securin, which binds and 
inactivates separase, a protease able to cleave the Scc1 cohesin subunit responsible 
for chromatid cohesion. Securin degradation results in loss of cohesion and 
detachment of the sister chromatids, which, if occurring prematurely, results in 
aneuploidy [162]. The spindle assembly checkpoint (SAC) controls chromosome 
segregation by blocking Cdc20, and hence the APC/C, until all the kinetochores are 
correctly attached to the mitotic spindle. Briefly, after nuclear envelope break down, 
unattached kinetochores recruit four SAC proteins (Mad1, Mad2, BubR1 and Mps1) 
[41]. Here, Mad1-Mad2 catalyze a conformational change in a second Mad2 protein, 
which then firmly binds and inhibits Cdc20. This transient SAC activation can be 
prolonged in case the cell is experiencing problems with kinetochore attachment. 
Robust Cdc20 inhibition is achieved by the further binding of Mad2-Cdc20 to Bub3 
and BubR1, forming the mitotic checkpoint complex (MCC), which can be free or 
APC/C-bound [163]. When all kinetochores are attached to the spindle microtubules, 
the SAC is satisfied and APC/C is reactivated in order for mitosis to proceed. In this 
regard, Cdc20 auto-ubiquitylation has been proposed to occur in an Apc15-
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dependent manner, resulting in MCC disassembly and its dissociation from the 
APC/C [164]. Moreover, p31comet disrupts the Mad2-BubR1 interaction, releasing the 
sequestered Cdc20 [165].  
 
 
Figure 8 Activation of the APC/C during the cell cycle. APC/C becomes activated in 
prophase (P) by binding of Cdc20, but its activity towards cyclin B and securin is retained until 
metaphase (M) by the spindle assembly checkpoint (SAC). However, some substrates, such 
as cyclin A, are already degraded during prometaphase (PM). During anaphase (A) and 
telophase (T), APC/CCdh1 is activated and mediates the destruction of additional mitotic 
regulators, such as Cdc20 and Plk1. APC/CCdh1 remains active throughout G1 and during this 
time window degrades different substrates, including its own E2 ubiquitin-conjugating enzyme 
(Ubc2C). Adapted from [150]. 
 
Securin and cyclin B1 degradation is initiated after the last kinetochore is attached 
to the mitotic spindle, enabling APC/CCdc20 activation [166]. Cdc20 is essential for the 
degradation of these two factors and loss of Cdc20 causes embryonic lethality in 
mice at the two-cell stage [167]. An absolute metaphase block is also achieved in 
human cell lines by depleting Cdc20 to very low levels [168, 169]. Once securin and 
cyclin B1 are degraded to a sufficient level, APC/C activity is directed towards a 
broader range of substrates, including those with KEN boxes, such as Plk1, Aurora 
kinases and Cdc20 itself [170]. This is partially achieved by switching the co-adaptors 
in APC/C from Cdc20 to Cdh1. Mitotic progression results in decreased CDK levels 
and activation of the Cdc14 phosphatase, enabling Cdh1 dephosphorylation and 
leading to the formation of the APC/CCdh1 complex [171-173]. Interestingly, depletion 
of Cdh1 stabilizes Aurora kinases, but does not affect Plk1 or Cdc20 degradation 
indicating that APC/CCdc20 activity is sufficient for sustaining mitotic exit [174, 175]. 
After its activation, APC/CCdh1 substrates are degraded in a sequential order during 
mitotic exit [176]. An in vitro study suggests that this sequential degradation is 
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achieved through an intrinsic property of the APC/C in promoting polyubiquitin chain 
formation [177]. On one hand, polyubiquitylation of “early” substrates occurs in a 
processive manner requiring a single APC/C-binding event to obtain a long chain and 
resulting in efficient proteasome-dependent clearance of the protein. On the other 
hand, “late’” substrates are modified in a distributive fashion, requiring multiple 
rounds of APC/C binding and hence more time to become polyubiquitylated and 
degraded [177].  
Even if Cdh1 seems to play a secondary role during mitosis, this APC/C co-
activator plays an important role during G1 phase. Indeed, APC/CCdh1 activity during 
G1 is required to keep S phase and M phase cyclins at low levels, retaining their 
accumulation until the cells decide to commit for another round of division. 
Interestingly, deletion of the Apc2 subunit of the APC/C in quiescent hepatocytes 
results in their re-entry in the cell cycle without requirement for proliferative stimuli 
[178]. Moreover, loss of Cdh1 results in the premature accumulation of cyclin A, 
which leads to unscheduled DNA replication [174, 175]. Other than by targeting cyclin 
A, APC/CCdh1 delays S phase by promoting degradation of Skp2, which is an adaptor 
of the SCF complex, targeting the CKI p27 for degradation. Therefore, stabilization of 
Skp2 in Cdh1-deficient cells, results in the de-stabilization of p27 and an increase in 
CDK activity that promotes premature initiation of DNA replication [179, 180]. 
Furthermore, the transcription factor and proto-oncogene Ets2 is stabilized in 
absence of Cdh1, resulting in increased cyclin D1 levels and enhanced proliferation 
[181, 182]. Under normal conditions, once cells decide to replicate, the APC/C 
activity is inhibited by a loop comprising different mechanisms. As mentioned above, 
Emi1 is a major player in promoting APC/C inhibition and is expressed at the G1/S 
transition in an E2F-dependent manner [183]. Additionally, APC/CCdh1 directly 
promotes the degradation of Ubc2C, its E2 ubiquitin-conjugating enzyme, and 
initiates the auto-ubiquitylation of Cdh1 [184, 185]. Finally, increasing CDK activity, 
results in phosphorylation of Cdh1 and its release from the APC/C complex [156]. 
Later in S phase, the SCFβTrCP complex targets phosphorylated Cdh1 for degradation 
[186, 187].  
 
1.4.3 APC/CCdh1 involvement in cancer and in the DDR 
APC/CCdh1 restricts the proliferative capacity of cells, by targeting various cell cycle 
regulators for degradation. Due to their essential role in cell cycle regulation, most 
germline knockout mice targeting the APC/C pathway are embryonic lethal. Cdh1 has 
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also been reported to be overexpressed in malignant but not benign tumor types 
[188]. Nevertheless, Cdh1 is often downregulated or lost in human cancers and Cdh1 
heterozygosity in mice results in increased susceptibility to spontaneous tumors 
formation [82, 175, 189, 190]. Moreover, Cdh1-deficient cells have aberrant 
chromosome numbers, including highly aneuploid cells with 100–150 chromosomes 
and high number of chromosome breaks [175]. Interestingly, loss of Cdh1 causes an 
increase in γH2AX foci even in absence of exogenous genotoxic treatment [174]. As 
a first indication in this direction, it was shown that after irradiation of S phase cells, 
Cdh1 becomes integrated in the APC/C, forming a catalytically active complex. 
Moreover, Cdh1-deficient cells are unable to maintain a G2 arrest after IR, but no 
difference between wild-type and Cdh1-deficient cells is observed if UV-irradiation is 
used [191]. Activation of the APC/CCdh1 in response to DNA damage during G2 was 
shown to depend on the release of the Cdc14B phosphatase from the nucleoli. This 
enables Cdc14B to de-phosphorylate Cdh1, resulting in the activation of the 
APC/CCdh1 complex, which finally leads to the degradation of Plk1 and the 
stabilization of the G2/M checkpoint. Interestingly, not all targets of the APC/CCdh1 are 
degraded under these conditions and it was suggested that USP28 is involved in 
counteracting APC/C activity [82]. Further experiments performed in Cdc14-deficient 
cells showed that those cells are proficient in the maintenance of the G2/M 
checkpoint following IR, but require longer time to repair DSBs. Moreover, depletion 
of Cdh1 does not affect the capacity of the cells to activate the G2/M checkpoint 
[192].  
Full activation of APC/CCdh1 is part of the long-term response to IR and requires 
the activation of p53 and its transcriptional target p21. Stabilization of p21 results in 
the degradation of the Emi1 inhibitor and the consequent activation of APC/CCdh1. 
Interestingly, also in this case, Cdc14B plays a secondary role for APC/CCdh1 
activation following genotoxic stress [193, 194]. Recently, different groups showed 
that in non-transformed cells, following p53 activation in G2, APC/CCdh1-dependent 
degradation of cyclin B1 determines the irreversible withdrawal from the cell cycle 
and the establishment of a senescence state [195-197]. Moreover, it was shown that 
damage-induced activation of the APC/CCdh1 is responsible for the degradation of two 
major histone methyltransferases, G9a and GLP, involved in the silencing of 
euchromatic genes.  This event results in the expression of IL-6/IL-8, which are pro-
inflammatory cytokines produced and secreted by senescent cells [198]. In summary, 
upon DNA damage in G2, Cdc14B-dependent dephosphorylation of Cdh1 promotes 
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the prompt activation of a fraction of APC/CCdh1, which is directed towards a subset of 
substrates. Prolonged exposure to DNA damage, leads to p53 activation, resulting in 
the p21-dependent degradation of Emi1, enabling the full activation of APC/CCdh1 and 
the establishment of senescence.  
 
1.5 DNA double-strand breaks 
DNA double-strand breaks (DSBs) arise when both DNA strands of the double 
helix break simultaneously in close proximity. Although they occur much less 
frequently than other kinds of DNA lesions, they pose a severe challenge to the cells 
as they can trigger genome rearrangements [28]. It has been shown that one single 
DSB can be lethal to radiosensitive mutants of budding yeast [199]. DSBs emerge 
because of endogenous or exogenous challenges. Replication is a major 
endogenous source of DSBs, since prolonged replication fork stalling at unrepaired 
DNA lesions can result in fork collapse and DSB formation. In this regard, treatment 
of cells with PARP inhibitors (e.g. olaparib) prevents detection and repair of SSBs, 
which are converted into DSBs during replication. In addition, various exogenous 
DNA damaging agents, such as IR and certain anti-cancer drugs, can induce DSBs. 
One important class of genotoxic drugs leading to DSB formation are DNA 
topoisomerase inhibitors. DNA topoisomerases solve topological problems 
associated with DNA replication, transcription, recombination, and chromatin 
remodeling by introducing temporary single- or double-strand breaks in the DNA 
[200]. Inhibition of a topoisomerase blocks the re-sealing of the nicked DNA, inducing 
a permanent break in the DNA. Topoisomerase type II inhibitors (e.g. Etoposide) 
directly induce DSBs, whereas inhibitors of type I topoisomerases (e.g. 
Camptothecin) cause SSBs, which give rise to DSBs during S phase. Moreover, 
different endonucleases, such as I-SceI, FokI or Cas9, can be used to induce DSBs 
at precise locations in the genome and, recently, different genome-editing methods, 
which rely on endonuclease-induced cuts, have been developed [201].  
DSB formation is also occurring in different physiological settings. For example, 
during meiosis, DSBs are induced and repaired by HR in order to increase genetic 
diversity. Other examples are the programmed DSBs that are induced at different 
stages of lymphocyte development to increase antibody and T cells receptor 
diversity. Early in development of B and T lymphocytes, rearrangement of the V(D)J 
region is initiated by RAG1 and RAG2, which introduce DSBs at specific recognition 
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sites. Repair through c-NHEJ (see below) favors the production of highly different 
antibody variable regions [202]. The second programmed DNA recombination 
process takes place in mature B cells. Class switch recombination (CSR) is initiated 
by the activation-induced cytidine deaminase (AID), which favor DSB formation in 
defined switch regions. Also in this case, the broken ends are repaired by c-NHEJ 
and recombination with a different region, leads to the formation of different classes 
of antibodies (e.g. IgG, IgE or IgA) [203].  
 
1.6 DSB repair pathways 
Cells have evolved two major pathways dedicated to DSB repair: homology-
directed repair (HDR) and non-homologous end joining (NHEJ). Both of them can 
additionally be subcategorized in homologous recombination (HR) versus single-
strand annealing (SSA) and classical NHEJ (c-NHEJ) versus alternative NHEJ (alt-
NHEJ), respectively [28]. HR and SSA require the formation of longer stretches of 
ssDNA, that are exposed in a nucleolytic process defined as DNA-end resection and 
that prevents repair through NHEJ [204-206]. In fact, alt-NHEJ only requires short 
stretches of ssDNA, whereas c-NHEJ does not require resection of the broken ends. 
Generally, these different requirements make the initiation and extent of DSB end 
processing a main decisional event in DSB repair pathway choice. The choice 
between the different repair pathways is influenced by various circumstances, as for 
instance the cell cycle stage [207]. Repair based on the use of a homology sequence 
template (HR, SSA), are mainly restricted to the S/G2 phases of the cell cycle. The 
temporal restriction of HDR is controlled both at the transcriptional and post-
transcriptional level. For instance, the expression of many HR factors including 
Rad51 and BRCA1 is cell cycle-dependent, being much lower in G0/G1 than in S/G2 
[208, 209]. In addition, CDKs, the key orchestrators of cell cycle, play an important 
role in the regulation of multiple HR components, especially of those involved in 
DNA-end resection [210]. CDK activity has been shown to be essential for DNA-end 
resection and HR both in yeast and vertebrate cells [211-213]. In human cells, Chk1 
activation requires CDK activity and the formation of RPA-coated ssDNA, mainly 
occurring in an MRN-dependent manner. Moreover, also the direct ATM-dependent 
activation of ATR is restricted to S/G2 [213]. Interestingly, CDK2 plays a redundant 
role for cell cycle progression, but the specific inhibition of this kinase results in 
defective checkpoint signaling and DSB repair [214].  
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1.6.1 Non-homologous end joining 
c-NHEJ does not require sequence homology for repairing the broken 
chromosomes and, in mammalian cells, is the main pathway for the repair of DSBs 
[215]. It is active throughout the cell cycle and it covers a particularly important role 
during G0/G1 phases [216]. c-NHEJ seems to be a relatively simple pathway, 
because it joins DNA ends by ligation without requirement of searching for an 
homologous template. Interestingly, this pathway is also able to re-ligate ends that 
are not blunt or complementary, indicating that the proteins involved are capable of 
“clean-up” modified nucleotides which may be present at the broken ends, in 
particular after IR. Even though c-NHEJ appears to have higher fidelity than alt-
NHEJ, repair through this pathway can cause short deletions/insertions and 
translocations, especially in case of “dirty” broken DNA ends [217, 218].  
 
 
Figure 9 Non-homologous end joining. Schematic comparison of the classical (c) and 
alternative (alt) NHEJ repair pathways. c-NHEJ is initiated by binding of the Ku heteroduplex 
to the broken DNA and the subsequent recruitment of the DNA-PK kinase. After short 
processing of the DNA ends, the break is re-sealed by action of the XRCC4-Ligase IV-XLF 
complex. Events involved in alt-NHEJ are less defined, but MRN/CtIP-dependent DNA-end 
resection is required to expose sequences containing microhomologies, which facilitate the 
repair process. Adapted from [233] 
 
Binding of the Ku70/80 heterodimer protects the DNA ends from possibly aberrant 
processing and enables the recruitment of DNA-PKcs [219, 220]. After its 
recruitment, DNA-PKcs promotes phosphorylation of different substrates, such as 
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Ku, Artemis, XRCC4, ligase IV and XLF [221]. Generally, inactivation of DNA-PKcs 
kinase activity is detrimental for cells and cause hypersensitivity toward DSB-
inducing agents and severely interfere with V(D)J recombination [222, 223]. DNA-
PKcs sits on a terminal DNA region, promoting contact between two opposing ends: 
an event that seems to be important for the full activation of the kinase [221, 224, 
225]. The in trans autophosphorylation of DNA-PKcs across the break causes 
changes in the kinase structure, which help its dissociation and increase accessibility 
for processing enzymes and ligases to the DNA ends [219, 226]. The majority of 
DSBs require limited DNA end processing before ligation and different enzymes are 
able to perform this task. For example, Artemis is able to process ssDNA overhangs 
or opening DNA hairpins, which are generated during V(D)J recombination [227-230]. 
Following a limited end processing step, DNA polymerases are required to fill in 
nucleotide gaps prior to DNA ligation. Three members of the polymerase X family 
have been associated with c-NHEJ in mammalian cells: pol λ, pol μ and the terminal 
deoxynucleotidyl transferase (TdT) [231]. The final step of the repair process is the 
ligation of the broken ends, performed by the XRCC4-ligase IV-XLF complex [232].  
alt-NHEJ was initially believed to be a backup system used by cells deficient for c-
NHEJ factors, but was afterwards observed also in c-NHEJ-proficient cells [234-237]. 
alt-NHEJ is often characterized by excessive deletions and presence of 
microhomologies at the junctions. Importantly, alt-NHEJ is much less faithful than c-
NHEJ and deficiency of c-NHEJ factors increases the number of alt-NHEJ-driven 
chromosomal translocations [238-240]. The precise mechanisms of alt-NHEJ remain 
unclear, but a resection step seems to be required to expose regions of 
microhomology, which are then used during the repair process. In this regard, 
depletion of CtIP or Mre11 decreases the amount of chromosomal translocation in 
cells lacking Ku70 or XRCC4 [236, 241, 242]. After DNA-end resection, DNA ligase 
III appears to promote re-ligation, in combination with its cofactor XRCC1. Moreover, 
in absence of ligase III and IV, ligase I was proposed to mediate ligation in a 
microhomology-independent manner [243, 244].  
 
1.6.2 Homology-directed repair 
Homology-directed repair (HDR) mechanisms use homologous sequences 
present in the genome as a template for repairing DSBs. A characteristic feature of 
these repair mechanisms is the exposure of relatively long stretches of ssDNA, which 
are used for homology search and recombination. Two distinct mechanisms of HDR 
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have been described in mammalian cells: homologous recombination (HR) and 
single-strand annealing (SSA). Since ssDNA is an intermediate for both HR and SSA, 
these two DSB repair pathways compete with each other and deficiency for some HR 
factors facilitates SSA repair [245]. HR is directed toward the homologous sequences 
present in the sister chromatid and restore the genetic information in a faithful 
manner [246]. Nevertheless, recombination with sequences of the homologous 
chromosome potentially leads to loss of heterozygosity (LOH) [247]. In somatic cells, 
the repair of DSBs through HR is restricted to the S/G2 phases of the cell cycle, with 
a peak of usage during S phase [216, 248, 249]. SSA involves the annealing of 
complementary single-stranded tails formed at repetitive sequences, such as ALU 
repeats, and is therefore considered to be highly mutagenic [250]. SSA has been 
suggested to be a significant pathway causing translocations in human cancers [251, 
252].  
 
1.6.2.1 DNA-end resection 
Long stretches of ssDNA are generated by 5’ to 3’ nucleolytic resection of DNA 
ends, resulting in 3’ single-stranded tails. DNA-end resection is a major decision-
making process for the usage of the different pathways [253]. Mainly based on data 
coming from yeast studies, a two-step model has been proposed for DSB resection in 
eukaryotic cells.  
 
Figure 10 DNA-end resection. During S/G2 phases of the cell cycle, DSB repair via HR is 
initiated by DNA-end resection. Initial short-range resection is carried out by the MRX/N 
complex and Sae2/CtIP. Next, long-range resection is catalyzed either by the 5′-3′ 
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exonuclease Exo1 or the helicase Sgs1/BLM in conjunction with the endonuclease Dna2. 
After formation, ssDNA is rapidly coated by RPA. Once adequate stretches of ssDNA are 
formed, RPA is replaced by Rad51 that is required for strand invasion of the sister chromatid 
and further downstream steps in HR. Adapted from [210]. 
 
The MRX complex, in combination with Sae2, initially resects the DNA ends to create 
a short 3’ overhang. Extension of the ssDNA track is subsequently performed by 
Sgs1-Dna2 and Exo1 [205, 254, 255]. Since Mre11 possesses endonuclease and 3’ 
to 5’ exonuclease activity, which is opposite to the direction in which DNA-end 
resection occurs, a bidirectional model has been proposed [256-258]. In this model, 
MRX nicks the DNA at 15-20 nt from the end in a Sae2-dependent manner. This 
event creates an entry point for MRX, which then resects the DNA towards the ends. 
In the meantime, Exo1 and Sgs1-Dna2 extend the ssDNA tracks in the opposite 
direction. Interestingly, in the absence of Ku, CDK1 activity is dispensable for the 
initiation of resection by MRX-Sae2, but is still needed for long-range resection by 
Exo1 or Sgs1-Dna2 [259].  
In higher eukaryotes, initial resection is performed by CtIP, the proposed Sae2 
homologue, in conjunction with the MRN complex [260, 261]. Interestingly, and in 
contrast to Sae2, CtIP has been reported to possess nuclease activity [258, 262, 
263]. The observation that the active site is outside the evolutionarily conserved C-
terminus of the protein, opens the possibility that CtIP possesses more functions than 
its yeast counterpart [264]. Similar to what has been observed in yeast, ssDNA 
overhangs are expanded by the Sgs1 homologue BLM, in combination with Dna2 
and Exo1 [265]. The so-formed ssDNA tracks at broken ends can extend up to 
several kilobases and they are promptly coated by the ssDNA binding protein RPA 
[266]. RPA is an evolutionarily conserved, heterotrimeric complex consisting of 
RPA1, RPA2, and RPA3. Owing to its high ssDNA binding affinity, RPA is required 
for most aspects of DNA metabolism including replication, repair and recombination 
[267]. Different studies have also implicated RPA in promoting long-range resection 
through stimulation of both Exo1- and Sgs1-Dna2-dependent pathways [268-270].  
 
1.6.2.2 Homologous recombination 
After the formation of long stretches of ssDNA, the repair process can be 
completed. For this to occur, ssDNA-bound RPA has to be substituted by the 
recombinase protein Rad51, however the high affinity of RPA for ssDNA interferes 
with this process. Therefore, mammalian cells possess diverse accessory factors, 
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such as BRCA2 and PALB2, which facilitate this exchange [271]. Once the Rad51 
nucleoprotein filament is formed, it promotes homology search and strand invasion. 
During synapsis formation, Rad51 facilitates the contact between the invading 
ssDNA and the homologous DNA duplex, in a structure called displacement loop (D-
loop) [272]. Finally, repair synthesis can be performed, using the invading strand as 
primer and the donor duplex as template. The required polymerases remain elusive 
in vivo, but polymerase η and other TLS polymerases were shown to fulfill this role in 
vitro [273, 274].  
 
 
Figure 11 DSB repair through HR. Repair is initiated by resection of a DSB to provide 3′ 
ssDNA overhangs, which enable strand invasion into a homologous sequence. In DSBR, after 
DNA synthesis the second DSB end is captured to form an intermediate with two Holliday 
junctions (HJs). After gap-repair DNA synthesis and ligation, the structure is resolved forming 
a non-crossover or a crossover product. Alternatively, in SDSA, the newly synthesized strand 
is displaced and after annealing to the other break end, gap-filling DNA synthesis and ligation 
take place. SDSA forms exclusively non-crossover products. Adapted from [271]. 
 
Downstream repair events can occur in different ways, leading to the formation of 
variable outcomes. On the one hand, during canonical DSB repair (DSBR), the 
second DNA end is captured, leading to the formation of a double Holliday junction 
(dHJ), of which endonucleolytic cleavage produces either crossover or non-crossover 
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products. Different structure-specific endonucleases, including Mus81/Eme1, Slx1-
Slx4 and Gen1, are able to cut HJs in vitro and have been proposed to act as 
“resolvases” in mammalian cells [275]. dHJs can also be dissolved and exclusively 
generate non-crossover products. Dissolution requires the BLM helicase, 
topoisomerase III α and RMI1-2 complex, which act in concert to permit branch 
migration and decatenation of the interlinked strands of the two HJs [276]. On the 
other hand, in case of synthesis-dependent strand annealing (SDSA), the newly 
synthetized strand is displaced and re-annealed to the second DNA end, forming a 
non-crossover product. SDSA is the preferred pathway during mitotic recombination, 
whereas both pathways are used during meiotic recombination [277]. In case 
resection occurs within highly repetitive DNA sequences, repair can occur through 
SSA. This pathway is Rad51-independent and relies on the activity of Rad52, which 
anneals the exposed sequences, leading to deletion of intervening regions [272].  
 
1.7 CtIP  
CtIP, also known as Rbbp8, is an 897 amino acid-long protein, whose primary 
amino acids sequence is significantly conserved among mammals. Moreover, the C-
terminal region of CtIP is extremely conserved from yeast to human and is crucial for 
DNA-end resection during the initial steps of HR [261, 278-280]. CtIP was first 
described as a transcription cofactor, interacting with the transcriptional repressor 
CtBP (thereby the name CtIP, which stands for CtBP interacting protein) and Rb 
(hence the name RBBP8, which stands for retinoblastoma-binding protein 8) [281-
283]. CtBP acts as a transcriptional corepressor of several tumor suppressors, such 
as E-cadherin, p16, p15 and PTEN, indicating a strong association with 
tumorigenesis and tumor progression [284]. It was further shown that the Rb/E2F 
pathway stimulates CtIP expression at the G1/S transition and that CtIP itself 
interacts with Rb, modulating its own promoter activity but also those of other E2F-
responsive genes, such as cyclin D1 [285, 286]. CtIP contains a LECEE motif, which 
mediates its interaction with Rb and other members of the same family: p107 and 
p130. Interestingly, ablation of CtIP in MEFs results in Rb hypophosphorylation and 
inhibition of the G1/S transition, but the underlying mechanism remains unresolved 
[287]. One possible explanation is that CtIP is involved in p130-mediated 
transcriptional repression by recruiting CtBP to specific promoters, one of which is 
encoding a direct regulator of Rb [281, 288]. Moreover, CtIP is interacting with 
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members of the Ikaros family, which are Krüppel-like zinc finger transcription factors 
involved in lymphoid development and differentiation [289]. Interestingly, deregulated 
expression of these proteins is often associated with leukemia [290]. Inactivation of 
both CtIP alleles in mice results in early embryonic lethality at stage E4, whereas 
heterozygous CtIP-/+ mice are viable but prone to the development of multiple tumors, 
which result in a shorter lifespan. Noteworthy, among the different types of tumors 
observed in CtIP-/+ mice, B and T cells lymphomas were the prevalent ones [287]. 
Lymphomas were shown to result from a MYC translocation, rendering this 
transcription factor hyperactive and hence driving the expression of different 
oncogenes [291]. One example is the overexpression of the oncogenic miRNA 17~92 
cluster, containing the miR-19a/b members [292], which were shown to control the 
levels of CtIP protein [293]. CtIP is ubiquitously expressed in different cell types with 
the highest levels observed in thymus and testis, in line with its role during meiotic 
recombination [283]. Even if CtIP has been suggested to be a tumor suppressor 
itself, no strong evidences support so far this hypothesis. For example, analysis of 
different human cancer cell lines derived from various tissues did not identify 
homozygous deletions of the CtIP gene. Nevertheless numerous mutations in CtIP 
sequence have been identified in those samples [283, 288].  
 
1.7.1 Cell cycle regulation of CtIP 
CtIP and its yeast orthologs Ctp1/Sae2 play a central role in the initiation of DNA-
end resection during DSB repair. In fission yeast, Ctp1 is absent during G0/G1 and its 
expression coincides with the initiation of DNA replication. This simple regulatory 
mechanism clearly restricts Ctp1 activity to the S/G2 phases of the cell cycle [280]. 
Differently, in budding yeast, CDK1 activity is required to phosphorylate Sae2 at Ser-
267 and this event is strictly required for Sae2 activity [278, 294]. Higher vertebrates 
seem to rely on a combination of both these regulatory mechanisms. In fact, CtIP 
levels were shown to be low in quiescent G0 cells and increased during S/G2 phases 
of the cell cycle [295]. Interestingly, the strong fluctuation in CtIP protein levels is not 
accompanied by a similar change in mRNA levels, suggesting a post-translational 
regulatory mechanism [286, 295]. In addition, similar to the phosphorylation of Ser-
267 in Sae2, CDKs are required to phosphorylate Thr-847 within the evolutionarily 
conserved C-terminus of CtIP to promote DNA-end resection [296]. Interestingly, in 
cells expressing a phospho-mimicking mutant (CtIP-T847E), resection can take place 
even in absence of active CDK1, yet not to the same extent as in normal cells. 
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Therefore, additional CDK sites, on CtIP itself or on other proteins, are probably 
required for optimal resection [210, 297]. Along these lines, it was recently proposed 
that phosphorylation of additional CDK sites in the central region of CtIP is required 
for DNA-end resection. Phosphorylation of this cluster seems to be needed for ATM-
dependent phosphorylation of CtIP through its association with Nbs1 [298]. 
Moreover, the CDK-dependent activation of CtIP has recently been challenged by the 
observation that in response to DSBs occurring during G1, Plk3 can substitute CDKs 
in phosphorylating CtIP at Thr-847. This phosphorylation triggers CtIP activity, 
promoting DNA-end resection events that result in alt-NHEJ and increased 
chromosomal translocations [299].  
CDKs are also responsible for phosphorylating CtIP at Ser-327 enabling CtIP to 
interact with the E3 ligase BRCA1, which promotes CtIP polyubiquitylation and 
chromatin recruitment [300-302]. Ser-327 phosphorylation is CDK2-dependent and 
facilitated by the interaction of CtIP with Mre11, which binds to both proteins, bringing 
them in close proximity [303]. The CtIP-BRCA1 interaction is mediated by the BRCT 
domain of BRCA1 and has been initially proposed to facilitate the interaction of these 
two proteins with MRN, and hence to promote efficient DNA-end resection [301, 302]. 
However, other groups have recently reported that CtIP-dependent resection does 
not require BRCA1 interaction [304, 305]. In fact, it was already shown that CtIP is 
able to directly bind DNA [306]. An additional layer of complexity to the cell cycle-
regulation of CtIP was added by the recent discovery that CDK-dependent 
phosphorylation of Thr-315 during S/G2, enables the interaction between PIN1 and 
CtIP [307]. PIN1 is a phosphorylation-specific peptidyl-prolyl cis/trans isomerase 
(PPIase), which mediates the interconversion between the two conformations 
(cis/trans) that can be adopted by proline bonds in proteins. PPIases-induced 
conformational changes not only control protein folding but also protein functions (Lu 
et al., 2007) [308]. Interestingly, after binding to Thr-315, PIN1 isomerizes the bond 
between Ser-276, which is phosphorylated by an as-yet-unknown kinase, and the 
following proline. CtIP isomerization results in its ubiquitylation and subsequent 
proteasomal degradation. Disruption of this regulatory circuit results in aberrant 
hyperresection of the broken DNA ends, which blocks NHEJ and favors error-prone 
homology-directed repair [307].  
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2 Aim of the study 
 
DSBs are particularly cytotoxic lesions because, if left unrepaired, they can lead to 
cell death. Furthermore, misrepaired DSBs can trigger genome instability and foster 
tumorigenesis. HR exploits homologous sequences present in the sister chromatid to 
repair DSBs in an error-free fashion. The temporal restriction of HR repair to S/G2 
mainly concerns factors involved in the initial step of HR, known as DNA-end 
resection. Human CtIP is essential for the initiation of DNA-end resection, and its 
activity is controlled by various post-translational modifications.  
 
The aim of my PhD project was to characterize a novel regulatory circuit by the 
APC/C E3 ligase, controlling the stability of CtIP during cell cycle progression and in 
response to DSBs.  
 
CtIP protein levels are low during G1 and increased during S/G2 phase. However, 
the mechanism behind these fluctuations has never been elucidated. The APC/CCdh1 
ubiquitin ligase is active during G1 and drive the proteasome-dependent degradation 
of different substrates containing two characteristic degron motifs: the D- and KEN 
boxes. We identified two evolutionary conserved KEN boxes of CtIP in silico and we 
set out to investigate whether APC/CCdh1 controls CtIP levels during cell cycle 
progression. Furthermore, upon treatment with genotoxic agents, APC/CCdh1 was 
shown to be transiently activated during G2 phase. The observation that Cdh1-/- mice 
have elevated levels of DNA damage and chromosomal aberrations suggests a more 
direct involvement of the APC/CCdh1 in the regulation of DSB repair. However, direct 
mechanistic insights into how the APC/CCdh1 ubiquitin ligase connects the cell cycle 
machinery to DNA repair is still lacking. Besides investigating the regulation of CtIP 
during G1, we also addressed the question whether APC/CCdh1 targets CtIP for 
degradation following DNA damaging events during G2.  
The results of this study were included in an article that was recently published in 
the peer-review scientific journal “The EMBO Journal”. The manuscript is part of the 
result section (chapter 3.1). 
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3.1 APC/CCdh1 controls CtIP stability during the cell cycle and in 
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APC/CCdh1 controls CtIP stability during the cell
cycle and in response to DNA damage
Lorenzo Lafranchi1,†, Harmen R de Boer2,†, Elisabeth GE de Vries2, Shao-En Ong3, Alessandro A Sartori1,*
& Marcel ATM van Vugt2,**
Abstract
Human cells have evolved elaborate mechanisms for responding to
DNA damage to maintain genome stability and prevent carcino-
genesis. For instance, the cell cycle can be arrested at different
stages to allow time for DNA repair. The APC/CCdh1 ubiquitin ligase
mainly regulates mitotic exit but is also implicated in the DNA
damage-induced G2 arrest. However, it is currently unknown
whether APC/CCdh1 also contributes to DNA repair. Here, we show
that Cdh1 depletion causes increased levels of genomic instability
and enhanced sensitivity to DNA-damaging agents. Using an inte-
grated proteomics and bioinformatics approach, we identify CtIP, a
DNA-end resection factor, as a novel APC/CCdh1 target. CtIP inter-
acts with Cdh1 through a conserved KEN box, mutation of which
impedes ubiquitylation and downregulation of CtIP both during G1
and after DNA damage in G2. Finally, we find that abrogating the
CtIP–Cdh1 interaction results in delayed CtIP clearance from DNA
damage foci, increased DNA-end resection, and reduced homolo-
gous recombination efficiency. Combined, our results highlight the
impact of APC/CCdh1 on the maintenance of genome integrity and
show that this is, at least partially, achieved by controlling CtIP
stability in a cell cycle- and DNA damage-dependent manner.
Keywords Cdh1; cell cycle; CtIP; DNA damage; DNA double-strand break
repair
Subject Categories Cell Cycle; DNA Replication, Repair & Recombination;
Post-translational Modifications, Proteolysis & Proteomics
DOI 10.15252/embj.201489017 | Received 16 May 2014 | Revised 7 September
2014 | Accepted 30 September 2014
Introduction
Our genome is constantly exposed to various forms of endogenous
and exogenous insults provoking different types of DNA lesions,
which can promote tumorigenesis. To maintain genomic integrity,
the DNA damage response (DDR) activates cell cycle checkpoints to
slow cell cycle progression, thereby allowing time for appropriate
repair (Jackson & Bartek, 2009). DNA double-strand breaks (DSBs)
are the most cytotoxic lesions induced by ionizing radiation (IR)
and certain anticancer drugs. Cells have evolved two major DSB
repair mechanisms: non-homologous end-joining (NHEJ) and
homologous recombination (HR) (Lieber, 2010).
In the G0/G1 phase of the cell cycle, NHEJ is the preferred mecha-
nism for DSB repair (Lieber, 2010). In this process, DNA ends are
joined without the requirement for a homologous sequence, making
NHEJ potentially mutagenic. In contrast, cells that have entered S
phase can use the sister chromatid as a template for high-fidelity
DSB repair through HR (Aylon et al, 2004; Ferreira & Cooper, 2004;
Sonoda et al, 2006). NHEJ and HR are mutually exclusive pathways
since DNA-end resection, which generates long stretches of single-
stranded DNA (ssDNA), commits cells to HR and prevents repair by
NHEJ. Mechanisms controlling DSB repair pathway choice are
under vigorous investigation (Chapman et al, 2012). The temporal
restriction of HR repair to S/G2 is controlled both at the transcrip-
tional and post-transcriptional level. The expression of many HR
factors including Rad51, Rad54, and Brca1 is cell cycle-dependent,
being much lower in G0/G1 than in S/G2 (Gudas et al, 1996;
Yamamoto et al, 1996). In addition, cyclin-dependent kinases
(CDKs), core components of the cell cycle machinery, play an
important role in DSB repair pathway choice through phosphoryla-
tion of multiple HR components, including members of the MRN
complex as well as Brca1 and Brca2 (Esashi et al, 2005; Ayoub et al,
2009; Falck et al, 2012). CDK-mediated regulation of DSB repair
occurs mainly at the level of DNA-end resection (Aylon et al, 2004;
Ira et al, 2004; Henderson et al, 2006; Jazayeri et al, 2006; Johnson
et al, 2011). Human CtIP is essential for the initiation of DNA-end
resection, and its function in this process is controlled by various
post-translational modifications including phosphorylation, ubiqui-
tylation, and acetylation (Sartori et al, 2007; Huertas & Jackson,
2009; Kaidi et al, 2010; Steger et al, 2013).
Likewise, targeted proteolysis through the ubiquitin-proteasome
system (UPS) is a highly regulated process that allows the removal
of potentially harmful proteins, thereby restricting their activity. The
anaphase-promoting complex/cyclosome (APC/C) is an E3 ubiquitin
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ligase involved in cell cycle regulation and becomes activated upon
sequential binding to the Cdc20 and Cdh1 adaptor proteins
(Peters, 2006; Pesin & Orr-Weaver, 2008). Cdc20 is associated with
the APC/C during early mitosis and principally regulates mitotic
progression, whereas Cdh1 interacts with the APC/C from late
mitosis onwards until the following G1/S transition (Kramer et al,
2000; Peters, 2006). In most cases, APC/CCdh1 interacts with its
substrates through the recognition of a short consensus motif called
the KEN box (Pfleger & Kirschner, 2000; Pines, 2011). During S/G2
phase, premature APC/C activation is at least in part prevented
through CDK-mediated phosphorylation of Cdh1, which hinders
association of Cdh1 with the APC/C (Lukas et al, 1999; Kramer
et al, 2000; Miller et al, 2006).
As a first indication of APC/CCdh1 playing a role in the DDR,
CDH1!/! chicken DT40 cells failed to maintain a G2 arrest after IR
(Sudo et al, 2001). In addition, activation of the APC/CCdh1 in
response to DNA damage during G2 phase was shown to depend on
the Cdc14B phosphatase and to result in the degradation of Polo-like
kinase 1 (Plk1) (Bassermann et al, 2008; Wiebusch & Hagemeier,
2010). Upon completion of DSB repair, Cdk1 and Plk1 are reacti-
vated to allow cell cycle progression from G2 into mitosis (van Vugt
et al, 2004). Further experiments performed in Cdc14B-deficient
cells showed that those cells are unable to repair DSBs even if they
efficiently arrest in G2 (Mocciaro et al, 2010). However, direct
participation of the APC/CCdh1 in the regulation of DSB repair has
never been reported. The observation that Cdh1-depleted cells or
Cdh1!/! mice have elevated levels of DNA damage and chromo-
somal aberrations (Garcı´a-Higuera et al, 2008; Sigl et al, 2009;
Delgado-Esteban et al, 2013) strengthens this notion, but direct
mechanistic insights into how the APC/CCdh1 ubiquitin ligase
connects the cell cycle machinery to DNA repair is still lacking and
the responsible substrates remain elusive.
In this study, we show that inactivation of Cdh1 results in geno-
mic instability in different human cell lines. Moreover, Cdh1-
depleted cells are hypersensitive toward DNA-damaging agents and
display reduced Rad51 foci upon IR treatment. Making use of an inte-
grated proteomics and bioinformatics approach, we identify the
DNA-end resection factor CtIP as a novel substrate of the APC/CCdh1
E3 ubiquitin ligase. CtIP–Cdh1 interaction is mediated by an evolu-
tionary conserved KEN box and is required for the downregulation
of CtIP protein levels both after mitotic exit and in late S/G2 in
response to DNA damage. U2OS cells inducibly expressing a CtIP
KEN box mutant exhibit increased DNA-end resection capacity,
which correlates with a decrease in HR and hypersensitivity to PARP
inhibition. Together, our data describe a novel regulatory role for the
APC/CCdh1 in DNA repair, at least in part by limiting CtIP-dependent
DNA-end resection activity in late S/G2 phases of the cell cycle.
Results
Cdh1 depletion provokes DNA damage and hypersensitivity to
DSB-inducing agents
To analyze the role of APC/CCdh1 in the maintenance of genome
stability, we stably suppressed Cdh1 in non-transformed, immortal-
ized human retina pigment epithelium (hTERT-RPE-1), HeLa cervi-
cal cancer, and MCF7 breast cancer cells using lentiviral shRNAs
(Fig 1A). Sustained downregulation of Cdh1 over the course of
5 days resulted in approximately twofold increase of cells in G2/M
phase accompanied by elevated levels of c-H2AX (Fig 1A–C). Also,
Cdh1 depletion resulted in upregulation of p53 in RPE-1 and MCF7
cells (Fig 1A and Supplementary Fig S1). Combined, these results
are indicative of DNA damage accumulation in Cdh1-depleted cells,
even in the absence of genotoxic agents, which is in line with obser-
vations in other cell types (Garcı´a-Higuera et al, 2008; Sigl et al,
2009; Delgado-Esteban et al, 2013; Eguren et al, 2013). We next
analyzed the distribution of cells over the various mitotic stages to
address whether the acquisition of DNA damage caused by Cdh1
downregulation translates into aberrant mitotic progression. While
Cdh1 depletion in MCF7 cells did not significantly alter the distribu-
tion of the various mitotic phases, it gave rise to a higher frequency
of bridging chromosomes in anaphase (Fig 1D). Such abnormal
chromosome segregation events are frequently observed in cells that
exhibit G2/M checkpoint or DNA repair defects (French et al, 2006;
Acilan et al, 2007; Chan et al, 2007; Laulier et al, 2011).
This prompted us to examine whether Cdh1 depletion leads to
increased sensitivity to DNA-damaging agents. Clonogenic survival
assays showed that Cdh1-depleted MCF7 cells are hypersensitive to
IR (Fig 2A). Notably, the colonies of irradiated Cdh1-depleted cells
were considerably smaller compared to control-depleted cells
(Fig 2A). In line with these results, we found that shRNA-mediated
depletion of Cdh1 reduced cell survival after treatment with doxoru-
bicin, a chemotherapeutic compound inducing DSBs (Fig 2B).
We next examined whether DSB repair mechanisms are affected
by Cdh1 depletion. Since cell cycle status significantly influences the
mode of DSB repair, we made use of the FUCCI system which allows
to specifically analyze S/G2 cells without employing synchroniza-
tion protocols (Supplementary Fig S2A) (Sakaue-Sawano et al,
2008). First, Cdh1 depletion did not affect IR-induced phosphoryla-
tion of KAP1 at S824, an early event in the DNA damage response
(Fig 2C) (White et al, 2006; Ziv et al, 2006). Interestingly, however,
Cdh1-depleted cells displayed significantly reduced numbers of
Rad51 foci at both 2 and 5 h after irradiation, without affecting
Rad51 levels (Fig 2C and D, and Supplementary Fig S2B). In
contrast, 53BP1 foci numbers remained largely unaffected by the
absence of Cdh1 (Fig 2D and Supplementary Fig S2C). Taken
together, our results demonstrate that Cdh1 ensures genome stabil-
ity, promotes survival under conditions of DNA damage, and influ-
ences the dynamics of IR-induced Rad51 foci formation, indicative
of a regulatory function of Cdh1 in HR.
Proteomic analysis of potential Cdh1 targets
We next set out to identify APC/CCdh1 substrates that contribute to
the role of Cdh1 in maintaining genome stability. To select for
potential candidates, we focused on two selection criteria. Firstly,
we screened for proteins that are downregulated when APC/CCdh1
activity is turned on after mitotic exit using quantitative mass spec-
trometry. Secondly, we analyzed the primary amino acid sequence
of each of those downregulated proteins for the presence of so-
called D-boxes and KEN boxes, through which Cdh1 recruits targets
to the APC/C (Pfleger et al, 2001; Liu et al, 2012). To identify proteins
that are degraded during the mitosis-to-G1 transition, we treated cells
with nocodazole, a reversible microtubule-depolymerizing agent that
activates the spindle assembly checkpoint, thereby causing cells to
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arrest in prometaphase. Subsequent removal of nocodazole allows
cells to synchronously exit mitosis along with APC/CCdh1 activation.
To compare protein abundance before and after mitotic exit, RPE-1
cells were grown in DMEM containing either light or heavy isotope-
labeled amino acids (Ong et al, 2002). Cells cultured in light
medium were lysed directly after nocodazole incubation, whereas
cells in heavy medium were harvested at 2.5 h after being released
from mitotic arrest (Fig 3A and B). In addition, a label-swap
experiment was performed with the SILAC labeling reversed. Cell
lysates were then mixed in a 1:1 ratio and analyzed by mass spec-
trometry. We measured relative up- or downregulation of > 3,300
proteins in G1 compared to M phase (Supplementary Data S1). To
interrogate the quality of our data set, we assessed whether specific
pathways were predominantly affected during mitotic exit. To this
end, protein entries were converted to gene entries and enrichment
was tested using Gene set enrichment analysis (GSEA) (Subramanian
et al, 2005). As expected, “cell cycle” and “mitotic” pathways
were significantly downregulated during mitotic exit (Fig 3C). In
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Figure 1. Cdh1 depletion results in genomic instability.
A RPE-1, HeLa, and MCF7 cells were infected with pLL-GFP or pLL-Cdh1 lentiviral shRNAs, and puromycin-resistant cells were harvested at 5 days after virus infection.
Immunoblotting was performed with anti-Cdh1, anti-p53, and anti-actin antibodies.
B HeLa cells treated as in (A) were harvested in ice-cold ethanol and co-stained for c-H2AX and phospho-histone H3 along with propidium iodide before analysis by
flow cytometry. Plots of at least 10,000 events are shown. Percentages indicate average amounts of G2/M cells, phospho-histone H3-positive cells, and c-H2AX-
positive cells.
C RPE-1, HeLa, and MCF7 cells were treated as in (B), and averages and standard deviations for three independent experiments are indicated for G2/M content,
phospho-histone H3-positive cells, and c-H2AX-positive cells.
D MCF7 cells were infected with the indicated shRNA viruses, grown on glass coverslips and stained with DAPI. From three experiments, at least 200 mitoses were
scored per condition. Anaphase figures were scored separately for the presence of lagging chromosomes. Averages and standard deviations are indicated.
Representative examples are indicated.
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contrast, proteins involved in translation and transcription were
upregulated, in line with observations that chromatin is
re-established after mitosis and that translational and transcriptional
processes are inactive during mitosis and need to be re-initiated
upon mitotic exit (Fig 3C) (Prescott & Bender, 1963; Bonneau &
Sonenberg, 1987).
Our data set for proteins that were considerably downregulated
after mitotic exit included various known APC/CCdh1 targets such as
p15-PAF, cyclin B1, Plk1, UbcH10, Aurora A, and Aurora B (Fig 3D
and Supplementary Fig S3A) (Pfleger et al, 2001; Littlepage &
Ruderman, 2002; Taguchi et al, 2002; Lindon & Pines, 2004; Rape &
Kirschner, 2004; Nguyen et al, 2005; Stewart & Fang, 2005; Emanuele
et al, 2011). As expected, both KEN box and D-box motifs were
significantly enriched in proteins downregulated during mitotic exit
compared to the entire proteomic data set (Fig 3E) (Liu et al, 2012).
When we applied “DNA damage response” (see Supplementary
Table S1 for list of Gene Ontology terms) as a functional criterion
for proteins downregulated during mitotic exit containing a
conserved destruction motif, we discovered various proteins
involved in the maintenance of genomic integrity including Rif1,
Smc5, Mdc1, CtIP, and Top2A (Fig 3F). DNA topoisomerase 2-alpha
was recently discovered as a novel Cdh1 substrate (Eguren et al,
2014). Interestingly, Rif1 has been reported to act as a 53BP1 effec-
tor protein, antagonizing the role of BRCA1 in promoting CtIP-
dependent resection and HR (Kumar & Cheok, 2014). However,
sequence analysis revealed that none of the predicted functional
destruction motifs in human Rif1 were evolutionary conserved,
whereas both putative KEN boxes in human CtIP were highly
conserved in vertebrates (Supplementary Fig S3). Therefore, we
decided to focus on the DNA-end resection factor CtIP as a potential
target of the APC/CCdh1 involved in the maintenance of genomic
integrity.
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Figure 2. Cdh1 depletion sensitizes to DNA-damaging agents and affects recruitment of DNA repair components.
A MCF7 cells were infected with the indicated shRNAs and selected with puromycin. pLL-GFP- or pLL-Cdh1-infected MCF7 cells were plated in 6-well plates and
subsequently irradiated with the indicated amounts of ionizing radiation. Surviving colonies were stained, and relative amounts of colony numbers compared to non-
irradiated cells are shown. Averages and standard deviations of three independent experiments are shown.
B pLL-GFP- or pLL-Cdh1-infected MCF7 cells were plated in 96-well plates and subsequently treated with the indicated amounts of doxorubicine for 4 days. Cellular
viability was assessed using MTT conversion, and untreated cells were used as a reference. Averages and standard deviations of three independent experiments are
shown.
C At 48 h after siRNA transfection, U2OS-FUCCI cells were irradiated (2 Gy). At 2 or 5 h after treatment, whole-cell extracts were prepared and analyzed by Western
blotting with the indicated antibodies.
D U2OS-FUCCI cells treated as in (C) were prepared for 53BP1 and Rad51 immunofluorescence. Graphs show the amounts of 53BP1 or Rad51 foci in S/G2 cells. At least
120 cells from three independent experiments were counted for each condition, and data are presented as box plots with whiskers representing the minimal and
maximal values. Unpaired Student’s t-tests (two-sided) were done to compare control-depleted and Cdh1-depleted conditions. Representative images can be found in
Supplementary Fig S2B and C.
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Figure 3. A combined proteomics/bioinformatics approach to identify potential APC/CCdh1 substrates.
A Overview of mass spectrometry analysis of changes in protein abundance during mitotic exit. RPE-1 cells were grown in “light” or “heavy” SILAC media and treated
with nocodazole. Mitotic cells were obtained by shake-off and were directly lysed or replated in nocodazole-free medium and lysed after 2.5 h. Alternatively,
treatments were swapped (“reverse SILAC”). Cell lysates were mixed 1:1 and analyzed by mass spectrometry.
B RPE-1 cells were treated and harvested in parallel to (A) and were stained for phospho-histone H3/Alexa-488.
C Gene set enrichment analysis (GSEA) of SILAC results. Indicated pathways are significantly affected during mitotic exit.
D Log2-transformed ratios are indicated for the > 3,300 proteins that were identified both in forward and in reverse SILAC. Negative ratios indicate downregulation
during mitotic exit. Established APC/CCdh1 targets are indicated in red.
E GPS-ARM software was used to identify D-box or KEN box sequences in mass spectrometry hits. GSEA was used to assess enrichment for destruction motif-
containing proteins within downregulated proteins.
F Venn diagram indicating proteins that are downregulated at least twofold, contain any destruction motif, and belong to the “DNA damage response/DNA repair”
gene set.
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CtIP is a substrate of APC/CCdh1 during mitotic exit
Confirming our mass spectrometry data, we observed that CtIP
protein levels decreased when RPE-1 cells exit mitosis following
release from a nocodazole-induced prometaphase arrest (Fig 4A–C).
Notably, CtIP downregulation followed a pattern similar to that of
Plk1, a known APC/CCdh1 substrate (Fig 4A–C) (Lindon & Pines,
2004). This was not due to nocodazole-induced microtubule depoly-
merization, as cells released from a mitotic block induced by Eg5
inhibition showed a similar behavior with regard to CtIP levels
(Supplementary Fig S4A). Likewise, when cells were enriched at the
G2/M transition using the reversible Cdk1 inhibitor RO-3306, and
subsequently followed during exit from mitosis, we observed that
CtIP protein levels gradually decreased (Fig 4D). Interestingly,
under these different synchronization conditions, we repeatedly
noticed that CtIP migrates much slower in mitotic cells compared to
G1 cells. We find that this shift is mainly attributed to phosphoryla-
tion, but further work is needed to explore whether there is a func-
tional interplay between CtIP phosphorylation and stability during
exit from mitosis (Supplementary Fig S4B).
In line with the APC/CCdh1 targeting CtIP for proteasomal degra-
dation, we observed increased CtIP protein levels after transfecting
RPE-1 and U2OS cells with Cdh1 siRNA oligos (Fig 4E and Supple-
mentary Fig S4C and D), which was not due to altered cell cycle
distribution profiles (Supplementary Fig S4C and D). Analogously,
treatment of asynchronously growing RPE-1 cells with the small
molecule APC/C inhibitor proTAME (Zeng et al, 2010) stabilized
CtIP as well as Plk1, albeit not to the same extent as treatment
with the proteasome inhibitor MG-132 (Fig 4F). Importantly, both
MG-132 and proTAME clearly blocked CtIP and Plk1 degradation
after cells synchronously exit mitosis and enter G1 phase (Fig 4G
and Supplementary Fig S4E). Taken together, our findings indicate
that CtIP is targeted by APC/CCdh1 during mitotic exit.
CtIP interacts with Cdh1 through a conserved KEN box
CtIP contains two conserved KEN box motifs, which are believed to
be recognized exclusively by APC/CCdh1 (Pfleger & Kirschner, 2000),
but only the second one between amino acids 467 and 469 matches
the recently reported consensus KEN box sequence ([D/N]-K-E-N-x-x-P)
(Fig 5A) (He et al, 2013). To test whether any of the two KEN box
motifs are functional, HEK293T cells were transfected with HA-Cdh1,
along with FLAG-CtIP mutated in one or both KEN box motifs.
Whereas CtIP-wt and CtIP-K179A are efficiently co-immunoprecipi-
tated with HA-Cdh1, mutating the second putative KEN box in CtIP
(K467A) abolished its interaction with Cdh1 (Fig 5B). Further-
more, only GFP-CtIP-wt, but not GFP-CtIP-K467A, was efficiently
co-immunoprecipitated with endogenous Cdh1 (Supplementary Fig
S5A). To strengthen these observations, we subjected HeLa nuclear
extracts to GST-CtIP pull-down assays and found that endogenous
Cdh1 interacts with wild-type recombinant CtIP, but not with the
CtIP-K467A mutant (Fig 5C). Moreover, this was unlikely due to
improper protein folding of bacterially expressed GST-CtIP-K467A,
as the mutant full-length protein was still able to pull-down Mre11
(Fig 5C). These results were confirmed using a CtIP fragment
covering both KEN box motifs (166–487), indicating that the coiled
coil domain (45–160) and the conserved Sae2-like C-terminal
domain (790–897) of CtIP are not required for Cdh1 interaction
(Fig 5A and C).
The APC/C is a multi-subunit E3 ubiquitin ligase that, once acti-
vated by either Cdc20 or Cdh1, mediates ubiquitin- and proteasome-
dependent degradation of key cell cycle regulatory proteins (Peters,
2006). Since CtIP was recently shown to be poly-ubiquitylated and
degraded by the proteasome (Steger et al, 2013), we next addressed
whether Cdh1 may promote CtIP ubiquitylation. To this end, we
transfected His-ubiquitin into HEK293 cells inducibly expressing
GFP-CtIP and analyzed the level of CtIP ubiquitylation after Ni-NTA
pull-down. Remarkably, depletion of Cdh1 using two independent
siRNAs severely impaired CtIP ubiquitylation (Fig 5D). Further-
more, the conjugation of ubiquitin chains was largely abolished in
the CtIP-K467A KEN box mutant compared to CtIP-wt, further indi-
cating that CtIP is a substrate of APC/CCdh1 (Fig 5E). To test whether
the conserved KEN box is required for CtIP degradation during
mitotic exit, we performed time-lapse fluorescence microscopy with
U2OS cells harboring siRNA-resistant inducible GFP-tagged CtIP-wt
or CtIP-K467A (Fig 5F). These cell lines progressed through the cell
cycle with similar kinetics and expressed comparable levels of GFP-
tagged CtIP upon doxycycline addition (Supplementary Fig S5B).
Importantly, whereas the fluorescence intensity of nuclear CtIP-wt
slowly decreased after exit from mitosis, CtIP-K467A levels remained
relatively constant throughout the entire time course (Fig 5F).
Combined, our data suggest that CtIP interacts with Cdh1 through a
conserved KEN box motif and this interaction promotes CtIP poly-
ubiquitylation and degradation in an APC/CCdh1-dependent manner.
▸Figure 4. CtIP is a substrate of the APC/CCdh1 during mitotic exit.A RPE-1 cells were left untreated (asynchronous, “AS”) or treated with nocodazole for 16 h. Mitotic cells were obtained by shake-off and replated in nocodazole-free
medium for indicated time periods. Cells were stained for phospho-histone H3 and propidium iodide, and at least 10,000 events were analyzed by flow cytometry.
Averages and standard deviations of three experiments are shown.
B Same cells as in (A) were immunoblotted for the indicated proteins.
C Western blots as shown in (B) were quantified, and averages and standard deviations of three independent experiments are shown.
D RPE-1 cells were treated for 18 h with the Cdk1 inhibitor RO-3306 (5 lM) to enrich for G2 cells. Subsequently, cells were washed 3 times with warm culture medium,
and 1 h later, mitotic cells were collected by mitotic shake-off (t = 0 h). At the indicated time points after replating, cells were harvested and further analyzed as in
(A) and (B).
E Asynchronously growing RPE-1 cells were transfected with indicated siRNAs for 48 h and processed for immunoblotting with the indicated antibodies. Western blots
were quantified, and averages and standard deviations of three independent experiments are shown.
F RPE-1 cells were cultured for 3 h in proTAME (12 lM), MG-132 (5 lM), or solvent controls. Whole-cell lysates were immunoblotted for the indicated proteins (left
panel). Average Western blot intensities and standard deviations of three independent experiments are shown (right panel).
G Mitotic RPE-1 cells were obtained by mitotic shake-off after nocodazole treatment. Cells were replated, and after 1 h, proTAME (12 lM) or MG-132 (5 lM) or solvent
was added to the culture medium. At 1 or 2.5 h after treatment, cells were harvested for Western blot analysis with the indicated antibodies. Western blots of a
representative experiment are indicated (left panel). In parallel, cells were fixed in ethanol and stained for phospho-histone H3 and propidium iodide, and at least
10,000 events were analyzed by flow cytometry. Averages and standard deviations of three independent experiments are shown (right panel).
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APC/C promotes CtIP degradation in response to DSBs
Since APC/CCdh1 has been described to be activated in G2 phase after
DNA damage (Sudo et al, 2001; Bassermann et al, 2008), we decided
to investigate whether CtIP is also targeted by the APC/C under these
conditions. To this end, we synchronized U2OS cells at the G1/S
transition using a single thymidine treatment and then allowed cells
to re-enter the cell cycle. At 7 h after the release, G2-enriched cells
were irradiated at low (2 Gy) or high dose (10 Gy) and analyzed
after 2 and 5 h by Western blotting (Fig 6A). Whereas CtIP levels
only slightly decreased at 5 h after 2 Gy, CtIP downregulation in
response to 10 Gy occurred to an extent that was similar to that
of Claspin, a previously reported APC/CCdh1 substrate (Fig 6B)
(Bassermann et al, 2008). These changes did not represent post-
mitotic degradation of CtIP, as judged by comparable cell cycle
profiles (Fig 6A). Importantly, CtIP and Claspin levels were partially
restored when proTAME was added to the cells immediately after IR
(Fig 6B), indicating that the APC/C is responsible for CtIP degrada-
tion in G2-irradiated cells. Similar results were obtained after treat-
ment of G2-enriched cells with doxorubicin (Supplementary Fig S6A
and B). Interestingly, we noticed that proTAME treatment led to an
increase in RPA2 phosphorylation following IR (Fig 6B, lane 7), while
other DNA damage signaling events including Chk1 and Chk2 phos-
phorylation remained largely unaffected. In line with a requirement
for the APC/C in CtIP degradation after DNA damage in G2 cells,
ubiquitylation of endogenous CtIP in response to IR was significantly
reduced in presence of proTAME (Fig 6C).
To strengthen these findings, we monitored GFP-CtIP-wt fluores-
cent intensity following irradiation of G2 cells using live-cell imag-
ing. Consistent with our Western blot data, CtIP levels drop to
approximately 50% starting at 4 h after IR (Fig 6D and Supplemen-
tary Fig S6C). Also in this case, the observed CtIP downregulation
was not due to post-mitotic degradation, since none of the analyzed
cells entered mitosis during the entire time-lapse experiments, most
likely due to a strong G2-arrest produced by 10 Gy (data not
shown). In line with our previous observation, GFP-CtIP-wt levels
in cells co-treated with proTAME remained constant throughout the
analyzed time frame, supporting our hypothesis that the APC/C is
required for CtIP downregulation in response to DNA damage in G2
cells (Fig 6D and Supplementary Fig S6C). Altogether, these data
suggest that CtIP is degraded after DSB induction in G2 and that this
regulatory mechanism is dependent on APC/C activity.
CtIP–Cdh1 interaction is required for CtIP downregulation after
DNA damage and clearance of IR-induced CtIP foci
Having established that CtIP is degraded in an APC/C-dependent
manner in response to DNA damage, we wanted to test whether this
requires physical interaction between Cdh1 and CtIP. Quantitative
live-cell imaging revealed that a functional KEN box is crucial for
IR-induced downregulation of CtIP, since GFP-CtIP-K467A levels
remained stable throughout the entire time course (Fig 7A and B).
Strikingly, we observed that CtIP-K467A IR-induced foci (IRIF)
persisted, whereas CtIP-wt IRIF were resolved over time, indicating
that APC/CCdh1 facilitates the spatiotemporal release of CtIP from
damaged chromatin (Fig 7C). Analysis of GFP-CtIP localization in
response to laser micro-irradiation further confirmed that both
CtIP-wt and CtIP-K467A are efficiently recruited to microlaser-
generated DSB tracks, and overlap with c-H2AX-decorated
chromatin (Supplementary Fig S7A).
To further investigate the role of Cdh1–CtIP interaction in
response to DNA damage, we isolated monoclonal cell lines,
inducibly expressing siRNA-resistant GFP-CtIP-wt and GFP-CtIP-
K467A. Importantly, expression of GFP-CtIP-wt rescued DNA-end
resection defects caused by CtIP depletion, as judged by the
restoration of RPA2 phosphorylation at S4/S8 in response to IR
treatment (Supplementary Fig S7B) (Sartori et al, 2007). The DNA-
end resection capacity of CtIP was previously shown to be
required for the maintenance of IR-induced G2 arrest (Kousholt
et al, 2012). In line with this report, depletion of CtIP did not
interfere with checkpoint initiation, but did result in defective
checkpoint maintenance (Supplementary Fig S7C). Notably,
expression of either GFP-CtIP-wt or GFP-CtIP-K467A rescued the
checkpoint maintenance defect (Supplementary Fig S7C), suggest-
ing that CtIP-K467A is proficient in DNA-end resection. In addi-
tion, we did not find any significant defects in initiation and
maintenance of the IR-induced G2 checkpoint upon Cdh1 depletion
(Supplementary Fig S7D).
In agreement with CtIP-K467A mutant cells being checkpoint
proficient, irradiation resulted in robust activation of ATM and
ATR, as assessed by Chk2 and Chk1 phosphorylation, respec-
tively (Fig 7D). Moreover, both CtIP-wt and CtIP-K467A were
able to promote RPA2 phosphorylation, with the KEN
box mutant being slightly more efficient than the wt, whereas
expression of the resection-deficient CtIP-T847A mutant largely
◀ Figure 5. CtIP interacts with Cdh1 through a conserved KEN box.A Schematic representation of human CtIP protein with its coil-coiled domain (45–160), Sae2-like domain (790–897), and putative KEN boxes (179–181 and 467–469).
Conservation of KEN box at 467 is shown for the indicated species.
B HEK293T cells were transfected with HA-Cdh1 in combination with indicated FLAG-CtIP plasmids. Cells lysates were used for anti-HA immunoprecipitations. Western
blotting was performed with the indicated antibodies for whole-cell lysate or immunoprecipitations.
C HeLa nuclear extract (NE) was incubated with GST fusion proteins with the indicated full-length (1–897) CtIP variants or CtIP fragment (166–487) variants. GST pull-
downs were immunoblotted for Mre11 and Cdh1.
D HEK293 Flp-In T-REx cells were induced to express GFP-CtIP-wt using doxycycline and were transfected with His-tagged ubiquitin (“His-Ub”) along with control
siRNA or Cdh1 siRNA. Before lysis, cells were treated with proteasome inhibitor MG-132 for 4 h. Cell lysates were used for Ni-NTA precipitations. Total cell lysates
(“input”) and Ni-NTA pull-downs (“PD”) were immunoblotted for the indicated proteins.
E HEK293 Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-K467A and transfected with His-tagged ubiquitin (“His-Ub”), and treated with
proteasome inhibitor MG-132 for 4 h. Cell lysates were subsequently used for Ni-NTA pull-down. Total cell lysates (“input”) and Ni-NTA pull-downs (“PD”) were
immunoblotted for the indicated proteins.
F U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-K467A and were transfected with control siRNA or siCtIP. Cell lysates were processed for
immunoblotting for CtIP and actin (upper right panel). U2OS cells were then imaged every 5 min for GFP expression or phase contrast using live-cell microscopy.
Representative stills from live-cell imaging are shown, in which anaphase onset was used as a reference time point (left panels). Quantifications of the average
nuclear GFP signal from time-lapse movies are indicated for GFP-CtIP-wt (n = 12) and GFP-CtIP-K467A (n = 18) (lower right panel).
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Figure 6. CtIP is degraded in response to DNA damage in G2 phase in an APC/C-dependent manner.
A U2OS cells were synchronized using a single thymidine block with 2 mM thymidine for 18 h. Seven hours after release, cells enriched in G2 phase were either fixed
directly (lane 1) or exposed to low (2 Gy) or high dose (10 Gy) of IR and harvested at the indicated time points following irradiation. Where indicated, cells were
treated with the APC inhibitor proTAME (20 lM) immediately after irradiation. Cells were stained with DAPI and analyzed by flow cytometry.
B Cells were treated as in (A) and lysed in RIPA buffer for immunoblotting with the indicated antibodies. The anti-RPA2 blot was reprobed with anti-pRPA2-S4/S8
antibody. The arrow indicates leftover signals of the unmodified RPA2 protein. The asterisk indicates hyperphosphorylated RPA2.
C HEK293 cells were transfected with HA-tagged ubiquitin (“HA-Ub”). Thirty hours post-transfection, cells were synchronized using a single thymidine block with 2 mM
thymidine for 18 h. Five hours after the release, cells enriched in late S/G2 phase were either lysed directly (lane 1), or further incubated for 5 h in the presence of
CDK1 inhibitor RO-3306 (9 lM) to keep cells in G2 (lane 2), or irradiated with 10 Gy in the absence (lane 3) or presence (lane 4) of the APC inhibitor proTAME (20 lM)
and lysed after 5 h. Where indicated, cells were treated with MG-132 (20 lM) for 5 h before lysis. Samples were then further processed for immunoprecipitation
using a polyclonal anti-CtIP antibody as indicated in Materials and Methods. Cell cycle profiles of corresponding samples are indicated on the right.
D U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt and transfected with CtIP siRNA. Cells were subsequently synchronized by thymidine incubation for
24 h and released from thymidine for 8 h. At 8 h after release, cells were treated with DMSO or proTAME (12 lM), subsequently irradiated with 10 Gy, and imaged
using fluorescence time-lapse microscopy. Representative stills of GFP and DIC movies are presented in Supplementary Fig S6C. Averages and standard deviations of
total nuclear GFP intensity are indicated from 9 and 12 movies for DMSO-treated and proTAME-treated cells, respectively.
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abolished RPA2 phosphorylation (Fig 7D) (Huertas & Jackson,
2009). These data suggest that CtIP–Cdh1 interaction is not
required for DNA-end resection, but may control the proper
timing of resection.
The CtIP–Cdh1 interaction facilitates homology-directed repair
The above findings prompted us to test whether CtIP–Cdh1 interac-
tion plays a role in DSB repair. To this end, we analyzed the repair
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Figure 7. CtIP–Cdh1 interaction is not required for CtIP recruitment to sites of DNA damage and initiation of DNA-end resection.
A U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-K467A and transfected with CtIP siRNA. Cells were subsequently synchronized by
thymidine incubation for 24 h and released for 8 h. GFP-CtIP-wt and GFP-CtIP-K467A were expressed to similar degree, and expression of GFP-CtIP-wt or GFP-CtIP-
K467A did not alter cell cycle progression as judged by flow cytometry (Supplementary Fig S5B). Cells were then irradiated with 10 Gy and imaged using fluorescence
time-lapse microscopy. Representative stills are indicated for GFP and DIC images.
B Quantifications of time-lapse movies from (A). Averages and standard deviations of total nuclear GFP intensity are indicated from 12 movies for each cell line.
C In the same experiment as described in (A), numbers of GFP-CtIP foci per nucleus were counted and plotted as a percentage of GFP-CtIP foci at the start of imaging.
Averages and standard deviations of 15 movies per cell line are indicated.
D U2OS Flp-In T-REx clones stably expressing doxycycline-inducible GFP-CtIP-wt, GFP-CtIP-T847A, and GFP-CtIP-K467A were transfected with siCtIP. At 24 h post-
transfection, cells were cultivated in the absence or presence of doxycycline. At 48 h post-transfection, cells were mock-treated or harvested at the indicated time
points following irradiation (10 Gy). Whole-cell lysates were immunoblotted using the indicated antibodies.
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of I-SceI-induced DSBs in HEK293 cell lines containing two different
reporters measuring HR (DR-GFP) and total NHEJ (EJ5-GFP). As
shown previously, CtIP depletion interfered with HR, and led to a
slight increase in total NHEJ (Fig 8A and B) (Bennardo et al, 2008).
Importantly, these effects could be rescued by expression of siRNA-
resistant FLAG-CtIP-wt (Fig 8A and B). Interestingly, expression of
the K467A mutant did not rescue HR, but caused a similar decrease
as compared to the DNA-end resection-defective T847A mutant
(Fig 8A and B). Surprisingly, unlike T847A, we observed that
expression of K467A does not lead to a significant increase in
total NHEJ (Fig 8C). The observation that CtIP-K467A impaired
homology-directed repair but does not result in compensation
through NHEJ, suggested a dominant negative effect of the KEN box
mutant. To test this hypothesis, FLAG-CtIP constructs were transfected
into HEK293 DR-GFP cells without siRNA-mediated depletion of
endogenous CtIP. Indeed, expression of CtIP-K467A caused a reduc-
tion in HR, whereas expression of CtIP-wt or CtIP-T847A did not
significantly alter HR (Fig 8D). Taken together, these results suggest
that abolishing the interaction between CtIP and Cdh1 does not inter-
fere with the initiation of DNA-end resection, which would otherwise
increase NHEJ efficiency. Instead, after resection has been initiated,
the CtIP–Cdh1 interaction appears to be required for the proper
execution of downstream HR events.
Defective HR was previously shown to result in increased
sensitivity to PARP inhibition (Bryant et al, 2005; Farmer et al,
2005). In line with a defect in HR, we observed that cells inducibly
expressing GFP-CtIP-K467A showed elevated sensitivity to the PARP
inhibitor olaparib, although not as pronounced as in GFP-CtIP-
T847A mutant cells (Fig 8E). Notably, depletion of Cdh1 also
resulted in an elevated sensitivity to PARP inhibition (Fig 8E).
However, GFP-CtIP-K467A-expressing cells did not display hypersen-
sitivity to IR or doxorubicin treatment, indicating that the inability of
Cdh1 to interact with CtIP cannot explain all phenotypic responses
associated with Cdh1 loss in combination with DNA damage
(Supplementary Fig S8A–C).
Besides decreased DNA-end resection capacity, also excessive or
temporally unrestricted resection may potentially impair HR. Since
we have observed that CtIP is targeted by the APC/C for proteaso-
mal degradation after DNA damage in G2, we monitored DNA-end
resection in wt and K467A mutant cells that had been synchronized
in G2 prior to IR (Fig 8F and Supplementary Fig S8D). Clearly,
expression of GFP-CtIP-K467A resulted in elevated levels of RPA2
phosphorylation at S4/S8, indicative of hyper-resection. This
matched our earlier observation of elevated levels of RPA2 phos-
phorylation upon proTAME treatment in irradiated cells (Fig 6B).
Remarkably, increased RPA2 phosphorylation in GFP-CtIP-K467A-
expressing cells coincided with lower amounts of Rad51 being
recruited to damaged chromatin (Fig 8F). Combined, these data
suggest that CtIP–Cdh1 interaction is involved in limiting DSB resec-
tion, which probably allows correct assembly of Rad51–ssDNA
nucleoprotein filaments, to facilitate HR.
Discussion
The response to DSBs is tightly regulated during the cell cycle. As a
consequence, deregulated cell cycle control may lead to aberrant DSB
repair and ensuing genomic instability. An example thereof is
provided by the APC/CCdh1 cell cycle regulator, as genetic inactivation
of Cdh1 in either mouse embryonic fibroblasts or primary human
cells has been shown to cause elevated levels of DNA damage and
chromosomal instability. We could recapitulate these findings in
Cdh1-depleted human cell lines of different origins. Moreover, we
were able to extend these findings and demonstrate that depletion of
Cdh1 results in hypersensitivity to DSB-inducing agents and nega-
tively affects Rad51 IRIF formation. Concerning potential APC/C
substrates responsible for these effects, Rhp54 (the fission yeast ortho-
log of Rad54) and Rad17 were shown to be degraded by the APC/C
(Trickey et al, 2008; Zhang et al, 2010). However, when Rad54 was
investigated in other species, no APC/C-dependent degradation was
observed, and the degradation of Rad17 by the APC/C appeared to be
UV-induced and appeared to control checkpoint duration rather than
DNA repair. Finally, Cdh1 was reported to control the duration of the
G2 cell cycle arrest in response to DSBs by targeting Polo-like kinase 1
(Plk1) for proteolytic degradation (Wa¨sch & Engelbert, 2005; Basser-
mann et al, 2008; Engelbert et al, 2008). So far, it remained elusive,
however, whether the APC/CCdh1 also contributes to the regulation of
DSB repair.
Using a proteomics analysis of mitotic exit combined with bio-
informatics analysis of the presence of KEN and D-box motifs, we
have identified a number of candidate APC/CCdh1 substrates. Several
of the putative Cdh1 targets play key roles in the regulation of DSB
repair, including Rif1, MDC1, SMC5, and CtIP. Detailed in silico
analysis of multiple protein sequences for the conservation of puta-
tive KEN and D-box motifs guided us to focus on CtIP as a previ-
ously unrecognized APC/CCdh1 substrate. Human CtIP contains two
conserved KEN box motifs, but only the second KEN box strongly
matches the consensus sequence recently proposed by Barford and
colleagues (He et al, 2013) and is required for Cdh1–CtIP interac-
tion. In addition to being targeted by the APC/CCdh1 for proteasomal
degradation in G1, we discovered that CtIP protein levels are
controlled by the APC/CCdh1 prior to mitotic entry in response to
DSBs. Concerning the activation of the APC/CCdh1 in response to
DNA damage in G2 cells, we noted that APC/C
Cdh1 activation is
achieved most efficiently after high levels of DNA damage. This
implies that especially under conditions provoking high amounts of
DNA damage, such as after chemotherapy or radiotherapy, the
APC/CCdh1 may acquire new functions, which under these circum-
stances may determine cell fate and genomic integrity.
Due to its crucial role in initiating DNA-end resection, CtIP is
essential for homology-directed repair of DSBs (Sartori et al, 2007;
Bennardo et al, 2008). DNA-end resection dictates the choice
between HR and NHEJ and is thus proposed to be tightly regulated
during the cell cycle (Ferretti et al, 2013). For instance, CtIP phos-
phorylation at T847 by cyclin-dependent kinases represents a key
step toward the commencement of DNA-end resection and, conse-
quently, a CtIP-T847A mutant abrogates HR (Huertas & Jackson,
2009). Here, we show that a CtIP KEN box mutant (K467A) compro-
mises HR to a similar extent as the T847A mutant, indicating that
the interaction between Cdh1 and CtIP facilitates HR. NHEJ requires
only very limited DSB processing and is therefore not suitable for
repairing DSBs which have undergone extensive resection. In other
words, NHEJ can only compensate for HR in cells that are defective
in DNA-end resection (Shibata et al, 2011). This is in line with our
results showing that CtIP-T847A results in higher levels of NHEJ. In
contrast, we find that CtIP-K467A does not lead to a concomitant
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Figure 8. CtIP–Cdh1 interaction limits DNA-end resection and is required for homologous recombination repair.
A–D HEK293 cell lines stably harboring DNA repair reporters for HR (DR-GFP; A, B, and D), or NHEJ (EJ5-GFP; C) were transfected with control siRNA, or with CtIP siRNA
in combination with the indicated siRNA-resistant FLAG-CtIP plasmids. After 24 h, cells were transfected with the I-SceI-expression plasmid, and 48 h later, GFP
positivity was assessed by flow cytometry. Averages and standard deviations of three independent experiments are indicated. In (B), representative Western blots
for (A) are shown. Lysates were immunoblotted using anti-CtIP and anti-Mre11 antibodies. HEK293-DR-GFP cells (D) were co-transfected with the indicated siRNA-
resistant FLAG-CtIP plasmids together with the I-SceI-expression plasmid. 48 h later, GFP positivity was assessed by flow cytometry.
E U2OS-GFP-CtIP-wt, U2OS-GFP-CtIP-K467A, or U2OS-GFP-CtIP-T847A clones were transfected with siCtIP and were induced to express GFP-CtIP-wt, GFP-CtIP-K467,
or GFP-CtIP-T847A at 24 h after transfection. Cells were replated for clonogenic survival 48 h after transfection and treated with the indicated olaparib
concentrations. Alternatively, U2OS cells were transfected with siCdh1#1 and replated for clonogenic survival at 48 h after transfection in the presence of the
indicated concentrations of olaparib. Standard error of the means of three experiments is shown. Statistical analysis was done using Student’s t-tests (n.s. indicates
not significant).
F U2OS Flp-In T-REx clones stably expressing doxycycline-inducible GFP-CtIP-wt, and GFP-CtIP-K467A were transfected with siCtIP, and protein expression was
simultaneously induced by adding doxycycline. After 6 h, cells were synchronized using a single thymidine block for 18 h. Seven hours after release, cells enriched
in S/G2 phase (see Supplementary Fig S8D for cell cycle profiles) were mock-treated or harvested at the indicated time points following irradiation. RIPA whole-cell
lysates or chromatin-enriched fractions were immunoblotted using the indicated antibodies.
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increase in NHEJ, suggesting that resection has occurred in those
cells. In fact, CtIP-K467A-expressing cells irradiated in G2 display
even heightened levels of DNA-end resection compare to CtIP-wt
cells, but are partially impaired in promoting efficient Rad51 recruit-
ment to damaged chromatin, which is similar to what we observed
in Cdh1-depleted cells. Moreover, reduced HR efficiency of K467A
mutant cells is in line with our data of decreased survival upon
PARP inhibition.
Combined, our data support a model in which APC/CCdh1 activity
is involved in negatively regulating the stability of CtIP both after
mitotic exit in unperturbed cells and after DNA damage in G2
(Fig 9). Moreover, we speculate that the APC/CCdh1 is required at a
late stage within the HR process, after initiation of resection has
occurred and NHEJ is no longer an option for DSB repair. One possi-
bility is that APC/CCdh1 mediates clearance of CtIP IRIF through
ubiquitin-mediated degradation, thereby limiting resection to
amounts of ssDNA that can be handled by the downstream recombi-
nation machinery. A similar mechanism has been recently reported
by Choi et al for the regulation of nuclear PTEN, in which Cdh1
promotes the removal of PTEN from chromatin during mitotic exit
(Choi et al, 2014).
Our observations that Rad51 IRIF are decreased in Cdh1-depleted
G2 cells, that CtIP-K467 IRIF persist much longer, and that Rad51
loading onto damaged chromatin is compromised in G2-enriched
cells expressing the CtIP KEN box mutant are in line with a role for
APC/CCdh1-dependent CtIP degradation in controlling HR. In its role
of keeping DNA-end resection in check, the APC/CCdh1 may play a
similar function in G1 and G2. In response to DNA breaks in G1 cells,
the end resection machinery cannot be activated due to lack of CDK
activity. In this context, APC/CCdh1-mediated degradation of CtIP
may serve as a backup mechanism to prevent unscheduled end
resection. In G2 cells, on the other hand, end resection is required for
error-free DSB repair by HR. Here, APC/CCdh1-mediated degradation
of CtIP, after initial resection has been performed, may be required
to limit end resection to levels that optimally facilitate HR repair.
Materials and Methods
Cell culture
hTERT-immortalized retinal pigment epithelium (RPE-1), U2OS,
U2OS-FUCCI, and HEK293T cells were grown in DMEM (Gibco, Life
Technologies). MCF7 cells were cultured in RPMI (Gibco, Life Tech-
nologies). HeLa cells were cultured in DMEM/Ham’s F12 (1:1)
medium (Gibco, Life Technologies). All culture media were supple-
mented with 10% fetal calf serum (FCS), 100 units/ml penicillin,
and 100 lg/ml streptomycin. U2OS and HEK293 Flp-In T-REx cells
were grown in DMEM supplemented with 10% Tet system approved
FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, 125 lg/ml
hygromycin B, and 12.5 lg/ml blasticidin S.
IR was given using a CIS international/IBL 637 irradiator
equipped with a cesium137 source (dose rate: 0.01083 Gy/s), or
using a Faxitron X-ray device. For serum starvation experiments,
RPE-1 cells were initially plated in medium containing 10% FCS and
were washed with phosphate-buffered saline (PBS) at 24 h after
plating and subsequently cultured without serum for another 24 h.
After serum starvation, serum was added to a final concentration of
20%. At the time of serum addition, bromodeoxyuridine (BrdU) was
added to a final concentration of 10 lM to measure replication
onset. If indicated, cells were treated with 5 lM of the proteasome
inhibitor MG-132 (Sigma-Aldrich, St. Louis, MO), 250 nM of the
microtubule polymerization inhibitor nocodazole (Sigma-Aldrich),
5 lM of the Eg5 inhibitor S-trityl-L-cysteine (STLC, Sigma-Aldrich),
5 lM of the Cdk1 inhibitor RO-3306 (Axon Medchem, Groningen,
the Netherlands), or with the APC/C inhibitor proTAME (Zeng et al,
2010) at a final concentration of 12 or 20 lM. ProTAME was kindly
provided by Randy King, Harvard Medical School, Boston MA, or
obtained from Boston Biochem.
Generation of stable GFP-CtIP cell lines
The Flp-In T-REx system (Invitrogen, Life Technologies) was used to
generate cell lines stably expressing different siRNA-resistant
GFP-CtIP constructs in an inducible manner. The GFP-CtIP-containing
pcDNA5/FRT/TO vector and the Flp recombinase expression plas-
mid pOG44 were mixed in a 1:9 ratio and transfected into Flp-In
T-REx 293 (Invitrogen, Life Technologies) and Flp-In T-REx U2OS
(a kind gift of Daniel Durocher, University of Toronto) cells using
APC/C
Cdh1p
p
p
CtIP
APC/C
Cdh1
G1
M
G2
S
unperturbed 
cell cycle
CtIP
resection
APC/C
Cdh1
CtIP
Ub
Ub
Ub
limitation of DNA-end
resection
CtIP
Ub
Ub
Ub
HR
NHEJ
Figure 9. Model of cell cycle- and DNA damage-dependent regulation of
CtIP by the APC/CCdh1.
The central area represents unperturbed cell cycle, when CtIP is degraded after
mitotic exit by the APC/CCdh1. Cells in G0/G1 lack CDK activity, which precludes
phosphorylation and consequent activation of CtIP. Post-mitotic CtIP
degradation by the APC/CCdh1 E3 ubiquitin ligase may contribute to prevent
unscheduled DNA-end resection in G0/G1 phase. In response to DSBs in S/G2
phase, CtIP promotes DNA-end resection to facilitate HR repair. In response to
high levels of DSBs, CtIP is initially recruited to DSBs to resect DNA ends and
promote HR repair. In a late response to high levels of DNA damage, the
APC/CCdh1 promotes ubiquitin-dependent proteolysis of CtIP. Downregulation of
CtIP by the APC/CCdh1 promotes its clearance from DSBs and prevents excessive
DNA-end resection, a prerogative for proper homology-directed repair.
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FuGENE 6 transfection reagent (Promega) at 60% confluency. After
6 h, medium was exchanged to fresh DMEM and cells were incu-
bated at 30°C (6% CO2). Two days later, cells were replated at
different dilutions in 10-cm plates. After 24 h, the medium was
supplemented with 250 lg/ml hygromycin B and 12.5 lg/ml
blasticidin S. The medium was replaced every 2–3 days, and cells
were selected for approximately 2 weeks. Resistant colonies were
picked and further characterized as single clones or pooled to gener-
ate bulk cultures. All cell lines were screened for inducible GFP-CtIP
expression by both immunofluorescence microscopy and immuno-
blotting. To induce expression of GFP-CtIP, cells were treated with
0.5 or 1 lg/ml doxycycline (Dox) for 24 h as indicated.
Immunoprecipitation and GST pull-down
For immunoprecipitation and glutathione S-transferase (GST) pull-
down assays, cells were lysed in NP-40 extraction buffer (50 mM
Tris–HCl, pH 7.5, 120 mM NaCl, 1 mM EDTA, 6 mM EGTA, 15 mM
sodium pyrophosphate, 1% NP-40), supplemented with phospha-
tase inhibitors (20 mM NaF, 1 mM sodium orthovanadate) and
protease inhibitors (1 mM benzamidine and 0.1 mM phenylmethyl-
sulfonyl fluoride (PMSF)), and clarified by centrifugation at
20,000 g. HeLa nuclear extracts (HNE) were purchased from Ipracell
(Belgium). Generation of the GST–CtIP constructs was described
previously (Sartori et al, 2007). GST fusion plasmids were grown in
BL21 RIL (CodonPlus) Escherichia coli (Stratagene), and recombi-
nant proteins were expressed by incubating the bacteria for 24 h at
16°C after the addition of 100 lM IPTG. After centrifugation, the
bacterial pellet was resuspended in cold PBS, supplemented with
1% Triton X-100 and protease inhibitors (1 mM PMSF, 1 mM benz-
amidine, and Roche protease inhibitor cocktail). After sonication
and centrifugation, GST-tagged proteins were purified from soluble
extracts using Glutathione Sepharose 4 Fast Flow beads (GE
Healthcare). GST fusion proteins bound to glutathione beads were
mixed with 1 mg of HeLa nuclear extract and incubated for 1 h at
4°C in 1 ml of TEN100 buffer (20 mM Tris–HCl (pH 7.4), 0.1 mM
EDTA, and 100 mM NaCl). Beads were then washed three times
with NTEN500 buffer (0.5% NP-40, 0.1 mM EDTA, 20 mM Tris–
HCl (pH 7.4), and 500 mM NaCl) and once with TEN100 buffer.
Recovered complexes were boiled in SDS sample buffer and
analyzed by SDS–PAGE followed by immunoblotting.
Immunoprecipitating antibodies were added to the cell lysates
and incubated overnight at 4°C. After 2 h incubation with protein A
or protein G beads, precipitated immunocomplexes were washed
four times with lysis buffer or three times with TNE buffer (50 mM
Tris–HCl (pH 7.4), 100 mM NaCl, 0.1 mM EDTA) containing 1%
Triton X-100 and once with TNE buffer, boiled in SDS sample
buffer, and loaded on an SDS–polyacrylamide gel. Proteins were
analyzed by immunoblotting as described below.
In vivo ubiquitylation assays
HEK293 Flp-In T-REx GFP-CtIP cells were transfected with His-
ubiquitin using the FuGENE 6 transfection reagent (Promega), and
after 24 h, GFP-CtIP expression was induced with 1 lg/ml Dox.
After 24 h, cells were treated for 4 h with 20 lM MG-132 and then
washed and scraped in 500 ll of ice-cold PBS. 2% of the cell suspen-
sion was used for direct Western blot analysis. The remaining
cells were lysed in “buffer A” (6 M guanidine–HCl, 0.1 M Na2HPO4/
NaH2PO4, pH 8.0, 10 mM imidazole), and lysates were incubated
with Ni2+-NTA agarose beads for 3 h under rotation at room temper-
ature. The beads were washed two times with buffer A, two times
with “buffer A/TI” (1 volume buffer A: 3 volume buffer “TI”
(25 mM Tris–HCl, pH 6.8, and 20 mM imidazole)), and two times
with buffer TI. Bound proteins were eluted by boiling the beads in
2× SDS sample buffer supplemented with 250 mM imidazole and
analyzed by immunoblotting. In case of siRNA treatment, cells were
first transfected with the indicated siRNA and after 24 h transfected
with His-ubiquitin using the FuGENE6 transfection reagent
(Promega). At the same time, GFP-CtIP expression was induced with
1 lg/ml Dox, and after 24 h, samples were processed as described
above.
To analyze ubiquitylation of endogenous CtIP, HEK293 cells
were transfected with HA-ubiquitin using the FuGENE 6 transfection
reagent (Promega) and enriched in S/G2 phase of the cell cycle by
releasing them from a single thymidine block. After treatment, cells
were lysed in (5 mM Tris–HCl (pH 7.5), 5 mM DTT, 1% SDS) and
boiled for 5 min (El-Shemerly et al, 2005). After sonication, samples
were clarified by centrifugation and diluted 4 times with NP-40
buffer supplemented with phosphatase inhibitors (20 mM NaF,
1 mM sodium orthovanadate), protease inhibitors (1 mM benzami-
dine and 0.1 mM phenylmethylsulfonyl fluoride (PMSF)), and the
deubiquitinases inhibitor N-ethylmaleimide (NEM, 20 mM). Immu-
noprecipitation was performed overnight at 4°C, using a polyclonal
rabbit antibody (612L, raised against CtIP N-terminus, a kind gift of
Prof. Richard Baer, Columbia University). After 2 h incubation with
protein A beads, precipitated immunocomplexes were washed three
times with NTEN500 buffer and once with TEN100 buffer, boiled in
SDS sample buffer, and loaded on an SDS–polyacrylamide gel. After
transfer, membranes were incubated for 30 min at 4°C in denaturing
buffer (6 M guanidine–HCl, 20 mM Tris–HCl (pH 7.5), 1 mM PMSF,
and 5 lM b-mercaptoethanol) as described in Penengo et al (2006).
After extensive washing with TBS-Tween buffer, membranes were
incubated with the appropriate antibody and further processed as
described below.
Immunoblotting
If not specified otherwise, cell extracts were prepared in Laemmli
buffer (4% SDS, 20% glycerol, 120 mM Tris–HCl pH 6.8). If indi-
cated, cells were lysed in RIPA buffer (50 mM Tris–HCl, pH 7.5, 1%
NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EDTA,
and 0.1% SDS) supplemented with phosphatase and protease inhibi-
tors. Proteins were resolved by SDS–PAGE and transferred to nitro-
cellulose. Immunoblots were performed using the appropriate
antibodies, and proteins were visualized using the ECL detection
system (Amersham). Primary antibodies used in this study are listed
in Supplementary Table S2. The anti-Claspin antibody was a kind
gift of Dr. Raimundo Freire, University of Tenerife) and was
described previously (Semple et al, 2007).
When indicated, a Triton X-100-insoluble (chromatin-enriched)
fraction was isolated as described in Pen˜a-Diaz et al (2012). Briefly,
cells were rinsed twice in cold PBS and incubated for 5 min on ice
in pre-extraction buffer (25 mM HEPES (pH 7.9), 50 mM NaCl,
1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 0.5% Triton X-100,
and protease inhibitors). After buffer removal and rinsing in PBS,
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adherent cellular material was harvested by scraping it into
Laemmli buffer. The chromatin-enriched fraction was then heat
denatured, sonicated, and analyzed by immunoblotting.
HR and NHEJ DNA repair assays
DSB repair efficiency by HR or NHEJ was measured in DR-GFP or
EJ5-GFP HEK293 cell lines as described previously (Bennardo et al,
2008). Briefly, 0.6 × 106 cells were plated in 6-well plates (poly-L-
lysine coated) and, after 24 h, cells were transfected with siRNA
oligos (40 nM). The next day, 0.24 × 106 cells were reseeded in
12-well plates. At 48 h after siRNA transfection, cells were either
mock-transfected or transfected with 0.6 lg I-SceI expression plas-
mid (pCBASce) in combination with 0.2 lg of the appropriate
FLAG-tagged CtIP constructs (pcDNA3) using 1.6 ll of JetPrime
(Polyplus). At 4 h after plasmids transfection, media were replaced
and a second transfection with siRNA oligos (15 nM) was
performed. Alternatively, cells were only transfected with 0.6 lg
I-SceI expression plasmid (pCBASce) in combination with 0.2 lg of
the appropriate FLAG-tagged CtIP constructs (pcDNA3) using 1.6 ll
of JetPrime (Polyplus). At 48 h after I-SceI transfection, cells were
analyzed for GFP expression by flow cytometry on a CyAn ADP 9
(Dako).
Laser micro-irradiation
Laser micro-irradiation to generate DSBs in a defined nuclear region
was performed as described previously (Lukas et al, 2003; Bekker-
Jensen et al, 2006). Briefly, 24 h before irradiation, culture medium
was supplemented with 10 lM BrdU. Around 100 cells were micro-
irradiated at room temperature (a procedure lasting around 10 min)
using the MMI CELLCUT system containing a UVA laser of 355 nm
(Molecular Machines and Industries, Zurich, Switzerland). The laser
intensity was set to 50% energy output, and each cell was generally
exposed to the laser beam for < 300 ms (Meerang et al, 2011).
DNA plasmids and RNA interference
Plasmids were transfected by using either the standard calcium
phosphate method or FuGENE 6 (Promega) according to manufac-
turer’s instructions. The epitope-tagged expression vectors for
human CtIP have been described previously (Yu et al, 2006; Sartori
et al, 2007). The HA-tagged expression vector for human Cdh1 was
described previously and was purchased from Addgene (plasmid
#11596) (Pfleger et al, 2001). The pcDNA3.1-6×His-ubiquitin plas-
mid was a kind gift of Matthias Peter (ETH Zurich, Switzerland),
whereas the HA-ubiquitin plasmid was described previously and
purchased from Addgene (plasmid #18712) (Kamitani et al, 1997).
All CtIP point mutants were introduced by site-directed mutagenesis
using Expand Long Template PCR System (Roche) and confirmed
by sequencing. shRNA interference for Cdh1 in RPE-1, MCF7, or
HeLa cells was performed using lentiviral infection with control
pLL3.7-GFP (targeting sequence: 50-GGCATCAAGGTGAACTTCA-30)
or pLL3.7-Cdh1 (targeting sequence: 50-GGATTAACGAGAATGA
GAA-30; provided by r, University of Freiburg, Germany) (Engelbert
et al, 2008). To this end, HEK293T cells were transfected with the
pLL3.7 plasmids along with the packaging plasmids pCMV-VSVG,
pCMV-dR8.2 (provided by Robert Weinberg, MIT, Cambridge, MA),
and pAdVAntage (Promega) in a 4:3:1:0.5 ratio. Virus-containing
supernatant was harvested at 24 and 48 h after transfection, filtered
through a 0.45-lM syringe filter, and used to infect target cells,
which were subsequently selected with 1 lg/ml puromycin. Analy-
sis of stable Cdh1-depleted cells was done at 5 days post-infection.
For transient siRNA experiments, RPE-1, MCF7, HeLa, or U2OS
cells were plated in 6-well plates and transfected with the indicated
amounts of siRNA oligos (40 nM final concentration of oligos) using
Oligofectamine or Lipofectamine RNAiMAX using manufacturer’s
guidelines (Invitrogen, Life Technologies). In brief, medium was
replaced with Opti-MEM (Gibco, Life Technologies) prior to incuba-
tion with siRNAs and Oligofectamine for 4 h. Thereafter, medium
containing FCS (10% final concentration) was added and cells were
analyzed at 48 or 72 h after transfection. siRNA oligos targeting
Cdh1 #1 (50-GGATTAACGAGAATGAGAAdTdT-30), Cdh1 #2 (50-AA
TGAGAAGTCTCCCAGTCAGdTdT-30), CtIP (50-GCUAAACAGGAACG
AAUCTTdTdT-30) (Sartori et al, 2007), or luciferase (50-CGUACGCG
GAAUACUUCGAdTdT-30) were purchased from Ambion (Life Tech-
nologies) or Microsynth (Balgach, Switzerland). In addition, “medium
GC duplex” control siRNA (Cat. No: 12935-300) was purchased from
Ambion (Life Technologies).
SILAC and mass spectrometry
For SILAC experiments, RPE-1 cells were cultured in ready-to-use
light and heavy DMEM media, containing light or heavy arginine
and lysine (“R0K0 DMEM” with 12C6-L-arginine and
12C6-L-lysine or
“R10K8 DMEM” with 13C6-L-arginine and
13C6-L-lysine, respec-
tively) and supplemented with dialyzed FBS. Media were obtained
from Silantes (Munich, Germany). SILAC labeling was performed as
previously described by Ong and Mann (Ong et al, 2002). Briefly,
RPE-1 cells were cultured in normal media or complete heavy
DMEM medium containing 10% dialyzed FBS for at least 10 cell
doublings (5 passages) to allow full incorporation of both labeled
amino acids within the proteome. Cells were subsequently treated
with nocodazole for 16 h (250 ng/ml) and collected by mitotic
shake-off. Cells were washed three times in pre-warmed PBS and
replated in the absence of nocodazole. Immediately after replating
or 2.5 h after replating, cells were harvested by trypsinization, snap-
frozen in liquid nitrogen, and resuspended in lysis buffer (6 M urea
and 2 M thio-urea). A label-swap replicate was also performed
where SILAC states and harvesting conditions were reversed
(Fig 3A). To determine protein concentration in lysates, 10 ll lysate
was added to 150 ll of 660 nM protein assay reagent (Pierce). Equal
amounts of protein from R0K0 and R10K8 were mixed, reduced with
1 mM DTT, and alkylated with 8 mM iodoacetamide. Proteins were
separated on SDS–PAGE 4–12% gradient gels and visualized by
staining by Coomassie staining. Gel lanes were divided into eight
slices and proteins digested with an in-gel digestion protocol with
trypsin. Peptides were desalted on C18 StageTips and loaded on a
10-cm-long 360 lm O.D. by 75 lm I.D. column packed with 3 lm
ReproSil-Pur C18 AQ 3beads (Dr. Maisch, Germany) with an Agilent
1100 nano-flow pump and autosampler. A 60 min gradient from 3
to 35% acetonitrile containing 1% formic acid at 200 nl/min was
applied to elute peptides for analysis in the LTQ-Orbitrap-Velos
(Thermo, Bremen) in a Top5 CID data-dependent acquisition mode.
Peptide identification and quantification was performed using
MaxQuant v.1.1.1.14 with the IPI human database ver. 3.70 with
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variable modifications of oxidized methionine and acetylated
protein N-termini. Cysteines were carbamidomethylated. Peptide
and protein FDR was set at 1%.
Flow cytometry
Cells were harvested at the indicated time points after treatment and
fixed in ice-cold 70% ethanol. Cells were stained with rabbit anti-
phospho-histone H3 antibody, mouse anti-MPM-2, and/or mouse
anti-c-H2AX (details of used antibodies are in Supplementary Table
S2), subsequently stained with Alexa488-conjugated and Alexa647-
conjugated secondary antibodies (Molecular Probes, 1:300), and
counterstained with propidium iodide/RNase (Sigma). Samples
were analyzed on a FACS-Calibur (Becton Dickinson) equipped with
Cell Quest software. Per sample, a minimum of 104 events was
analyzed and indicated results show averages and standard devia-
tions of three independent experiments.
Immunofluorescence microscopy
MCF7, MEFs, or HeLa cells were cultured on glass coverslips and, if
indicated, were irradiated at 24 h after plating. After treatment, cells
were fixed in formaldehyde (3.7% in PBS) for 15 min at room
temperature. After washing with PBS, cells were permeabilized with
Triton X-100 (0.1% in PBS) for 5 min at room temperature. After
extensive washing, cells were stained with mouse anti-Cdh1, mouse
anti-p53 diluted in PBS, 0.05%Tween-20, 2.5%BSA for 16 h at 4°C.
After extensive washing, cells were stained with Alexa488-,
Alexa568-, or Alexa647-conjugated secondary antibodies for 30 min
at room temperature and counterstained with DAPI. Images were
obtained using a Leica DM6000B microscope, equipped with 63×
immersion lens (PL-S-APO, numerical aperture: 1.30) and Xenon
light source using LAS-AF software (Leica).
Alternatively, U2OS-FUCCI cells were grown on glass coverslips
and, at different time points after treatment, fixed directly in 4%
formaldehyde (w/v) in PBS for 15 min as described previously
(Eid et al, 2010). After incubation with rabbit anti-Rad51 or rabbit
anti-53BP1 and appropriate secondary antibodies the coverslips
were mounted and sealed with Vectashield (Vector Laboratories)
containing DAPI. Images were acquired on a Leica DMRB
fluorescence microscope.
For live-cell microscopy, stable U2OS cells were plated in cham-
bered coverglass 8-well plates (LabTek-II, Nunc). At 24 h before
imaging, GFP-CtIP expression was induced by adding doxycycline to
a final concentration of 1 lg/ml. GFP and DIC images were obtained
every 5 min on a DeltaVision Elite microscope, equipped with a
CoolSNAP HQ2 camera, 40× immersion objective (U-APO 340,
numerical aperture: 1.35). In the Z-plane, 12 images were acquired
at 0.5-lm interval, which were subsequently deconvolved using
SoftWorx 5.5 software (Applied Precision). Nuclear fluorescence
intensity was quantified using ImageJ software.
Clonogenic and short-term survival assays
HeLa or MCF7 cells were cultured in 6-well plates. One day after
plating, cells were irradiated with 1, 2, or 4 Gy. When surviving
colonies were approximately 50 cells in size, cells were fixed
and stained using methanol/ acidic acid/water in a 5:2:3 ratio,
supplemented with 0.01% Coomassie brilliant blue. Surviving frac-
tions were calculated using the plating efficiencies with non-
irradiated conditions as a reference. Shown averages are from three
experiments, with three replicates each. Alternatively, clonal U2OS
cells expressing GFP-CtIP variants were transfected with siRNAs
and, if indicated, were treated with doxycycline 24 h later to induce
expression of GFP-CtIP. At 48 h after transfection, cells were trypsi-
nized and replated in 6-well plates. During replating, indicated doses
of doxorubicin or the PARP inhibitor olaparib (Axon Medchem,
Groningen, the Netherlands) were added. To test whether Cdh1-
depleted cells also are more sensitive to PARP inhibition, U2OS cells
were transfected with siCdh1#1, and after 48 h, cells were replated
in the presence of olaparib. Statistical testing was done using the
Student’s t-test.
For short-term survival assays, 2,000 cells were plated in 96-wells
plates and treated at 24 h after plating. At 4 days after treatment
initiation, 20 ll of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) was added to the culture medium to a final concen-
tration of 5 mg/ml for 3 h. Formazan crystals were dissolved in
DMSO, and absorbance was analyzed at 520 nM using a Bio-Rad
benchmark III microtiter spectrophotometer. Survival was calculated
as a percentage of untreated cells.
Gene set enrichment analysis (GSEA) and destruction
motif analysis
GSEA was performed with GSEA 2.0 (Broad Institute, Cambridge,
MA) (Mootha et al, 2003; Subramanian et al, 2005). A significance
threshold was set at a nominal P-value of 0.05 and a false discovery
rate (FDR) of 0.30. In our analysis, we transformed protein names
from SILAC MS analysis to HUGO gene symbols and tested enrich-
ment in Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene
Map Annotator and Pathway Profiler (GenMAPP) (Dahlquist et al,
2002; Kanehisa et al, 2012), and the BioCarta database (http://
www.biocarta.com). Within the set of identified proteins from the
SILAC MS analysis, we used GPS-ARM (Liu et al, 2012) to identify
proteins with a D-box or a KEN box using a threshold setting of
“high” for D-boxes and “medium” for KEN boxes. Subsequently,
GSEA was used to test for enrichment of KEN box or D-box contain-
ing proteins in the downregulated fraction. FDR rates of 0.25 were
used in combination with 10,000 permutations. Conservation of
KEN or D-boxes was done using Clustal Omega. In order to identify
proteins related to the DNA damage response and DNA damage
repair, a combined list of genes was compiled by merging the
following Gene Ontology gene sets (see also Supplementary Table
S1): GO:0006302 (“double-strand break repair); GO:0006974 (“cellu-
lar response to DNA damage stimulus”); GO:0000077 (“DNA
damage checkpoint”); and GO:0000724 (“double-strand repair via
homologous recombination”). In total, 255 genes were included in
this combined gene set (Supplementary Table S1), which in Fig 3 is
referred to as “DNA damage response”.
Supplementary information for this article is available online:
http://emboj.embopress.org
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Legends to Supplementary Figures: 
 
Supplementary Figure S1: 
MCF-7 cells were infected with pLL-GFP or pLL-Cdh1 and selected with puromycin. 
Cells were grown on glass coverslips, fixed with 3.7% formaldehyde in PBS and 
stained with anti-p53 and DAPI. Ten microscopic fields were counted for p53 
positivity. Averages and standard deviations of 10 fields of cells are indicated.  
 
Supplementary Figure S2: 
A. Schematic representation of the FUCCI system, which was used in the experiments 
depicted in Figures 2C and 2D. In these cells, fragments of geminin and Cdt1 are 
tagged with fluorescent reporters, which allow the discrimination of G1 and S/G2 
cells. B/C. U2OS-FUCCI cells treated as described in Figure 2C were prepared for 
Rad51 (panel B) and 53BP1 (panel C) immunofluorescence. Shown are representative 
images of the different time-points. Scale bars correspond to 20 µm. 
 
Supplementary Figure S3: 
A. Indicated are established substrates of the APC/CCdh1 that were identified in our 
mass spectrometry analysis. Log2-transformed ratios between t=2.5 and t=0 hours 
after release from nocodazole-mediated mitotic arrest are indicated. Literature 
references to these APC/CCdh1 are provided in Table S3. 
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B. Proteins that were downregulated at least 1.0 (log2-transformed SILAC ratios) and 
were   part   of   the   ‘DNA   Damage   response’   (see   Supplementary Table S2), were 
queried for the presence of KEN or D-box destruction motifs. To this end, GPS-ARM 
software (Liu et al, 2012) was used to identify D-boxes and KEN boxes. Open orange 
squares represent any D-box, whereas filled orange squares represent an optimal D-
box. Likewise, open green squares represent any KEN box, whereas filled green 
squares represent optimal KEN box motifs. Subsequently,   protein   sequences   from  
orthologs   from   indicated   species   were   aligned   using   Clustal   Omega  
(www.ebi.ac.uk/Tools/msa/clustalo/  ) using default settings. Boxes indicate 
evolutionary conserved destruction motifs. Grey filled boxes indicated evolutionary 
conservation of an optimal destruction motif. Numbers above destruction motifs 
indicate the amino acid location of the start position of the destruction motif in the 
human sequence. 
 
Supplementary Figure S4: 
A. RPE-1 cells were treated for 18 hours with S-Trityl-L-Cysteine (STLC, 5 µM) and 
mitotic cells were collected by shake-off. Mitotic cells were subsequently washed 
with warm culture medium and subsequently replated. Total cell lysates were 
immunoblotted with anti-CtIP, anti-Plk1 and anti-Actin. In parallel to obtaining total 
cell lysates, cells were fixed in ethanol and stained for the mitotic marker MPM-2. 
Representative plots are shown. B. HeLa cells were left untreated (asynchronous, 
“AS”)  or  were   treated  with  nocodazole  (75  ng/ml)   for  14  hours.  Subsequently, cells 
were lysed in RIPA buffer, containing 0.1% SDS; PMSF and benzamidine. Next, the 
samples of asynchronous or nocodazole-treated cells were incubated for 30 minutes in 
the absence or presence of -phosphatase  (“-PPase”).  Control  samples  treated with a 
combination of -PPase and inhibitors (50 mM EDTA and 10 mM sodium 
orthovanadate) were included. C. U2OS cells were transfected with indicated siRNAs 
and total cell lysates were made at 48 hours after transfection. Western blotting was 
performed with indicated antibodies. In parallel, cells were fixed in ethanol, stained 
with PI/RNAse and subsequently analyzed by flow cytometry. D. RPE-1 cells were 
treated as described for Figure 4D. In parallel to making total cell lysates for Western 
blotting, cells were fixed in ethanol and stained for anti-phospho-HistoneH3/Alexa-
488 in combination with PI/RNAse. Representative DNA profiles and phospho-
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Histone-H3 plots are shown. Numbers indicate averages and standard deviations of 
phospho-Histone-H3 content from three independent experiments. E. RPE-1 cells 
were treated as for Figure 4F. In parallel to obtaining total cell lysates, cells were 
fixed in ethanol and stained for phospho-Histone-H3. Representative plots are shown. 
 
Supplementary Figure S5: 
A. HEK293 Flp-In T-REx cells were induced to express GFP-CtIP-wt or GFP-CtIP-
K467A using doxycycline. Cell lysates were used for Cdh1 immunoprecipitations. 
Total   cell   lysates   (‘input’)   and   Cdh1   immunoprecipitations   (‘anti-Cdh1   IP’)   were  
immunoblotted for indicted proteins. B. Polyclonal U2OS Flp-In T-REx cells were 
induced to express GFP-CtIP-wt (upper panels) or GFP-CtIP-KA (middle panels) 
using doxycycline for 24 hours. Subsequently, cells were synchronized using a single 
thymidine block. After release from the thymidine treatment, cells were treated with 
nocodazole (250 ng/ml) and at indicated time points, cells were harvested, fixed in 
ethanol and stained for the mitotic marker MPM-2. Lower panels: Cells were treated 
as for upper and middle panels. At the moment of thymidine wash-out, cells were 
fixed in ethanol and levels of GFP-CtIP-wt or GFP-CtIP-KA were assessed using 
flow cytometry. Black lines indicate untreated cells, green lines indicate doxycycline-
treated cells. 
 
Supplementary Figure S6: 
A. U2OS cells were synchronized for 18 hours using thymidine (2 mM). Cells were 
then released from the S-phase block to allow progression towards G2. At 7 hours 
post-release,   cells   were   treated   with   doxorubicin   (‘dox’,   0.5   μM)   for   1   hour.  
Subsequently, fresh (dox-free) medium was added, and cells were left untreated or 
were  treated  with  proTAME  (‘PT’,  20  μM)  for  5  hours.  At  indicated  time  points,  cells  
were fixed and analyzed for cell cycle distribution. B. Same cells as in panel A were 
lysed in RIPA buffer at indicated time points. Whole cell extracts were analyzed by 
immunoblotting  with  indicated  antibodies.  (‘short’)  and  (‘long’)  depict  short  and  long  
exposures  of  the  same  membrane,  respectively.  ‘*’  indicate  phosphorylated  species  of  
proteins. C. U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt using 
doxycycline (1g/ml) for 24 hours. Subsequently, cells were synchronized using a 
single thymidine block. At 8 hours after release, cells were treated with DMSO or 
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proTAME   (12   μM),   subsequently   irradiated with 10 Gy, and imaged using 
fluorescence time-lapse microscopy. Representative stills of GFP and DIC movies are 
indicated. 
 
Supplementary Figure S7: 
A. Polyclonal U2OS Flp-In T-REx cells were induced to express GFP-CtIP-wt or 
GFP-CtIP-K467A using doxycycline. Lysates were immunoblotted using anti-CtIP 
and anti-TFIIH. In parallel, U2OS Flp-In T-REx cells were induced to express GFP-
CtIP-wt or GFP-CtIP-K467A and subsequently micro-irradiated. Cells were then 
fixed and stained for -H2AX to visualize laser-induced DNA damage. B. 
Monoclonal U2OS-GFP-CtIP-wt were transfected with CtIP siRNA, and if indicated, 
cells were induced to express GFP-CtIP-wt using doxycycline (0.5 g/ml). Cells were 
irradiated with 10 Gy and harvested after 1 or 4 hours. Total cell lysates were 
immunoblotted   with   indicated   antibodies.   ‘*’   indicates   phosphorylated   species   of  
proteins. C. Monoclonal U2OS-GFP-CtIP-wt or U2OS-GFP-CtIP-K467A cells were 
transfected with indicated siRNA. If indicated, cells were induced to express GFP-
CtIP-wt or GFP-CtIP-K467A using doxycycline (0.5 g/ml and 1 g/ml 
respectively). 24 hours after transfection. At 48 hours after transfection, cells were 
harvested,  and   total  cell   lysates  were   immunoblotted   for  CtIP  and  Actin.   ‘Short  ex’  
indicates short exposure  and  ‘long  ex’  indicates  long  exposure.  In  parallel,  cells  were  
irradiated (2 Gy) at 48 hours after transfection, and nocodazole was added 1.5 hours 
after irradiation to trap cells in mitosis. Samples were fixed in ethanol at 4 hours and 8 
hours after irradiation, stained with the mitotic marker MPM-2 in combination with 
propidium iodide/RNAse treatment and subsequently analyzed by flow cytometry. 
Percentages of mitotic cells are indicated. Averages and standard deviations of three 
experiments are indicated. D. U2OS cells were transfected with siCTRL or siCdh1 
and treated as for panel C. Lysates were blotted using anti-Cdh1 and anti-Actin.  
 
Supplementary Figure S8: 
 
A-C. Monoclonal U2OS-GFP-CtIP-wt, U2OS-GFP-CtIP-K467A and U2OS-GFP-
CtIP-T847A cells were transfected with siCtIP and were induced to express GFP-
CtIP-wt (0.5 g/ml doxycycline), GFP-CtIP-K467 or GFP-CtIP-T847A (1 g/ml 
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6XSSOHPHQWDU\ Figure 65
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6XSSOHPHQWDU\ Figure 67
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Uniprot(identifierGene(symbolGene(Ontology(terms Description Gene(symbol(aliases
Q9NY61 AATF GO:0006974 Protein(AATF AATF|AATF_HUMAN|CHE1|DED|HSPC277
P00519 ABL1 GO:0006974 TyrosinePprotein(kinase(ABL1 ABL|ABL1|ABL1_HUMAN|JTK7
Q9H9F9 ACTR5 GO:0006302 ActinPrelated(protein(5 ACTR5|ARP5|ARP5_HUMAN
Q9BT30 ALKBH7 GO:0006974 AlphaPketoglutaratePdependent(dioxygenase(alkB(homolog(7,(mitochondrialABH7|ALKB7_HUMAN|ALKBH7|SPATA11|UNQ6002/PRO34564
Q96BT7 ALKBH8 GO:0006974 Alkylated(DNA(repair(protein(alkB(homolog(8ABH8|ALKB8_HUMAN|ALKBH8
Q9NUS5 AP5S1 GO:0000724 APP5(complex(subunit(sigmaP1 AP5S1|AP5S1_HUMAN|C20orf29
O43299 AP5Z1 GO:0000724 APP5(complex(subunit(zetaP1 AP5Z1|AP5Z1_HUMAN|KIAA0415|SPG48
O00213 APBB1 GO:0006974;(GO:0006302 Amyloid(beta(A4(precursor(proteinPbinding(family(B(member(1APBB1|AP B1_HUMAN|FE65|RIR
R4GMU6 APC GO:0006974 Adenomatous(polyposis(coli(protein APC|R4GMU6_HUMAN
Q8N2Z9 APITD1 GO:0006974 Centromere(protein(S APITD1|CENPS|CENPS_HUMAN|FAAP16|MHF1
Q8IW19 APLF GO:0006974;(GO:0006302 Aprataxin(and(PNKPlike(factor APLF|APLF_HUMAN|C2orf13|PALF|XIP1
Q7Z2E3 APTX GO:0006974;(GO:0006302 Aprataxin APTX|APTX_HUMAN|AXA1
Q9UBL3 ASH2L GO:0006974 Set1/Ash2(histone(methyltransferase(complex(subunit(ASH2ASH2L|ASH2L1|ASH2L_HUMAN
Q96QE3 ATAD5 GO:0006974 ATPase(family(AAA(domainPcontaining(protein(5ATAD5|ATAD5_HUMAN|C17orf41|FRAG1
P15336 ATF2 GO:0006974 Cyclic(AMPPdependent(transcription(factor(ATFP2ATF2|ATF2_HUMAN|CREB2|CREBP1
Q13315 ATM GO:0006974;(GO:0000077;(GO:0000724;(GO:0006302SerinePprotein(kinase(ATM ATM|ATM_HUMAN
O43313 ATMIN GO:0006974 ATM(interactor ATMIN|ATMIN_HUMAN|KIAA0431|ZNF822
Q13535 ATR GO:0006974;(GO:0000077 Serine/threoninePprotein(kinase(ATR ATR|ATR_HUMAN|FRP1
Q8WXE1 ATRIP GO:0000077 ATRPinteracting(protein AGS1|ATRIP|ATRIP_HUMAN
Q9NWV8 BABAM1 GO:0006302 BRISC(and(BRCA1PA(complex(member(1 BABA1_HUMAN|BABAM1|C19orf62|HSPC142|MERIT40|NBA1
Q99728 BARD1 GO:0006974 BRCA1Passociated(RING(domain(protein(1BARD1|BARD1_HUMAN
Q16520 BATF GO:0006974 Basic(leucine(zipper(transcriptional(factor(ATFPlikeBATF|BATF_HUMAN
Q07812 BAX GO:0006974 Apoptosis(regulator(BAX BAX|BAX_HUMAN|BCL2L4
Q9UIG0 BAZ1B GO:0006974;(GO:0006302 TyrosinePprotein(kinase(BAZ1B BAZ1B|BAZ1B_HUMAN|WBSC10|WBSCR10|WBSCR9|WSTF
Q9BXH1 BBC3 GO:0006974 BclP2Pbinding(component(3 BBC3|BBC3_HUMAN|PUMA
P10415 BCL2 GO:0006974 Apoptosis(regulator(BclP2 BCL2|BCL2_HUMAN
P20749 BCL3 GO:0006974 BPcell(lymphoma(3(protein BCL3|BCL3_HUMAN|BCL4|D19S37
P41182 BCL6 GO:0006974 BPcell(lymphoma(6(protein BCL5|BCL6|BCL6_HUMAN|LAZ3|ZBTB27|ZNF51
P54132 BLM GO:0006974;(GO:0000724 Bloom(syndrome(protein BLM|BLM_HUMAN|RECQ2|RECQL3
P38398 BRCA1 GO:0006974;(GO:0000724;(GO:0006302Breast(cancer(type(1(susceptibility(proteinBRCA1|BRCA1_HUMAN|RNF53
E9PIQ1 BRCA2 GO:0000724;(GO:0006302 Breast(cancer(type(2(susceptibility(proteinBRCA2|E9PIQ1_HUMAN
P46736 BRCC3 GO:0006302 LysP63Pspecific(deubiquitinase(BRCC36 BRCC3|BRCC36|BRCC3_HUMAN|C6.1A|CXorf53
O60885 BRD4 GO:0006974 BromodomainPcontaining(protein(4 BRD4|BRD4_HUMAN|HUNK1
Q9NXR7 BRE GO:0006974;(GO:0006302 BRCA1PA(complex(subunit(BRE BRCC45|BRE|BRE_HUMAN
Q9BX63 BRIP1 GO:0000077;(GO:0006302 Fanconi(anemia(group(J(protein BACH1|BRIP1|FANCJ|FANCJ_HUMAN
Q8TDC3 BRSK1 GO:0006974 Serine/threoninePprotein(kinase(BRSK1 BRSK1|BRSK1_HUMAN|KIAA1811|SAD1|SADB
P78543 BTG2 GO:0006974 Protein(BTG2 BTG2|BTG2_HUMAN|PC3
B4DMA1 C11orf82 GO:0006974 Nitric(oxidePinducible(gene(protein B4DMA1_HUMAN|C11orf82
C9JXR7 CASP3 GO:0006974 CaspaseP3(subunit(p12 C9JXR7_HUMAN|CASP3
P55211 CASP9 GO:0006974 CaspaseP9 CASP9|CASP9_HUMAN|MCH6
Q8N163 CCAR2 GO:0006974 Cell(cycle(and(apoptosis(regulator(protein(2CCAR2|CCAR2_HUMAN|DBC1|KIAA1967
P24385 CCND1 GO:0006974 G1/SPspecific(cyclinPD1 BCL1|CCND1|CCND1_HUMAN|PRAD1
O75909 CCNK GO:0006974 CyclinPK CCNK|CCNK_HUMAN|CPR4
Q96FF9 CDCA5 GO:0006302 Sororin CDCA5|CDCA5_HUMAN
P38936 CDKN1A GO:0006974 CyclinPdependent(kinase(inhibitor(1 CAP20|CDKN1|CDKN1A|CDN1A_HUMAN|CIP1|MDA6|PIC1|SDI1|WAF1
Q96MT8 CEP63 GO:0000077 Centrosomal(protein(of(63(kDa CEP63|CEP63_HUMAN
Q9BRQ6 CHCHD6 GO:0006974 CoiledPcoilPhelixPcoiledPcoilPhelix(domainPcontaining(protein(6,(mitochondrialCHCH6_HUMAN|CHCHD6|CHCM1
Q86WJ1 CHD1L GO:0006974 ChromodomainPhelicasePDNAPbinding(protein(1PlikeALC1|CHD1L|CHD1L_HUMAN
O14757 CHEK1 GO:0006974;(GO:0000077 Serine/threoninePprotein(kinase(Chk1 CHEK1|CHK1|CHK1_HUMAN
O96017 CHEK2 GO:0006974;(GO:0000077;(GO:0006302Serine/threoninePprotein(kinase(Chk2 CDS1|CHEK2|CHK2|CHK2_HUMAN|RAD53
Q99828 CIB1 GO:0006974;(GO:0006302 Calcium(and(integrinPbinding(protein(1 CIB|CIB1|CIB1_HUMAN|KIP|PRKDCIP
O15516 CLOCK GO:0000077 Circadian(locomoter(output(cycles(protein(kaputBHLHE8|CLOCK|CLOCK_HUMAN|KIAA0334
Q9HAW4 CLSPN GO:0000077 Claspin CLSPN|CLSPN_HUMAN
Q2NKJ3 CTC1 GO:0006974 CST(complex(subunit(CTC1 C17orf68|CTC1|CTC1_HUMAN
P16410 CTLA4 GO:0006974 Cytotoxic(TPlymphocyte(protein(4 CD152|CTLA4|CTLA4_HUMAN
B3KSJ7 DCLRE1C GO:0006302 cDNA(FLJ36438(fis,(clone(THYMU2012113,(highly(similar(to(Artemis(protein((EC(3.1.P.P)B3KSJ7_HUMAN|DCLRE1C
P35638 DDIT3 GO:0006974 DNA(damagePinducible(transcript(3(proteinCHOP|CHOP10|DDIT3|DDIT3_HUMAN|GADD153
Q92499 DDX1 GO:0006302 ATPPdependent(RNA(helicase(DDX1 DDX1|DDX1_HUMAN
Q9NZJ0 DTL GO:0006974 Denticleless(protein(homolog CDT2|CDW1|DCAF2|DTL|DTL_HUMAN|L2DTL|RAMP
Q8TDB6 DTX3L GO:0006974;(GO:0006302 E3(ubiquitinPprotein(ligase(DTX3L BBAP|DTX3L|DTX3L_HUMAN
Q92630 DYRK2 GO:0006974 Dual(specificity(tyrosinePphosphorylationPregulated(kinase(2DYRK2|DYRK2_HUMAN
Q01094 E2F1 GO:0000077 Transcription(factor(E2F1 E2F1|E2F1_HUMAN|RBBP3
Q9H6Z9 EGLN3 GO:0006974 Egl(nine(homolog(3 EGLN3|EGLN3_HUMAN
K7EK97 ERCC1 GO:0006302 DNA(excision(repair(protein(ERCCP1 ERCC1|K7EK97_HUMAN
Q92889 ERCC4 GO:0000724 DNA(repair(endonuclease(XPF ERCC11|ERCC4|XPF|XPF_HUMAN
Q13216 ERCC8 GO:0006974 DNA(excision(repair(protein(ERCCP8 CKN1|CSA|ERCC8|ERCC8_HUMAN
Q99502 EYA1 GO:0006302 Eyes(absent(homolog(1 EYA1|EYA1_HUMAN
Q99504 EYA3 GO:0006302 Eyes(absent(homolog(3 EYA3|EYA3_HUMAN
Q6NZ36 FAAP20 GO:0006974 Fanconi(anemiaPassociated(protein(of(20(kDaC1orf86|FAAP20|FAP20_HUMAN|FP7162
Q6UWZ7 FAM175A GO:0006302 BRCA1PA(complex(subunit(Abraxas ABRA1|CCDC98|F175A_HUMAN|FAM175A|UNQ496/PRO1013
Q9Y2M0 FAN1 GO:0000724 FanconiPassociated(nuclease(1 FAN1|FAN1_HUMAN|KIAA1018|MTMR15
C9JSE3 FANCG GO:0006974 Fanconi(anemia(group(G(protein C9JSE3_HUMAN|FANCG
Q9NW38 FANCL GO:0006974 E3(ubiquitinPprotein(ligase(FANCL FANCL|FANCL_HUMAN|PHF9
Q5XUX0 FBXO31 GO:0006974 FPbox(only(protein(31 FBX14|FBX31|FBX31_HUMAN|FBXO31|PP2386
P0C2W1 FBXO45 GO:0006974 FPbox/SPRY(domainPcontaining(protein(1FBSP1_HUMAN|FBX45|FBXO45
Q9NRD1 FBXO6 GO:0000077 FPbox(only(protein(6 FBG2|FBS2|FBX6|FBX6_HUMAN|FBXO6
Q969H0 FBXW7 GO:0006974 FPbox/WD(repeatPcontaining(protein(7 FBW7|FBX30|FBXW7|FBXW7_HUMAN|SEL10
P39748 FEN1 GO:0006302 Flap(endonuclease(1 FEN1|FEN1_HUMAN|RAD2
Q9NZ56 FMN2 GO:0006974 ForminP2 FMN2|FMN2_HUMAN
O00409 FOXN3 GO:0000077 Forkhead(box(protein(N3 C14orf116|CHES1|FOXN3|FOXN3_HUMAN
Q12778 FOXO1 GO:0006974 Forkhead(box(protein(O1 FKHR|FOXO1|FOXO1A|FOXO1_HUMAN
O43524 FOXO3 GO:0006974 Forkhead(box(protein(O3 FKHRL1|FOXO3|FOXO3A|FOXO3_HUMAN
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A6NCE0 FOXO6 GO:0006974 Forkhead(box(protein(O6 A6NCE0_HUMAN|FOXO6
P36915 GNL1 GO:0006974 Guanine(nucleotidePbinding(proteinPlike(1GNL1|GNL1_HUMAN|HSR1
P16104 H2AFX GO:0006974;(GO:0000077;(GO:0000724;(GO:0006302Histone(H2AX H2AFX|H2AX|H2AX_HUMAN
H3BNH8 H3BNH8 GO:0006974 Uncharacterized(protein H3BNH8_HUMAN
O95714 HERC2 GO:0006974 E3(ubiquitinPprotein(ligase(HERC2 HERC2|HERC2_HUMAN
Q9BQA5 HINFP GO:0000077 Histone(H4(transcription(factor HINFP|HINFP_HUMAN|MIZF|ZNF743
O60921 HUS1 GO:0006974;(GO:0000724;(GO:0000077Checkpoint(protein(HUS1 HUS1|HUS1_HUMAN
Q8NHY5 HUS1B GO:0000077 Checkpoint(protein(HUS1B HUS1B|HUS1B_HUMAN
Q9Y6K9 IKBKG GO:0006974 NFPkappaPB(essential(modulator FIP3|IKBKG|NEMO|NEMO_HUMAN
Q9NRY2 INIP GO:0006974 SOSS(complex(subunit(C C9orf80|HSPC043|HSPC291|INIP|SOSSC_HUMAN|SSBIP1
Q9ULG1 INO80 GO:0000724;(GO:0006302 DNA(helicase(INO80 INO80|INO80A|INO80_HUMAN|INOC1|KIAA1259
Q68E01 INTS3 GO:0006974 Integrator(complex(subunit(3 C1orf193|C1orf60|INT3_HUMAN|INTS3
Q9NVH2 INTS7 GO:0000077 Integrator(complex(subunit(7 C1orf73|INT7_HUMAN|INTS7
Q14653 IRF3 GO:0006974 Interferon(regulatory(factor(3 IRF3|IRF3_HUMAN
Q92985 IRF7 GO:0006974 Interferon(regulatory(factor(7 IRF7|IRF7_HUMAN
Q92993 KAT5 GO:0006302 Histone(acetyltransferase(KAT5 HTATIP|KAT5|KAT5_HUMAN|TIP60
Q15004 KIAA0101 GO:0006974 PCNAPassociated(factor KIAA0101|L5|NS5ATP9|PAF|PAF15_HUMAN
O60870 KIN GO:0006974 DNA/RNAPbinding(protein(KIN17 BTCD|KIN|KIN17|KIN17_HUMAN
P18858 LIG1 GO:0000724;(GO:0006302 DNA(ligase(1 DNLI1_HUMAN|LIG1
P49917 LIG4 GO:0006302 DNA(ligase(4 DNLI4_HUMAN|LIG4
P07948 LYN GO:0006974 TyrosinePprotein(kinase(Lyn JTK8|LYN|LYN_HUMAN
Q9BQ69 MACROD1 GO:0006974 OPacetylPADPPribose(deacetylase(MACROD1LRP16|MACD1_HUMAN|MACROD1
A1Z1Q3 MACROD2 GO:0006974 OPacetylPADPPribose(deacetylase(MACROD2C20orf133|MACD2_HUMAN|MACROD2
Q9UI95 MAD2L2 GO:0006302 Mitotic(spindle(assembly(checkpoint(protein(MAD2BMAD2B|MAD2L2|MD2L2_HUMAN|REV7
Q96JY0 MAEL GO:0006974 Protein(maelstrom(homolog MAEL|MAEL_HUMAN
P28482 MAPK1 GO:0006974 MitogenPactivated(protein(kinase(1 ERK2|MAPK1|MK01_HUMAN|PRKM1|PRKM2
E7EX54 MAPK14 GO:0000077 MitogenPactivated(protein(kinase(14 E7EX54_HUMAN|MAPK14
B3KR49 MAPK3 GO:0006974 cDNA(FLJ33690(fis,(clone(BRAWH2002967,(highly(similar(to(MitogenPactivated(protein(kinase(3((EC(2.7.11.24)B3KR49_HUMAN|hCG_1983753|MAPK3
P49137 MAPKAPK2 GO:0006974 MAP(kinasePactivated(protein(kinase(2 MAPK2_HUMAN|MAPKAPK2
Q96GX5 MASTL GO:0006974 Serine/threoninePprotein(kinase(greatwallGW|GWL|GWL_HUMAN|MASTL|THC2
P33993 MCM7 GO:0006974 DNA(replication(licensing(factor(MCM7 CDC47|MCM2|MCM7|MCM7_HUMAN
Q9UJA3 MCM8 GO:0006974;(GO:0000724 DNA(helicase(MCM8 C20orf154|MCM8|MCM8_HUMAN
Q9NXL9 MCM9 GO:0006974;(GO:0000724 DNA(helicase(MCM9 C6orf61|MCM9|MCM9_HUMAN|MCMDC1
Q9ULC4 MCTS1 GO:0006974 Malignant(TPcellPamplified(sequence(1 MCT1|MCTS1|MCTS1_HUMAN
Q14676 MDC1 GO:0000724;(GO:0006302 Mediator(of(DNA(damage(checkpoint(protein(1KIAA0 70|MDC1|MDC1_HUMAN|NFBD1
O00255 MEN1 GO:0006974 Menin MEN1|MEN1_HUMAN|SCG2
Q29983 MICA GO:0006974 MHC(class(I(polypeptidePrelated(sequence(AMICA|MICA_HUMAN|PERB11.1
Q9NYL2 MLTK GO:0000077 MitogenPactivated(protein(kinase(kinase(kinase(MLTHCCS4| K|MLTK_HUMAN|ZAK
Q96T76 MMS19 GO:0006974 MMS19(nucleotide(excision(repair(protein(homologMMS19|MMS19L|MMS19_HUMAN
Q6ZRQ5 MMS22L GO:0000724 Protein(MMS22Plike C6orf167|MMS22L|MMS22_HUMAN
P41218 MNDA GO:0006974 Myeloid(cell(nuclear(differentiation(antigenMNDA|MNDA_HUMAN
Q9UBU8 MORF4L1 GO:0000724 Mortality(factor(4Plike(protein(1 FWP006|HSPC008|HSPC061|MO4L1_HUMAN|MORF4L1|MRG15|PP368
P49959 MRE11A GO:0006974;(GO:0000724;(GO:0006302DoublePstrand(break(repair(protein(MRE11AHNGS1|MRE11|MRE11A|MRE11_HUMAN
P43246 MSH2 GO:0006302 DNA(mismatch(repair(protein(Msh2 MSH2|MSH2_HUMAN
P01106 MYC GO:0006974 Myc(protoPoncogene(protein BHLHE39|MYC|MYC_HUMAN
Q96AH0 NABP1 GO:0006974;(GO:0000724 SOSS(complex(subunit(B2 NABP1|OBFC2A|SOSB2_HUMAN|SSB2
Q9BQ15 NABP2 GO:0006974;(GO:0000724 SOSS(complex(subunit(B1 LP3587|NABP2|OBFC2B|SOSB1_HUMAN|SSB1
O60934 NBN GO:0000077;(GO:0000724;(GO:0006302Nibrin NBN|NBN_HUMAN|NBS|NBS1|P95
Q14686 NCOA6 GO:0006974 Nuclear(receptor(coactivator(6 AIB3|KIAA0181|NCOA6|NCOA6_HUMAN|RAP250|TRBP
Q96PY6 NEK1 GO:0006974 Serine/threoninePprotein(kinase(Nek1 KIAA1901|NEK1|NEK1_HUMAN
Q13469 NFATC2 GO:0006974 Nuclear(factor(of(activated(TPcells,(cytoplasmic(2NFAC2_HUMAN|NFAT1|NFATC2|NFATP
C9JWV4 NHEJ1 GO:0006302 NonPhomologous(endPjoining(factor(1 C9JWV4_HUMAN|NHEJ1
Q6KC79 NIPBL GO:0006974 NippedPBPlike(protein IDN3|NIPBL|NIPBL_HUMAN
Q8IXT1 NOXIN GO:0006974 Nitric(oxidePinducible(gene(protein C11orf82|NOXIN|NOXIN_HUMAN
E5RFJ1 NSMCE2 GO:0000724 E3(SUMOPprotein(ligase(NSE2 E5RFJ1_HUMAN|NSMCE2
O60285 NUAK1 GO:0006974 NUAK(family(SNF1Plike(kinase(1 ARK5|KIAA0537|NUAK1|NUAK1_HUMAN|OMPHK1
Q96FW1 OTUB1 GO:0006974 Ubiquitin(thioesterase(OTUB1 HSPC263|OTB1|OTU1|OTUB1|OTUB1_HUMAN
Q86YC2 PALB2 GO:0000724 Partner(and(localizer(of(BRCA2 FANCN|PALB2|PALB2_HUMAN
Q5XG87 PAPD7 GO:0006302 DNA(polymerase(sigma PAPD7|PAPD7_HUMAN|POLS|TRF4
Q86W56 PARG GO:0006974 Poly(ADPPribose)(glycohydrolase PARG|PARG_HUMAN
P09874 PARP1 GO:0006302 Poly([ADPPribose](polymerase(1 ADPRT|PARP1|PARP1_HUMAN|PPOL
Q9UKK3 PARP4 GO:0006974 Poly([ADPPribose](polymerase(4 ADPRTL1|KIAA0177|PARP4|PARP4_HUMAN|PARPL
Q8IXQ6 PARP9 GO:0006302 Poly([ADPPribose](polymerase(9 BAL|BAL1|PARP9|PARP9_HUMAN
O43189 PHF1 GO:0006974 PHD(finger(protein(1 PCL1|PHF1|PHF1_HUMAN
H0YE55 PIDD GO:0006974 p53Pinduced(protein(with(a(death(domainH0YE55_HUMAN|PIDD
Q9H4B4 PLK3 GO:0006974 Serine/threoninePprotein(kinase(PLK3 CNK|FNK|PLK3|PLK3_HUMAN|PRK
Q13794 PMAIP1 GO:0006974 PhorbolP12PmyristateP13PacetatePinduced(protein(1APR_HUMAN|NOXA|PMAIP1
P06746 POLB GO:0006974 DNA(polymerase(beta DPOLB_HUMAN|POLB
O75807 PPP1R15A GO:0006974 Protein(phosphatase(1(regulatory(subunit(15AGADD34|PPP1R15A|PR15A_HUMAN
F5GX40 PRKDC GO:0006302 DNAPdependent(protein(kinase(catalytic(subunitF5GX40_HUMAN|PRKDC
E7ES96 PSEN1 GO:0006974 PresenilinP1 E7ES96_HUMAN|PSEN1
O00487 PSMD14 GO:0000724 26S(proteasome(nonPATPase(regulatory(subunit(14POH1|PSDE_HUMAN|PSMD14
Q14997 PSME4 GO:0006974 Proteasome(activator(complex(subunit(4KIAA0077|PSME4|PSME4_HUMAN
Q06124 PTPN11 GO:0000077 TyrosinePprotein(phosphatase(nonPreceptor(type(11PTN11_HUMAN|PTP2C|PTPN11|SHPTP2
O60671 RAD1 GO:0006974;(GO:0000077 Cell(cycle(checkpoint(protein(RAD1 RAD1|RAD1_HUMAN|REC1
D6RHU1 RAD17 GO:0006974;(GO:0000077 Cell(cycle(checkpoint(protein(RAD17 D6RHU1_HUMAN|RAD17
C9J0Q4 RAD18 GO:0006974 E3(ubiquitinPprotein(ligase(RAD18 C9J0Q4_HUMAN|RAD18
O60216 RAD21 GO:0006302 DoublePstrandPbreak(repair(protein(rad21(homologHR21|KIAA0078|NXP1|RAD21|RAD21_HUMAN
Q9H4I0 RAD21L1 GO:0006302 DoublePstrandPbreak(repair(protein(rad21Plike(protein(1RAD21L|RAD2 L1|RD21L_HUMAN
K7ENJ0 RAD23A GO:0006974 UV(excision(repair(protein(RAD23(homolog(AK7ENJ0_HUMAN|RAD23A
Q5W0S5 RAD23B GO:0006974 UV(excision(repair(protein(RAD23(homolog(BQ5W0S5_HUMAN|RAD23B
Q92878 RAD50 GO:0006974;(GO:0000724;(GO:0006302DNA(repair(protein(RAD50 RAD50|RAD50_HUMAN
Q06609 RAD51 GO:0006974;(GO:0000724;(GO:0006302DNA(repair(protein(RAD51(homolog(1 RAD51|RAD51A|RAD51_HUMAN|RECA
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Q96B01 RAD51AP1 GO:0000724 RAD51Passociated(protein(1 PIR51|R51A1_HUMAN|RAD51AP1
F5GX95 RAD52 GO:0000724;(GO:0006302 DNA(repair(protein(RAD52(homolog F5GX95_HUMAN|RAD52
Q9Y620 RAD54B GO:0000724 DNA(repair(and(recombination(protein(RAD54BRA54B_HUMAN|RAD54B
Q92698 RAD54L GO:0000724 DNA(repair(and(recombination(protein(RAD54PlikeRAD54A|RAD54L|RAD54_HUMAN
Q99638 RAD9A GO:0006974;(GO:0000077 Cell(cycle(checkpoint(control(protein(RAD9ARAD9A|RAD9A_HUMAN
B4DX60 RAD9B GO:0000077 Cell(cycle(checkpoint(control(protein(RAD9BB4DX60_HUMAN|hCG_41292|RAD9B
Q9NS23 RASSF1 GO:0006974 Ras(association(domainPcontaining(protein(1RASF1_HUMAN|RASSF1|RDA32
Q15291 RBBP5 GO:0006974 RetinoblastomaPbinding(protein(5 RBBP5|RBBP5_HUMAN|RBQ3
Q99708 RBBP8 GO:0000724 DNA(endonuclease(RBBP8 COM1_HUMAN|CTIP|RBBP8
Q9BSD3 RHNO1 GO:0000077 RAD9,(HUS1,(RAD1Pinteracting(nuclear(orphan(protein(1C12orf32|HKMT1188|RHINO|RHNO1|RHNO1_HUMAN
Q5UIP0 RIF1 GO:0006974 TelomerePassociated(protein(RIF1 RIF1|RIF1_HUMAN
Q8IYW5 RNF168 GO:0006974;(GO:0006302 E3(ubiquitinPprotein(ligase(RNF168 RN168_HUMAN|RNF168
Q8NCN4 RNF169 GO:0006974 E3(ubiquitinPprotein(ligase(RNF169 KIAA1991|RN169_HUMAN|RNF169
F8WEW6 RNF8 GO:0006974;(GO:0006302 E3(ubiquitinPprotein(ligase(RNF8 F8WEW6_HUMAN|RNF8
I3L2M5 RPA1 GO:0000724;(GO:0006302 Replication(protein(A(70(kDa(DNAPbinding(subunitI3L2M5_HUMAN|RPA1
P15927 RPA2 GO:0000724;(GO:0006302 Replication(protein(A(32(kDa(subunit REPA2|RFA2_HUMAN|RPA2|RPA32|RPA34
P35244 RPA3 GO:0000724;(GO:0006302 Replication(protein(A(14(kDa(subunit REPA3|RFA3_HUMAN|RPA14|RPA3
Q13156 RPA4 GO:0000077 Replication(protein(A(30(kDa(subunit RFA4_HUMAN|RPA4
Q71UM5 RPS27L GO:0006974 40S(ribosomal(protein(S27Plike RPS27L|RS27L_HUMAN
P23396 RPS3 GO:0006974 40S(ribosomal(protein(S3 OK/SWPcl.26|RPS3|RS3_HUMAN
Q9Y6P5 SESN1 GO:0006974 SestrinP1 PA26|SESN1|SESN1_HUMAN|SEST1
Q7Z333 SETX GO:0006302 Probable(helicase(senataxin ALS4|KIAA0625|SCAR1|SETX|SETX_HUMAN
Q86XK3 SFR1 GO:0000724 Swi5Pdependent(recombination(DNA(repair(protein(1(homologC10o f78|MEI5|MEIR5|SFR1|SFR1_HUMAN
E9PJN2 SGK1 GO:0006974 Serine/threoninePprotein(kinase(Sgk1 E9PJN2_HUMAN|SGK1
P60896 SHFM1 GO:0000724 26S(proteasome(complex(subunit(DSS1 DSS1|DSS1_HUMAN|SHFDG1|SHFM1
Q96EB6 SIRT1 GO:0006974 NADPdependent(protein(deacetylase(sirtuinP1SIR1_HUMAN|SIR2L1|SIRT1
Q9Y6E7 SIRT4 GO:0006974 NADPdependent(protein(deacetylase(sirtuinP4SIR2L4|SIR4_HUMAN|SIRT4
Q9BQ83 SLX1A GO:0000724 StructurePspecific(endonuclease(subunit(SLX1GIYD1|GIYD2|SLX1|SLX1A|SLX1B|SLX1_HUMAN
Q8IY92 SLX4 GO:0000724 StructurePspecific(endonuclease(subunit(SLX4BTBD12|KIAA1784|KIAA1987|SLX4|SLX4_HUMAN
O60264 SMARCA5 GO:0006302 SWI/SNFPrelated(matrixPassociated(actinPdependent(regulator(of(chromatin(subfamily(A(member(5SMARCA5|SMCA5_HUMAN|SNF2H|WCRF135
Q8IY18 SMC5 GO:0000724 Structural(maintenance(of(chromosomes(protein(5KIAA0594|SMC5|SMC5L1|SMC5_HUMAN
C9JMN1 SMC6 GO:0000724 Structural(maintenance(of(chromosomes(protein(6C9JMN1_HUMAN|SMC6
P00441 SOD1 GO:0006302 Superoxide(dismutase([CuPZn] SOD1|SODC_HUMAN
Q8TC71 SPATA18 GO:0006974 MitochondriaPeating(protein MIEAP|MIEAP_HUMAN|SPATA18
Q5MJ70 SPDYA GO:0006974 Speedy(protein(A SPDY1|SPDYA|SPDYA_HUMAN|SPY1
Q14159 SPIDR GO:0006974;(GO:0000724 DNA(repairPscaffolding(protein KIAA0146|SPIDR|SPIDR_HUMAN
Q9H040 SPRTN GO:0006974 SprTPlike(domainPcontaining(protein(SpartanC1orf124|DVC1|SPRTN|SPRTN_HUMAN|UNQ1880/PRO4323
Q15831 STK11 GO:0006974 Serine/threoninePprotein(kinase(STK11 LKB1|PJS|STK11|STK11_HUMAN
Q1ZZU3 SWI5 GO:0000724 DNA(repair(protein(SWI5(homolog C9orf119|SAE3|SWI5|SWI5_HUMAN
Q6NVH7 SWSAP1 GO:0000724 ATPase(SWSAP1 C19orf39|SWAP1_HUMAN|SWSAP1
P21675 TAF1 GO:0006974 Transcription(initiation(factor(TFIID(subunit(1BA2R|CCG1|CCGS|TAF1|TAF1_HUMAN|TAF2A
Q16594 TAF9 GO:0006974 Transcription(initiation(factor(TFIID(subunit(9TAF2G|TAF9|TAF9_HUMAN|TAFII31
Q7L7X3 TAOK1 GO:0006974 Serine/threoninePprotein(kinase(TAO1 KIAA1361|MAP3K16|MARKK|TAOK1|TAOK1_HUMAN
Q9UL54 TAOK2 GO:0006974 Serine/threoninePprotein(kinase(TAO2 KIAA0881|MAP3K17|PSK|PSK1|TAOK2|TAOK2_HUMAN|UNQ2971/PRO7431
Q9H2K8 TAOK3 GO:0006974 Serine/threoninePprotein(kinase(TAO3 DPK|JIK|KDS|MAP3K18|TAOK3|TAOK3_HUMAN
Q9NUW8 TDP1 GO:0006302 TyrosylPDNA(phosphodiesterase(1 TDP1|TYDP1_HUMAN
O95551 TDP2 GO:0006302 TyrosylPDNA(phosphodiesterase(2 ADP022|EAP2|TDP2|TTRAP|TYDP2_HUMAN
Q5H9I0 TFDP3 GO:0006974 Transcription(factor(Dp(family(member(3DP4|HCA661|TFDP3|TFDP3_HUMAN
Q9UNS1 TIMELESS GO:0006974 Protein(timeless(homolog TIM|TIM1|TIMELESS|TIMELESS1|TIM_HUMAN
H3BQ83 TIPIN GO:0006974;(GO:0000077 TIMELESSPinteracting(protein H3BQ83_HUMAN|TIPIN
O75663 TIPRL GO:0000077 TIP41Plike(protein TIPRL|TIPRL_HUMAN
Q9UKI8 TLK1 GO:0006974 Serine/threoninePprotein(kinase(tousledPlike(1KIAA0137|TLK1|TLK1_HUMAN
Q86UE8 TLK2 GO:0006974 Serine/threoninePprotein(kinase(tousledPlike(2TLK2|TLK2_HUMAN
Q96HA7 TONSL GO:0000724 TonsokuPlike(protein IKBR|NFKBIL2|TONSL|TONSL_HUMAN
P11388 TOP2A GO:0006974 DNA(topoisomerase(2Palpha TOP2|TOP2A|TOP2A_HUMAN
Q92547 TOPBP1 GO:0006974 DNA(topoisomerase(2Pbinding(protein(1KIAA0259|TOPB1_HUMAN|TOPBP1
Q9NS56 TOPORS GO:0006974 E3(ubiquitinPprotein(ligase(Topors LUN|TOPORS|TOPRS_HUMAN|TP53BPL
P04637 TP53 GO:0006974;(GO:0006302 Cellular(tumor(antigen(p53 P53|P53_HUMAN|TP53
Q12888 TP53BP1 GO:0006974;(GO:0000724;(GO:0006302Tumor(suppressor(p53Pbinding(protein(1TP53BP1|TP53B_HUMAN
Q9Y2A0 TP53TG1 GO:0006974 TP53Ptarget(gene(1(protein P53TG1|T53G1_HUMAN|TP53AP1|TP53TG1
O15350 TP73 GO:0006974 Tumor(protein(p73 P73|P73_HUMAN|TP73
Q14669 TRIP12 GO:0006974 E3(ubiquitinPprotein(ligase(TRIP12 KIAA0045|TRIP12|TRIPC_HUMAN|ULF
Q15645 TRIP13 GO:0006302 Pachytene(checkpoint(protein(2(homologPCH2|PCH2_HUMAN|TRIP13
P63146 UBE2B GO:0006974 UbiquitinPconjugating(enzyme(E2(B RAD6B|UBE2B|UBE2B_HUMAN
P61088 UBE2N GO:0000724 UbiquitinPconjugating(enzyme(E2(N BLU|UBE2N|UBE2N_HUMAN
Q9NPD8 UBE2T GO:0006974 UbiquitinPconjugating(enzyme(E2(T HSPC150|PIG50|UBE2T|UBE2T_HUMAN
O95071 UBR5 GO:0006974 E3(ubiquitinPprotein(ligase(UBR5 EDD|EDD1|HYD|KIAA0896|UBR5|UBR5_HUMAN
Q96RL1 UIMC1 GO:0006302 BRCA1PA(complex(subunit(RAP80 RAP80|RXRIP110|UIMC1|UIMC1_HUMAN
Q9Y5T5 USP16 GO:0006974 Ubiquitin(carboxylPterminal(hydrolase(16MSTP039|UBP16_HUMAN|USP16
Q96RU2 USP28 GO:0006974;(GO:0000077 Ubiquitin(carboxylPterminal(hydrolase(28KIAA1515|UBP28_HUMAN|USP28
Q96K76 USP47 GO:0006974 Ubiquitin(carboxylPterminal(hydrolase(47UBP47_HUMAN|USP47
Q9UKW4 VAV3 GO:0006974 Guanine(nucleotide(exchange(factor(VAV3AV3|VAV3_HUMAN
P55072 VCP GO:0006974;(GO:0006302 Transitional(endoplasmic(reticulum(ATPaseTERA_HUMAN|VCP
Q9BTA9 WAC GO:0006974 WW(domainPcontaining(adapter(protein(with(coiledPcoilKIAA1844|WAC|WAC_HUMAN
Q14191 WRN GO:0006974;(GO:0006302 Werner(syndrome(ATPPdependent(helicaseRECQ3|RECQL2|WRN|WRN_HUMAN
P98170 XIAP GO:0006974 E3(ubiquitinPprotein(ligase(XIAP API3|BIRC4|IAP3|XIAP|XIAP_HUMAN
O43543 XRCC2 GO:0000724 DNA(repair(protein(XRCC2 XRCC2|XRCC2_HUMAN
O43542 XRCC3 GO:0006974 DNA(repair(protein(XRCC3 XRCC3|XRCC3_HUMAN
Q13426 XRCC4 GO:0006302 DNA(repair(protein(XRCC4 XRCC4|XRCC4_HUMAN
P13010 XRCC5 GO:0006302 XPray(repair(crossPcomplementing(protein(5G22P2|XRCC5|XRCC5_HUMAN
P12956 XRCC6 GO:0006302 XPray(repair(crossPcomplementing(protein(6G22P1|XRCC6|XRCC6_HUMAN
P46937 YAP1 GO:0006974 Yorkie(homolog YAP1|YAP1_HUMAN|YAP65
P25490 YY1 GO:0006974;(GO:0000724 Transcriptional(repressor(protein(YY1 INO80S|TYY1_HUMAN|YY1
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Q9NUA8 ZBTB40 GO:0006974 Zinc(finger(and(BTB(domainPcontaining(protein(40KIAA0478|ZBT40_HUMAN|ZBTB40
Q68DK2 ZFYVE26 GO:0000724 Zinc(finger(FYVE(domainPcontaining(protein(26KIAA0321|ZFY26_HUMAN|ZFYVE26
Q9HA38 ZMAT3 GO:0006974 Zinc(finger(matrinPtype(protein(3 PAG608|WIG1|ZMAT3|ZMAT3_HUMAN
Q96PM9 ZNF385A GO:0006974 Zinc(finger(protein(385A HZF|RZF|Z385A_HUMAN|ZNF385|ZNF385A
Q5FWF4 ZRANB3 GO:0006974 DNA(annealing(helicase(and(endonuclease(ZRANB3ZRAB3_HUMAN|ZRANB3
Q19AV6 ZSWIM7 GO:0000724 Zinc(finger(SWIM(domainPcontaining(protein(7SWS1|ZSWIM7|ZSWM7_HUMAN
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Supplementary Table S2: Primary antibodies 
Antibody target Species Catalog number (supplier) Application* 
53BP1 rabbit Ab21083 (Abcam) IF 
Actin (AC-15) mouse Clone #A-5441 (Sigma) IB 
ATM (2C1) mouse GTX70103 (GeneTex) IB 
pATM S1981  rabbit 2152-1 (Epitomics)  IB 
Cdh1  mouse MA5-11496 (Neomarkers) IB 
Cdh1  mouse sc-56312 (Santa Cruz) IB 
Cdh1 mouse Ab3242 (Abcam) IP/IB 
Claspin rabbit Gift from Dr. R. Freire IB 
CtIP (14-1) mouse gift from Richard Baer IB 
CtIP (612L) rabbit gift from Richard Baer IP 
CtIP (D-4) mouse sc-271339 (Santa Cruz) IB 
CtIP (T-16) goat sc-5970 (Santa Cruz) IB 
Chk1 (G4) mouse sc-8408 (Santa Cruz) IB 
pChk1 S345 rabbit 2341(Cell Signaling) IB 
Chk2 rabbit gift from Grant Stewart IB IB 
pChk2 T68 (C13C1) rabbit 2197P (Cell Signaling) IB 
Cyclin B1 (GNS1) mouse sc-245 (Santa Cruz) IB 
Cyclin B1 mouse  05-373 (Upstate) IB 
FK2 mouse PW8810 (Enzo life sciences) IB 
FLAG mouse F3165 (Sigma) IB 
GFP rabbit Ab290 (Abcam) IB 
GFP mouse sc-9996 (Santa Cruz) IB 
pHistone-H3 S10 rabbit #06570 (Upstate) FC  
HA mouse sc-7392 (Santa Cruz) IP and IB 
γH2AX  (JBW301) mouse 05-636 (Millipore) IF and FC 
γH2AX  (20E3) rabbit 9718 (Cell Signaling) IB and IF 
KAP1 mouse sc-81411 (Santa Cruz) IB 
pKAP1 pS824 rabbit A300-767A (Bethyl) IB 
MPM-2 mouse 05-368 (Millipore) FC 
Mre11 mouse GTX70212 (GeneTex) IB 
Mre11 rabbit NB100-142 (Novus) IB 
p53 (DO-1) mouse sc-126 (Santa Cruz) IB 
Plk1 rabbit #06-813 (Millipore) IB 
Rad51 (H-92) rabbit Sc-8349 (Santa Cruz) IB 
Rad51  rabbit Ab63801 (Abcam) IF 
RPA2 (Ab-3) mouse NA19L (Calbiochem) IF and IB 
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pRPA S4/S8 (BL647) rabbit A300-245A (Bethyl) IB 
TFIIH (S-19) rabbit sc-293 (Santa Cruz) IB 
*IB: Immunoblotting, IF: Immunofluorescence, IP: Immunoprecipitation, FC: flow cytometry 
Resultsxxixxxxxi 
 77 
 
Supplementary Table S3 
 
APC/C substrate analysis: 
APC/C target Gene symbol Reference 
P15-PAF KIAA0101 (Emanuele et al, 2011) 
CKAP2 CKAP2 (Seki & Fang, 2007) 
KIFC1 KIFC1/HSET (Zhao et al, 2008) 
Aurora A AURKA (Littlepage & Ruderman, 2002; Taguchi et al, 
2002) 
Cyclin B CCNB (Pfleger et al, 2001; Glotzer et al, 1991) 
Cenp-F CENPF (Gurden et al, 2010) 
Kif11/Eg5 KIF11 (Zhao et al, 2008) 
Plk1 PLK (Lindon & Pines, 2004) 
ECT2 ECT2 (Pfleger et al, 2001; Liot et al, 2011) 
Thymidine kinase TK1 (Ke et al, 2005) 
Anillin ANLN (Zhao & Fang, 2005) 
GTSE-1 GTSE-1 (Michael et al, 2008) 
UbcH10 UBCH10 (Rape & Kirschner, 2004) 
Bub1 BUB1 (Qi & Yu, 2007) 
Aurora B AURKB (Nguyen et al, 2005; Stewart & Fang, 2005) 
Kif2C/MCAK KIF2C (Zhao et al, 2008) 
NDC80/Hec1 NDC80 (Li et al, 2011) 
Thymidylate kinase DTYMK (Ke et al, 2005) 
 
Supplemental references: 
 
Emanuele MJ, Ciccia A, Elia AEH & Elledge SJ (2011) Proliferating cell nuclear 
antigen (PCNA)-associated KIAA0101/PAF15 protein is a cell cycle-regulated 
anaphase-promoting complex/cyclosome substrate. Proc. Natl. Acad. Sci. U.S.A. 
108: 9845–9850 
Glotzer M, Murray AW & Kirschner MW (1991) Cyclin is degraded by the ubiquitin 
pathway. Nature 349: 132–138 
Gurden MDJ, Holland AJ, van Zon W, Tighe A, Vergnolle MA, Andres DA, 
Spielmann HP, Malumbres M, Wolthuis RMF, Cleveland DW & Taylor SS 
(2010) Cdc20 is required for the post-anaphase, KEN-dependent degradation of 
centromere protein F. J. Cell. Sci. 123: 321–330 
Ke P-Y, Kuo Y-Y, Hu C-M & Chang Z-F (2005) Control of dTTP pool size by 
anaphase promoting complex/cyclosome is essential for the maintenance of 
genetic stability. Genes Dev. 19: 1920–1933 
Li L, Zhou Y, Wang G-F, Liao S-C, Ke Y-B, Wu W, Li X-H, Zhang R-L & Fu Y-C 
(2011) Anaphase-promoting complex/cyclosome controls HEC1 stability. Cell 
Prolif. 44: 1–9 
Lindon C & Pines J (2004) Ordered proteolysis in anaphase inactivates Plk1 to 
contribute to proper mitotic exit in human cells. J. Cell Biol. 164: 233–241 
Liot C, Seguin L, Siret A, Crouin C, Schmidt S & Bertoglio J (2011) APC(cdh1) 
mediates degradation of the oncogenic Rho-GEF Ect2 after mitosis. PLoS ONE 6: 
e23676 
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Littlepage LE & Ruderman JV (2002) Identification of a new APC/C recognition 
domain, the A box, which is required for the Cdh1-dependent destruction of the 
kinase Aurora-A during mitotic exit. Genes Dev. 16: 2274–2285 
Liu Z, Yuan F, Ren J, Cao J, Zhou Y, Yang Q & Xue Y (2012) GPS-ARM: 
computational analysis of the APC/C recognition motif by predicting D-boxes 
and KEN-boxes. PLoS ONE 7: e34370 
Michael S, Travé G, Ramu C, Chica C & Gibson TJ (2008) Discovery of candidate 
KEN-box motifs using cell cycle keyword enrichment combined with native 
disorder prediction and motif conservation. Bioinformatics 24: 453–457 
Nguyen HG, Chinnappan D, Urano T & Ravid K (2005) Mechanism of Aurora-B 
degradation and its dependency on intact KEN and A-boxes: identification of an 
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Qi W & Yu H (2007) KEN-box-dependent degradation of the Bub1 spindle 
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Stewart S & Fang G (2005) Destruction box-dependent degradation of aurora B is 
mediated by the anaphase-promoting complex/cyclosome and Cdh1. Cancer Res. 
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Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett. 
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Zhao W-M & Fang G (2005) Anillin is a substrate of anaphase-promoting 
complex/cyclosome (APC/C) that controls spatial contractility of myosin during 
late cytokinesis. J. Biol. Chem. 280: 33516–33524 
Zhao W-M, Coppinger JA, Seki A, Cheng X-L, Yates JR & Fang G (2008) RCS1, a 
substrate of APC/C, controls the metaphase to anaphase transition. Proc. Natl. 
Acad. Sci. U.S.A. 105: 13415–13420 
  
 
Discussion 
 79 
4 Discussion 
4.1 APC/CCdh1 targets CtIP for degradation after mitotic exit 
The precise regulation of DSB repair pathways is pivotal to ensure genome 
stability. DSB repair through HR is limited to S/G2 phases when the intact sister 
chromatid is available to provide sequence homology. This cell cycle-dependent 
regulation of HR occurs at many different levels and mainly applies to proteins 
involved in DNA-end resection, the first step of HR. Human CtIP is essential for the 
initiation of DNA-end resection, and its function in this process is controlled by 
various post-translational modifications including phosphorylation, ubiquitylation, and 
acetylation. Moreover, CtIP protein levels are low during G1 and increased during 
S/G2 phase while mRNA levels are rather constant [295]. Nevertheless, the 
mechanisms controlling CtIP protein fluctuations remained elusive so far.  
We initiated our study by recapitulating the observation that CtIP protein levels 
fluctuate during cell cycle progression. Therefore we synchronized cells using 
different approaches and followed CtIP levels over time, confirming that CtIP protein 
levels are high during S/G2/M phases, but rapidly decline following mitotic exit. 
Treatment with the proteasome inhibitor MG-132 counteracted the decrease of CtIP 
levels, indicative for a proteasome-dependent degradation of CtIP. It is known that 
the E3 ubiquitin ligase APC/C orchestrates the exit from mitosis by targeting 
substrates for degradation and that it remains active throughout G1. Thus, it 
represents a good candidate to explain CtIP down-regulation at this stage of the cell 
cycle. We confirmed this hypothesis by using the APC/C inhibitor proTAME, which 
stabilized CtIP in G1, as well as Plk1, a well-studied APC/C substrate [176, 309]. 
APC/C binds its substrates through the cell cycle-dependent and mutually exclusive 
association with two co-activators, Cdc20 and Cdh1 [124]. Cdc20 is associated with 
APC/C during early mitosis and principally regulates mitotic progression, whereas 
Cdh1 is active from late mitosis to the G1/S transition and shows a broad spectrum of 
substrates [310]. The timing of CtIP degradation suggests that Cdh1 is the 
responsible co-activator mediating CtIP recognition. In fact, proteins targeted by 
Cdc20 are promptly degraded during mitosis, whereas CtIP is detectable during 
mitosis and rather follows the degradation pattern of Cdh1 substrates [147, 166, 
171]. Accordingly, we showed that Cdh1 depletion results in CtIP stabilization and 
decreased CtIP polyubiquitylation. Moreover, after overexpressing tagged versions of 
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CtIP and Cdh1 in HEK293T cells, we used co-immunoprecipitation experiments to 
show that the two proteins interact in vivo. This interaction was confirmed by pull-
down experiments, in which a bacterially expressed GST-CtIP construct was used to 
pull-down endogenous Cdh1 from HeLa nuclear extracts.  
Cdh1 and Cdc20 recognize short destruction motifs, the so-called KEN and D-
boxes, in disordered regions of their substrate proteins. Analysis of the primary 
amino acid sequence of CtIP revealed the presence of two putative KEN boxes in the 
central region of the protein and five putative D-boxes: two in the N- and three in the 
C-terminus of the protein. The two KEN boxes are highly conserved throughout 
evolution, whereas all D-boxes are only partially conserved. To identify which motif is 
mediating CtIP-Cdh1 interaction, we substituted the respective lysine residue of both 
KEN boxes with alanine (CtIP-K179A and -K467A). In the case of other substrates, 
mutation of the first amino acid of a KEN box was demonstrated to completely 
abrogate the recognition by Cdh1 [311]. Using this approach, we showed that the 
KEN box at position 467-469 in CtIP is required for the interaction with Cdh1. 
Moreover, pull-down experiments using a GST-CtIP fragment only containing the two 
KEN boxes, excluded a major role for the various D-boxes in the interaction. 
Interestingly, the KEN box motif in CtIP perfectly matches the updated consensus 
sequence ([D/N]-K-E-N-x-x-P) that was based on the analysis of 46 previously 
validated KEN boxes [148]. Various studies reported that Cdh1 preferentially binds its 
substrates through the recognition of KEN boxes, but the efficient ubiquitylation of a 
substrate harboring both D- and KEN boxes seems to depend on the presence of 
both degrons [312, 313]. In fact, the Apc10 subunit of the APC/C complex plays a 
role in stabilizing the interaction between APC/CCdh1 and the target protein by binding 
to D-boxes present in the substrate [131, 144]. In our study, we did not further 
address an auxiliary role for the D-boxes in CtIP degradation, however they could 
potentially be involved in the processivity of CtIP polyubiquitylation by APC/CCdh1. 
Based on our interaction data, we generated stable cell lines inducibly expressing 
GFP-tagged wild-type (wt) or K467A mutant CtIP. Using an in vivo ubiquitylation 
assay, we observed that polyubiquitylation was severely reduced in the K467A 
mutant when compared to wild-type CtIP. Moreover, live-cell microscopy experiments 
performed in asynchronous cells confirmed that CtIP-wt was degraded following 
mitotic exit, whereas CtIP-K467A was more stable in G1.  
It has been reported that CtIP is post-translationally modified during cell cycle 
progression and after DNA damage. These modifications include phosphorylation, 
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ubiquitylation and acetylation [307, 314, 315]. Thus, one could speculate whether 
APC/CCdh1-dependent degradation of CtIP during G1 is required for the removal of 
modified CtIP. In this manner, cell cycle- and damage-dependent modified CtIP 
would be erased altogether and only the newly expressed and naïve CtIP would be 
present at the beginning of a new cell cycle. For example, we observed that in 
response to DNA damage, cells expressing the CtIP-K467A mutant were faster in 
initiating resection of DSBs compared to cells expressing CtIP-wt. Intriguingly, the 
K467A mutant could be differently modified than CtIP-wt and therefore have a 
functional advantage after damage detection. Nevertheless the uncontrolled activity 
of CtIP, resulting in unscheduled DNA-end resection, would force DSB repair towards 
HR increasing the chances of forming complex chromosomal rearrangements [296]. 
In the above-mentioned cell cycle synchronization experiments, we noticed that 
CtIP migrated much slower on SDS-PAGE in samples prepared from cells arrested in 
M phase by nocodazole than in samples from untreated cells. The mobility shift in 
CtIP was most likely not caused by prolonged mitosis enforced by the nocodazole 
treatment as we obtained a similar migration pattern of CtIP in mitotic extracts using 
different synchronization protocols. Interestingly, we observed that the shift was 
abrogated in lysates from nocodazole-arrested cells treated with λ-phosphatase, 
indicating that CtIP is hyperphosphorylated during mitosis. It was shown that DSBs 
induced in mitosis are not repaired and that key DDR factor such as 53BP1 and 
BRCA1 are not recruited to sites of DNA damage [316-318]. Moreover, it has been 
reported recently that this phenomenon is, at least partially, mediated by inhibitory 
phosphorylation of RNF8 and 53BP1 [319]. We therefore speculate that CtIP 
hyperphosphorylation during mitosis is an inhibitory mechanism protecting cells from 
unwanted DNA-end resection. In fact, DSBs detected during mitosis are only repaired 
during the next G1 phase and inheritance of resected DSBs would force the cell to 
use error-prone repair mechanisms, such as alt-NHEJ [320-322]. Alternatively, it is 
possible that CtIP hyperphosphorylation protects the protein from being bound by the 
APC/C during mitosis, and that degradation can only take place after post-mitotic 
dephosphorylation has occurred. Similarly, it has been shown that Cdc6 and Skp2, 
two APC/CCdh1 substrates, are protected from degradation by CDK2-dependent 
phosphorylation [323, 324].  
Finally, our study showed that inhibition of APC/C by using a small molecule 
inhibitor results in a stabilization of CtIP after mitotic exit and during G1. Even if the 
activity of CtIP is posed under CDK-dependent control, stabilization of CtIP could 
Discussion 
 82 
result in an increased frequency of aberrant resection of DSBs occurring in G1. 
Especially in the light of the recent discovery that Plk3 can (mis-)activate CtIP during 
G1 by mediating the phosphorylation of Ser-327 and Thr-847 to repair complex DSBs, 
although at the cost of chromosome translocations and large-scale genome deletions 
[299]. Therefore, it appears to be vital to keep CtIP levels low during G1. With a two-
layered control over CtIP activity, based on both reduced CtIP protein levels and 
required phosphorylation events, c-NHEJ would be the favored DSB repair pathway 
during G1. Nevertheless, a low amount of CtIP molecules could be needed to address 
complex DSBs formed during G1, whereas excessive CtIP levels could result in 
genomic instability. So far, we did not address the question whether cells expressing 
CtIP-K467A are more prone to resect DSBs during G1, although it would be 
extremely interesting to express the CtIP-K467A mutant under the control of the 
endogenous CtIP promoter. With this approach it would be possible to follow the 
behavior of the recombinant protein over several cell cycles and challenge cells in 
different phases of the cell cycle with genotoxic agents.  
 
4.2 APC/CCdh1 reduces CtIP levels after DNA damage in G2 
Besides its predominant role in degrading specific substrate proteins during mitotic 
exit and G1 phase, APC/CCdh1 was also implicated in the response to DNA damage 
occurring in G2 phase of the cell cycle [82, 191]. Damage-dependent activation of the 
APC/C results in a stabilization of the G2/M checkpoint and eventually in the 
establishment of a senescence state [195, 196]. Interestingly, we discovered that 
APC/CCdh1 also negatively regulates CtIP protein levels in response to DSBs prior to 
mitotic entry. Moreover, we observed that APC/C-mediated degradation of CtIP is 
dose-dependent, occurring most efficiently after high levels of DNA damage. This 
implies that especially under conditions provoking high amounts of DNA damage, 
such as those inflicted by high-dose irradiation, premature APC/CCdh1 activation may 
contribute to determine cell fate and genomic integrity. Remarkably, and in contrast 
to previous findings, we found that Claspin was readily degraded in an APC/C-
dependent manner in irradiated G2 cells [82]. Under normal conditions, Claspin is 
required for checkpoint-mediated cell cycle arrest in response to DNA damage. 
However, it has been proposed that DNA damage-induced senescence suppresses 
checkpoint signaling and, according to our data, APC/C-dependent degradation of 
Claspin could be an initiating molecular event for checkpoint inactivation in order to 
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promote senescence [325]. APC/C inhibition in irradiated G2 cell resulted in a 
stabilization of CtIP and a decrease in ATM-mediated Chk2 phosphorylation. This 
could be explained by the notion that progressive DNA-end resection is promoting 
the switch from the ATM/Chk2 to the ATR/Chk1 signaling cascade [17, 73]. The 
stabilization of CtIP resulted in an increase of RPA2 phosphorylation, which serves 
as an indirect readout for DNA-end resection. Nevertheless, we did not observe an 
increase in Chk1 phosphorylation, suggesting that the downstream signaling of both 
branches of the G2/M DNA damage checkpoint is impaired in those cells. 
Interestingly, the hyper-resection phenotype upon APC/C inhibition in irradiated G2 
cells was also observed in our cells expressing the CtIP-K467A mutant.  
We did not further investigate whether increased RPA phosphorylation, and, thus, 
increased formation of ssDNA, was due to either a higher number of DSBs 
undergoing normal resection or same number of DSBs undergoing more extensive 
resection. It has been proposed that during G2 phase, HR is responsible for the repair 
of 15-30% of IR-induced DSBs emerging during G2, whereas the majority of the 
DSBs is addressed by NHEJ [326-328]. On the one hand, it is possible to speculate 
that an over-active CtIP mutant could increase the number of resected DNA breaks, 
and this should result in an increased number of RPA foci observed in irradiated cells 
expressing the CtIP-K467A mutant. Alternatively, if after damage CtIP would not be 
degraded, the protein would have the potential of continuously start resecting new 
DSBs. We therefore hypothesize that, especially in presence of many DSBs, cells try 
to limit the number of DSBs repaired via the onerous HR pathway. To this end, the 
degradation of the factor responsible for the initiation of DNA-end resection would 
shift DSB repair in direction of NHEJ pathways. Furthermore, shortly resected DSBs 
are the required intermediate for the alt-NHEJ pathway. It would therefore be 
interesting to investigate whether CtIP-K467A-expressing cells favor the use of 
mutagenic alt-NHEJ, over the more faithful c-NHEJ repair pathway [236, 329]. On the 
other hand, a more extensive resection of the same number of DSBs would result in 
the same number of foci in CtIP-K467A- and CtIP-wt-expressing cells, but those in 
CtIP-K467A-expressing cells should be bigger or brighter. This question could be 
addressed using a ChIP-based approach in which, after a DSB has been induced at 
a precise location, RPA-bound DNA could be immunoprecipitated using an RPA 
antibody and the extent of resection analyzed using primers annealing at different 
distances from the break site [330]. CtIP is mainly responsible for initiating DNA-end 
resection and not for the expansion of the resected tracts. Nevertheless, CtIP is 
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required to restrain Exo1 activity in vitro and mis-regulation of CtIP could result in 
uncontrolled Exo1-dependent resection in vivo [331]. 
In the live-cell microscopy experiments, we noted that IR-induced CtIP-K467A foci 
persisted much longer than CtIP-wt foci, indicating that APC/CCdh1 may be involved in 
the removal of CtIP from DSBs. A similar mechanism was proposed for the 
degradation of chromatin-bound PTEN during mitosis [332]. Interestingly, Apc3, a 
structural subunit of the APC/C complex, has been shown to interact with MDC1 in a 
damage-dependent manner [333], MDC1 directly binds to γH2AX and, thus, is one of 
the first proteins recruited to DSBs [21, 334]. Although the role of this interaction has 
never been elucidated, MDC1 may recruit APC/C to sites of DSBs to subsequently 
facilitate the clearance of CtIP and other DDR factors. Moreover, it was shown that 
the prolyl-isomerase PIN1 isomerizes CtIP after DNA damage, thereby promoting its 
proteasome-dependent degradation and limiting its activity [307]. CtIP isomerization 
could therefore be a mechanism to facilitate CtIP recognition by the APC/CCdh1 
complex or a different as yet undefined E3 ligase. However, we did not 
experimentally address this question. 
Remarkably, using a GFP reporter assay we observed that expression of the CtIP-
K467A mutant resulted in a similar decrease in HR as seen in the resection-deficient 
CtIP-T847A mutant. In line with this data, and previous results showing reduced 
numbers of IR-induced Rad51 foci upon Cdh1 depletion, Rad51 loading onto 
chromatin is impaired in CtIP-K467A-expressing cells. Taken together, these findings 
suggest that excessive resection of DSB generates stretches of ssDNA that are 
ineffective to produce recombinogenic Rad51-ssDNA filaments. Moreover, decreased 
HR and Rad51 loading on chromatin could also be due to the prolonged presence of 
CtIP on chromatin, which would sterically hinder Rad51 recruitment. Finally, other 
components of the HR repair pathway could be under control of the APC/C complex, 
or a related mechanism, and stabilization of CtIP alone does not lead to a functional 
outcome because the downstream factors are anyways degraded or not functional.  
To conclude our study, we tested the survival of CtIP-K467A-expressing cells after 
treatment with different genotoxic agents (such as doxorubicin and IR) and the PARP 
inhibitor olaparib. Even if these cells were less capable in repairing DSBs in different 
assays, they were only mildly sensitive towards olaparib treatment, which caused 
hypersensitivity in cells expressing the resection-deficient mutant CtIP-T847A. 
Moreover, CtIP-K467A-expressing cells were not sensitive to IR or doxorubicin, 
however low doses of these agents cause lesions that are mainly repaired in a CtIP-
Discussion 
 85 
independent manner [261]. Altogether, these results indicate that cells can partially 
tolerate an increase in DNA-end resection but most likely DSB repair would occur 
through mutagenic repair pathways. Cells will therefore survive the genotoxic 
treatment, but at the cost of acquiring mutations [296, 299]. Nevertheless, this 
hypothesis would need to be addressed experimentally. 
 
 
Conclusions and perspectives 
 86 
5 Conclusions and perspectives 
In my PhD thesis I have discovered a novel role for the APC/CCdh1 E3 ubiquitin 
ligase in regulating CtIP stability and, hence, controlling DSB repair. CtIP plays a 
pivotal role during DSB repair by initiating DNA-end resection and channeling the 
repair to HR. Based on our data, we hypothesize that APC/CCdh1-mediated 
degradation of CtIP, both during G1 and after DNA damage in G2, contributes in 
choosing the appropriate DSB repair pathway. In G1, due to the absence of the sister 
chromatids, cells prefer to fix DSBs by using the c-NHEJ repair pathway, therefore 
DNA-end resection events are limited by the low levels of CtIP. Differently, after 
detection of a lesion in G2, cells initiate repair of a subset of DSBs through the error-
free HR, but subsequently limit DNA-end resection by promoting CtIP degradation 
and hence addressing the remaining DSBs using the faster NHEJ pathway. In fact, 
excessive HR has been suggested to compromise genome stability [335, 336]. For 
example, in budding yeast, the inability of completing HR potentially leads to the 
accumulation of repair intermediates, which cause genomic instability and cell death 
[337]. Interestingly, work form several laboratories proposed that p53 plays direct role 
in suppressing HR [338]. One could therefore speculate that p53-dependent 
activation of APC/CCdh1 and the subsequent degradation of CtIP is part of this anti-
recombinogenic mechanism. Moreover, under DNA damage conditions, p53 
promotes the maturation of several miRNAs with growth-suppressive functions [339]. 
We have recently shown that after prolonged DNA damage induction this mechanism 
results in a miR-19a/b-dependent decrease in CtIP protein and mRNA levels [293]. 
In response to excessive genotoxic stress during S/G2, cells quickly have to 
decide whether it is favorable to either transiently arrest the cell cycle and repair the 
lesions or to irreversibly withdraw from the cell cycle. It has been shown, that the 
p53- and p21-dependent import of cyclin B1 in the nucleus and its subsequent 
degradation in an APC/C-dependent manner commit the cells to establish a 
senescence state [195, 196]. In fact, in order to retain the ability to re-enter the cell 
cycle after the activation of the G2/M checkpoint, cells need to maintain high levels of 
cell cycle regulators, such as cyclin B1. Interestingly, U2OS cells are impaired in their 
capability of importing cyclin B1 to the nucleus, therefore they maintain recovery 
competence much longer than non-transformed cells [197, 340]. Since in U2OS cells, 
similarly to other transformed cells [341], cyclin B1 is excluded from the nucleus, it is 
possible to speculate that these cells could specifically exploit the fast and Cdc14B-
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dependent activation of the APC/C complex, without the risk of degrading this 
important cell cycle regulator. Therefore, some cancer cells could use this 
mechanism to increase their resistance towards genotoxic treatments, by rapidly 
dampening HR to favor the use of more efficient DNA repair pathways. To test 
whether this hypothesis holds true, the short- and long-term responses of 
transformed and untransformed cells should be compared. Moreover a better 
understanding of the DNA damage-dependent targets of the APC/C complex is 
needed. To this end, exploiting an APC/C inhibitor such as proTAME in different 
SILAC studies could be extremely informative. Finally, a characterization of the 
factors that limit APC/C activity to a defined subset of substrates after DNA damage, 
will help to understand this regulatory mechanism. 
 
In conclusion, the APC/C is a multisubunit ubiquitin ligase that plays a central role 
in ensuring the timely progression of the cell cycle. The co-activators Cdh1 and 
Cdc20 bind to APC/C at different stages of the cell cycle, thereby directing APC/C 
activity towards defined substrates. Cdc20 expression is positively correlated with 
human cancers, whereas a possible tumor suppressor role for Cdh1 is suggested for 
some cancers [342]. The APC/CCdc20 complex is essential for the completion of 
mitosis: efficient depletion of Cdc20 in cultured cells results in apoptosis, whereas 
knock-out of Cdc20 causes mouse embryonic lethality at the two-cell stage [167-
169]. For these reasons, the APC/C complex has been proposed to be a good 
therapeutic target for killing cancer cells by prolonged and irreversible mitotic arrest 
[168, 343]. To date, two APC/C inhibitors have been developed: proTAME and apcin 
[309, 344]. On one hand, proTAME inhibits APC/C activity by preventing Cdc20 and 
Cdh1 binding to the APC/C core [309]. On the other hand, apicin binds in close 
proximity to the WD-40 domain of Cdc20 and inhibits the ability of the co-activator to 
interact with substrates [344]. Since both inhibitors irreversibly block mitotic exit, by 
interfering with APC/C function in different ways, the synergistic use of the two drugs 
achieved the best inhibition of APC/C activity [344]. Residual activity of the APC/C 
complex would enable cells to escape the mitotic arrest [309, 345], but could be 
insufficient to ensure the DDR-related functions of APC/C hence resulting in genome 
instability. Therefore, exploiting APC/C inhibitors to specifically kill cancer cells is an 
appealing strategy, but the emerging role of the APC/CCdh1 in maintaining genome 
stability has to be taken into consideration. 
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SUMMARY
The regulation of DNA double-strand break (DSB)
repair by phosphorylation-dependent signaling
pathways is crucial for the maintenance of genome
stability; however, remarkably little is known about
the molecular mechanisms by which phosphoryla-
tion controls DSB repair. Here, we show that PIN1,
a phosphorylation-specific prolyl isomerase, inter-
acts with key DSB repair factors and affects the rela-
tive contributions of homologous recombination (HR)
and nonhomologous end-joining (NHEJ) to DSB
repair. We find that PIN1-deficient cells display
reduced NHEJ due to increased DNA end resection,
whereas resection and HR are compromised in
PIN1-overexpressing cells. Moreover, we identify
CtIP as a substrate of PIN1 and show that DSBs
become hyperresected in cells expressing a CtIP
mutant refractory to PIN1 recognition. Mechanisti-
cally, we provide evidence that PIN1 impinges on
CtIP stability by promoting its ubiquitylation and sub-
sequent proteasomal degradation. Collectively,
these data uncover PIN1-mediated isomerization as
a regulatory mechanism coordinating DSB repair.
INTRODUCTION
In response toDNAdouble-strand breaks (DSBs), cells initiate an
elaborate signaling cascade known as the DNA damage
response (DDR) to maintain genomic integrity (Jackson and Bar-
tek, 2009). The DDR coordinates cell-cycle checkpoints and
DNA repair or—if the damage cannot be repaired—triggers
specialized programs such as apoptosis and senescence (Ciccia
and Elledge, 2010). DSBs are the most cytotoxic lesions that are
induced by ionizing radiation (IR) and DNA topoisomerase II poi-
sons, such as etoposide (ETOP) and doxorubicin (Jackson and
Bartek, 2009). They also frequently arise during S phase when
replication forks encounter persistent single-strand breaks that
are caused by camptothecin (CPT), a DNA topoisomerase I poi-
son, or poly(ADP-ribose) polymerase (PARP) inhibitors (Pom-
mier, 2006; Rouleau et al., 2010). Although DSBs are suitable
substrates for both homologous recombination (HR) and nonho-
mologous end-joining (NHEJ), DSBs resulting from replication
fork collapse are preferentially repaired by HR, whereas those
induced by IR and ETOP are mostly addressed by NHEJ (Helle-
day, 2010; Shibata et al., 2011). It has been shown that NHEJ
largely contributes to genomic instability and cytotoxicity in
HR-defective cells treated with CPT or PARP inhibitors (Adachi
et al., 2004; Eid et al., 2010; Patel et al., 2011). In contrast, HR
is able to compensate to some degree for the repair of IR-in-
duced DSBs in NHEJ mutant cells during late S/G2 phase
(Beucher et al., 2009; Shibata et al., 2011).
HR is a rather slow,multistep repair process restricted to S/G2
phase when the intact sister chromatid is available to allow error-
free repair (Heyer et al., 2010). Briefly, HR requires 50 to 30 nucle-
olytic degradation of DSB ends to generate long stretches of sin-
gle-stranded DNA (ssDNA) - a mechanism generally described
as DNA end resection. In vertebrates, DNA end resection is initi-
ated by the collaborative action of the MRE11-RAD50-NBS1
(MRN) complex together with CtIP (Sartori et al., 2007). Subse-
quently, EXO1 and BLM are involved in long-range resection
exposing long 30 ssDNA tails that are immediately coated with
RPA (Gravel et al., 2008). Finally, BRCA2 promotes the exchange
of RPA with RAD51, allowing ssDNA-RAD51 nucleoprotein fila-
ments to carry out homology search and DNA strand invasion
(Heyer et al., 2010). In contrast, NHEJ occurs with faster kinetics
and functions throughout the cell cycle (Shibata et al., 2011).
Besides cell-cycle stage and DSB complexity, the division of la-
bor between the twoDSB repair pathways was shown to depend
on the chromatin state around the lesion (Goodarzi et al., 2010).
Mechanistically, however, DNA end resection is the key determi-
nant of DSB repair pathway choice, because it prevents repair
by NHEJ and commits cells to HR (Chapman et al., 2012).
Besides ATM-mediated phosphorylation of substrates at
S/T-Q motifs in response to DSBs, phosphorylation at S/T-P
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motifs is another major signaling mechanism in the regulation of
cell-cycle progression and various stress responses (Matsuoka
et al., 2007; Bennetzen et al., 2010). Enzymes responsible for
S/T-P phosphorylation belong to a large family of proline-
directed protein kinases, including cyclin-dependent kinases
(CDKs) and mitogen-activated protein kinases (MAPKs) (Uber-
sax and Ferrell, 2007). Strikingly, CDK activity is required for
DNA end resection and HR (Aylon et al., 2004; Ira et al., 2004;
Huertas et al., 2008). However, it is currently unclear how, mech-
anistically, phosphorylation affects DSB repair pathway choice.
Interestingly, a subset of proteins phosphorylated at S/T-P mo-
tifs exist in two different configurations, namely as cis and trans
isoforms. The intrinsically slow interconversion between these
two forms can be catalyzed by PIN1, which specifically binds
phosphorylated S/T-P motifs through its WW domain and cata-
lyzes cis/trans isomerization through its peptidylprolyl isomerase
(PPIase) domain (Yaffe et al., 1997). In this way, PIN1 acts as a
molecular switch to control the function of several proteins,
including cell-cycle regulators and transcription factors, but so
far has not been linked to DNA repair processes (Liou et al.,
2011).
Here, we report that PIN1 interacts with prominent DSB repair
factors including 53BP1, BRCA1-BARD1, and CtIP. Using
immortalized and cancer cell lines, we find that PIN1 overexpres-
sion attenuates HR, while PIN1 depletion reduces NHEJ as a
result of increased DNA end resection. We further demonstrate
that PIN1-mediated isomerization of CtIP requires CtIP phos-
phorylation at two conserved S/T-P motifs (S276 and T315)
and show that CDK2 activity is required for PIN1-CtIP interac-
tion. We report that cells expressing a phosphomutant form of
CtIP (CtIP-2A) deficient in PIN1 interaction exhibit hyperre-
section phenotypes similar to PIN1-deficient cells. Finally, we
provide evidence that PIN1 negatively regulates CtIP protein sta-
bility by promoting CtIP polyubiquitylation and subsequent pro-
teasomal degradation. Altogether, our findings uncover a key
role for the prolyl isomerase PIN1 in controlling CtIP-dependent
DNA end resection and, consequently, DSB repair.
RESULTS
PIN1 Isomerase Is Involved in the Regulation of DSB
Repair
The importance of S/T-P phosphorylation in the regulation of
DSB repair and the fact that PIN1 modulates the function of pro-
teins phosphorylated at S/T-P motifs through proline isomeriza-
tion prompted us to examine whether PIN1 interacts with DSB
repair proteins. To this end, we performed pull-down experi-
ments with recombinant GST-tagged PIN1, followed by mass
spectrometry (MS) analysis. Besides known PIN1 substrates
and many potentially novel PIN1 interaction partners, we identi-
fied several prominent DDR factors implicated in DSB repair,
including BRCA1, 53BP1, and CtIP (see Figure S1 and Table
S1 available online). Since all these factors were shown to be
involved in DSB repair pathway choice, we examined whether
PIN1 affects the repair of DSB by NHEJ or HR using cell lines
bearing EJ5-GFP or DR-GFP reporter cassettes, respectively
(Bennardo et al., 2008). Depletion of PIN1 decreased NHEJ fre-
quencies to levels similar to those achieved by depleting key
NHEJ factors such as XRCC4 and 53BP1 (Figure 1A) (Bunting
et al., 2010). Conversely, we observed a slight but statistically
significant increase in HR efficiency upon PIN1 depletion in
both HEK293 and U2OS DR-GFP cells, while CtIP depletion
resulted in a strong reduction in HR, as expected (Figure 1B
and Figure S2A) (Sartori et al., 2007; Bennardo et al., 2008).
Based on these observations, we speculated that high levels of
PIN1 could interfere with HR. Indeed, transient overexpression
of PIN1 caused a significant decrease in the HR reporter signal,
without affecting the cell-cycle distribution (Figure 1C and Fig-
ure S2B). Importantly, the negative effect of PIN1 on HR was
dependent on both substrate recognition and isomerization, as
overexpression of a phospho-binding mutant (W34A) or a cata-
lytic mutant (C113A) diminished HR to a lesser extent (1.4- and
2.0-fold, respectively) compared to wild-type (WT) (3.1-fold)
(Figure 1C).
Next, we examined whether DSB signaling is altered in U2OS
cells depleted for PIN1 by analyzing the phosphorylation status
of prominent DDR factors after ETOP treatment. Interestingly,
knockdown of PIN1 caused a marked increase in RPA2 hyper-
phosphorylation, indicative of increased ssDNA formation, but
did not alter cell-cycle distribution profiles (Figure 1D, Figures
S2C and S2D) (Sartori et al., 2007; Kousholt et al., 2012). More-
over, in agreement with increased rates of DNA end resection,
we found that PIN1-depleted cells were more resistant to CPT
than control-depleted cells, a phenotype which is reminiscent
of NHEJ-deficient cells (Figure S2E) (Adachi et al., 2004; Eid
et al., 2010; Shibata et al., 2011).
To further investigate whether loss of PIN1 indeed compro-
mises NHEJ, we used pulsed-field gel electrophoresis (PFGE)
to monitor the efficiency of Pin1 knockout mouse embryonic
fibroblasts (MEFs) in repairing ETOP-induced DSBs. Pin1!/!
MEFs displayed both increased RPA2 phosphorylation and
slower repair kinetics compared to PIN1-complemented cells,
indicative of a defect in NHEJ caused by increased DNA resec-
tion (Figure 1E and Figure S2F). Consistent with impaired DNA
end resection, we detected a clear reduction in IR-induced
phosphorylation of RPA2 at S4/S8 after transient overexpres-
sion of PIN1-wt compared to mock-transfected cells or to cells
overexpressing PIN1-W34A (Figure 1F and Figure S2G). Since
we have identified the DNA end resection factor CtIP in our
screen for PIN1 interactors (Figure S1), we addressed whether
CtIP could be responsible for the observed hyperresection
phenotype of PIN1-deficient cells. To this end, we depleted
PIN1, CtIP, or both factors together from U2OS cells and moni-
tored RPA foci formation in response to ETOP treatment as
readout for DSB resection (Figure 1G and Figure S2H). As
expected, approximately 25% of control-depleted cells
exhibited RPA foci, and their formation was strictly CtIP depen-
dent (Helleday, 2010; Shibata et al., 2011). Furthermore, and
consistent with increased RPA2 phosphorylation, depletion
of PIN1 led to an almost 2-fold increase in RPA-foci-positive
cells. Remarkably, this increase was entirely dependent on
CtIP, suggesting that PIN1 limits the resection activity of
CtIP. Similarly, codepletion of CtIP partially rescued the NHEJ
defect in PIN1-depleted HEK293 EJ5-GFP reporter cells,
further demonstrating that PIN1 promotes NHEJ by counteract-
ing CtIP-dependent DNA resection (Figure 1H). The fact that
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CtIP depletion did not fully restore NHEJ could be explained by
the possibility that, besides restricting the function of CtIP in
DNA end resection, PIN1 may facilitate NHEJ through alterna-
tive mechanisms. For instance, we have identified 53BP1 and
BRCA1 as putative PIN1 substrates (Figure S1), both playing
key roles in the regulation of DSB repair pathway choice (Bun-
ting et al., 2010).
PIN1 Interacts with CtIP Phosphorylated at Two S/T-P
Motifs
To confirm the result of our MS analysis, suggesting that PIN1
and CtIP form a complex, we subjected whole-cell extracts
from U2OS cells or from U2OS cells stably expressing GFP-
tagged CtIP to GST-PIN1 pull-down assays. We found that
both endogenous CtIP and GFP-CtIP interact with PIN1-wt but
not with the PIN1-W34A mutant, indicating that the interaction
is mediated by phosphorylation (Figure 2A). Consistently, treat-
ment of extracts with l-phosphatase prior to GST-PIN1 pull-
down completely abolished the interaction with CtIP (Figures
S3A and S3B). Next, we verified whether endogenous PIN1-
CtIP complexes exist in cells by performing proximity ligation as-
says (in situ PLA), an elegant method to detect protein-protein
interactions in situ (So¨derberg et al., 2006). As shown in Fig-
ure 2B, we detected robust PLA signals in most of the cells,
demonstrating interaction between PIN1 and CtIP. Moreover,
we repeatedly observed more PLA signals per nucleus in EdU-
positive cells than in EdU-negative cells, indicative of an
increased PIN1-CtIP interaction during S phase (Figure 2B and
Figure S3C).
Human CtIP contains in total 12 S/T-P motifs that could be
targeted by proline-directed kinases (Figure S3D). To identify
which of these motifs are recognized by PIN1, we tested the
binding of PIN1 to a panel of serine/threonine to alanine point
mutants of CtIP in a series of GST pull-down experiments
Figure 1. PIN1 Regulates DSB Repair
(A) HEK293 EJ5-GFP cells were transfected with the indicated siRNAs. Two days later, cells were transfected with the I-SceI expression plasmid and harvested
after 48 hr for flow cytometry and immunoblot analysis.
(B) HEK293 DR-GFP cells were transfected with the indicated siRNAs and further processed as in (A).
(C) HEK293 DR-GFP cells were cotransfected with the indicated HA-PIN1 variants together with the I-SceI plasmid and further processed as in (A).
(D) Control- or PIN1-depleted U2OS cells were treatedwith etoposide (ETOP, 20 mM) for 6 hr, andwhole-cell extracts were analyzed by immunoblotting. Asterisks
indicate hyperphosphorylated forms of CtIP and RPA2, respectively.
(E) Pin1!/! MEFs complemented with empty vector (EV, pLPC) or PIN1 were treated with ETOP (10 mM) for 2 hr and lysed at the indicated times after ETOP
removal. Whole-cell extracts were analyzed by immunoblotting, and the amount of broken DNA was assessed by PFGE followed by ethidium bromide (EtBr)
staining (see also Figure S2F for quantification of the PFGE signals).
(F) HEK293T cells were transfected with empty vector (EV, pcDNA3.1) or HA-PIN1-wt for 72 hr. Cells were irradiated (30 Gy) and whole-cell extracts were
prepared at indicated times and analyzed by immunoblotting. Asterisk indicates hyperphosphorylated form of RPA2.
(G) Forty-eight hours after transfection with the indicated siRNAs, U2OS cells grown on coverslips were treated with ETOP (5 mM) for 1 hr, fixed, and coim-
munostained for g-H2AX and RPA2 (see also Figure S2H). In each sample at least 50 cells were scored. Graph shows the percentage of cells exhibiting more than
10 RPA foci/nuclei. Immunoblot analysis of the same samples is shown below.
(H) Shown is NHEJ assay and immunoblot analysis after transfection with the indicated siRNAs as in (A). In (A), (B), (C), (G), and (H), data are represented as
mean ± SEM (nR 3). See also Figure S2.
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(Figures S3E–S3G). Our analysis revealed that PIN1-CtIP inter-
action is mainly mediated by T315 and is almost completely
abolished in cells expressing a CtIP-S276A/T315A double
mutant (CtIP-2A; Figure 2C). To corroborate these findings, we
performed anti-HA immunoprecipitation experiments in
HEK293T cells cotransfected with FLAG-CtIP and HA-PIN1
expression constructs. As expected, CtIP-wt did not interact
with PIN1-W34A but was efficiently coprecipitated with PIN1-
wt and PIN1-C113A (Figure S3H). Moreover, we were able to
confirm that mutating either S276 or T315 to nonphosphorylat-
able alanine reduced the binding to PIN1, while PIN1-CtIP inter-
action is almost completely abolished in the CtIP-2A mutant
(Figure 2D). In addition, far-western blot analysis indicated that
this interaction is direct and that CtIP-T315 is more crucial for
PIN1 binding than CtIP-S276 (Figure 2E and Figure S3I). Finally,
we addressed whether PIN1-CtIP interaction is influenced by
DNA damage and observed a slight increase in complex forma-
tion upon ETOP treatment, suggesting that CtIP phosphoryla-
tion at S276 and/or T315 may be induced upon DNA damage
(Figure 2F).
CtIP-T315 Phosphorylation Promotes PIN1-CtIP
Interaction
By examining the amino acid sequences surrounding S276 and
T315, we noticed that both residues are highly conserved in
mammals, suggesting that they are possibly targeted by pro-
line-directed kinases in vivo (Figure S4A). In order to address
whether T315 and S276 are indeed phosphorylated in vivo, we
raised individual phospho-specific antibodies. As a first line of
evidence, both phospho-antibodies recognized wt CtIP tran-
siently overexpressed in cells, but not the corresponding alanine
substitution mutants (Figure 3A). Second, we specifically
detected CtIP-T315 after immunoprecipitating endogenous
CtIP from HEK293T cells followed by immunoblotting with the
anti-pT315 antibody, whereas the signal completely disap-
peared upon pretreatment of the extracts with l-phosphatase
(Figure 3B).
We next investigated whether CtIP-T315 phosphorylation
increased after ETOP treatment but did not observe any signifi-
cant changes in pT315 levels, suggesting that the enhanced
binding of PIN1 to CtIP in presence of DNA damage (Figure 2F)
Figure 2. PIN1 Interacts with CtIP through Phosphorylated S/T-P Motifs
(A) GST-PIN1-wt or -W34A fusion proteins were immobilized on glutathione-Sepharose beads and incubated with whole-cell extracts from either U2OS cells
(lanes 1–3) or U2OS cells stably expressing GFP-CtIP (lanes 4–6). Inputs and precipitated bead fractions from the pull-downs were subjected to immunoblotting
with anti-CtIP antibodies.
(B) (Left) Detection of endogenous PIN1-CtIP complexes by in situ proximity ligation assay (PLA). U2OS cells were pulse labeled with 50-ethynyl-20-deoxyuridine
(EdU, 10 mM) for 15 min, fixed, and incubated with antibodies against PIN1 and CtIP prior to detection of protein-protein interactions using a fluorescently labeled
probe (PLA-613). Nuclei were visualized by DAPI staining, and EdU incorporation was detected according to the manufacturer’s instructions (see also Fig-
ure S3C). (Right) Quantification of the PLA signals/cell. For both conditions, PLA signals from at least 50 cells were enumerated. Scale bar, 5 mm.
(C) (Left) GST-PIN1 pull-down assay using extracts of HEK293T cells expressing indicated FLAG-tagged versions of CtIP. The band intensities were quantified
using ImageJ and represented as input/pull-down (I/P) ratios. (Right) Data are represented as mean values of densitometric quantification ± SEM (nR 5).
(D) HEK293T cells were cotransfected with HA-PIN1 and the indicated FLAG-CtIP plasmids. HA-PIN1 was immunoprecipitated from whole-cell extracts using
anti-HA antibody, and immunocomplexes were analyzed by western blotting.
(E) Anti-FLAG immunoprecipitates from empty vector- or FLAG-CtIP-transfected HEK293T cells were subjected to far-western blotting using purified GST-PIN1
as a probe, followed by immunodetection with anti-GST antibody. After stripping, the same membrane was reprobed using anti-FLAG antibody.
(F) HEK293T cells were cotransfected with GFP-CtIP (wt and 2A) and HA-PIN1 for 48 hr before treatment with ETOP (10 mM) for 2 hr. Whole-cell extracts were
analyzed by western blotting before (input) and after immunoprecipitation (IP) using anti-GFP antibody. See also Figure S3.
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is mediated more by CtIP-S276 phosphorylation (Figure S4B).
Finally, we were able to confirm the phosphorylation on T315
in vivo by MS analysis of CtIP immunoprecipitated from
HEK293T cells (Figure S4C). To further substantiate our previous
findings that pT315 is more crucial for PIN1 binding compared
to pS276 (Figures 2C and 2D), we used synthetic CtIP phospho-
peptides and examined their ability to compete for PIN1 binding
in GST-PIN1 pull-down experiments. Remarkably, we found that
increasing amounts of pT315 peptides completely abolished
PIN1-CtIP interaction, whereas pS276 peptides and the non-
phosphopeptides failed to do so, strongly suggesting that
CtIP-pT315 is the preferred PIN1 binding site (Figure 3C and
Figure S5A).
CtIP-S276 Phosphorylation Promotes CtIP
Isomerization by PIN1
To determine whether PIN1 catalyzes cis/trans isomerization of
the phosphorylated S/T-P motifs in CtIP, we applied nuclear
magnetic resonance (NMR) spectroscopy to monitor exchange
processes in the aforementioned CtIP phosphopeptides in the
presence of recombinant PIN1 proteins (Wang et al., 2010).
ROESY spectra of both phosphopeptides recorded in the
absence of PIN1 were devoid of any crosspeaks that are indica-
tive of an exchange process between the cis and trans species
(data not shown). Importantly, upon addition of PIN1, we
detected exchange crosspeaks in the spectrum of the CtIP-
pS276 peptide, which were absent in the presence of a catalyti-
cally inactive mutant of PIN1 (C113A) and in the nonphosphory-
lated peptide (Figure 3D and Figures S5B–S5E). However, we
could not detect any cis/trans isomerization signals in the CtIP-
pT315 peptide (Figure S5F). Based on previously published
data, we speculated that the presence of two consecutive proline
residues in this peptide (pT-P-P) may hinder PIN1 isomerization
(Lippens et al., 2007). Interestingly, we observed exchange
crosspeaks in the ROESY spectrum of a modified CtIP-pT315
peptide in which the second proline was replaced with leucine
(P317L; Figure S5G). In order to addresswhether PIN1 also isom-
erizes CtIP-pS276 in the setting of an intact CtIP protein, we per-
formed limited proteolysis experiments using FLAG-CtIP purified
from HEK293T cells (Stukenberg and Kirschner, 2001). In large
agreement with our NMR data, V8 protease cleavage pattern
of CtIP-S276A was clearly different compared to CtIP-wt and
CtIP-T315A, indicating that pS276-P277 rather than pT315-
P317 is isomerized in vivo (Figure 3E). Collectively, our findings
support a model in which CtIP-pT315 is the major PIN1 docking
site, whereas CtIP-pS276 serves as a PIN1 isomerization site.
CDK2 Activity Is Required for CtIP-T315
Phosphorylation
Next, we aimed at identifying the protein kinase(s) responsible
for CtIP phosphorylation at S276 and T315 and, thus, for CtIP
recognition by PIN1. Considering recent data showing that
CtIP is targeted by CDKs, we examined whether CDK activity
is required for CtIP-PIN1 interaction (Chapman et al., 2012).
Interestingly, we found that a short treatment of cells with Rosco-
vitine (a general CDK inhibitor), but not with RO-3306 (a selective
CDK1 inhibitor), strongly reduced the binding of PIN1 to CtIP
(Figure 4A and Figure S6A). Moreover, consistent with CtIP-
T315 being the major PIN1 interaction site, cells treated with
Roscovitine also displayed reduced phosphorylation of T315,
while phosphorylation of S276 was not affected by CDK inhibi-
tion (Figures 4B and 4C). To further substantiate the role of
CDKs in promoting CtIP-PIN1 interaction, we transiently
expressed dominant-negative (dn) forms of CDK1, CDK2, and
CDK4 in HEK293T cells and examined their effect on PIN1 bind-
ing to CtIP. As shown in Figure 4D, we observed the strongest
reduction in CtIP-PIN1 complex formation in the absence of
CDK2 activity, which did not affect cell-cycle distribution (Fig-
ure S6B). Furthermore, we found that overexpression of wt
CDK2 resulted in a considerable increase in CtIP-PIN1 interac-
tion (Figure S6C). Consistent with a role for CDK2 in the phos-
phorylation of T315, CtIP-pT315 levels steadily increased during
S phase, peaked at late S/G2 phase, and were lowest in G1
(Figure S6D). From this data, we conclude that CDK2, by phos-
phorylating CtIP at T315, is predominantly responsible for the
interaction between CtIP and PIN1.
CtIP-2A Phosphomutant Promotes Hyperresection of
DSBs
To investigate the potential functions of CtIP isomerization at the
cellular and molecular level, we generated stable U2OS cell
Figure 3. CtIP-T315 and CtIP-S276 Are Phosphorylated to Promote
PIN1 Binding and cis/trans Isomerization
(A) Extracts from HEK293T cells transfected for 48 hr with the indicated FLAG-
CtIP constructs were immunoblotted with either rabbit polyclonal antibodies
raised against CtIP phosphopeptides or with anti-FLAG antibody.
(B) Extracts from HEK293T cells were treated with l-PPase, immunoprecipi-
tated using anti-CtIP antibody, and immunoblotted with the indicated anti-
bodies.
(C) GST-PIN1 pull-down assays were performed using U2OS whole-cell
extracts (0.5 mg) supplemented with the indicated CtIP peptides (80 mg).
(D) Shown is selected region of the two-dimensional ROESY spectra of the
CtIP-pS276 peptide after incubation with purified, recombinant GST-PIN1.
(E) HEK293T cells were transfected with the indicated FLAG-CtIP constructs
for 72 hr. CtIP proteins were purified using M2 magnetic beads, eluted with
3xFLAG peptides, digested with V8 protease, and analyzed by western blot-
ting using anti-CtIP antibody. See also Figure S4 and Figure S5.
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clones that expressed siRNA-resistant GFP-tagged wt (GFP-
CtIP-wt) or mutant CtIP in which both S276 and T315 were
changed to nonphosphorylatable alanine (GFP-CtIP-2A) (Figures
5A and 5B). Importantly, the GFP-CtIP-2A mutant protein was
still able to interact with BRCA1 and MRE11 (Figure S7A) and
to localize to DSB-containing tracks generated by laser microir-
radiation (Figure 5C and Figure S7B). From this we concluded
that PIN1 is required neither for CtIP complex formation with
BRCA1 andMRN nor for CtIP recruitment to damaged chromatin
that occurs exclusively in S/G2 cells (Sartori et al., 2007; Chen
et al., 2008). Moreover, similar to PIN1 depletion, cells express-
ing CtIP-2A were slightly more CPT resistant than cells express-
ing CtIP-wt (Figure 5D and Figure S7C). However, the observed
increase in CPT resistance could be, at least in part, due to
higher expression levels of GFP-CtIP-2A compared to GFP-
CtIP-wt (Figure 5A and Figure S7C). Strikingly, like PIN1-
depleted cells, CtIP-2A mutant cells treated with ETOP
displayed both increased RPA2 hyperphosphorylation and
RPA foci formation, indicating higher rates of DSB resection (Fig-
ures 5E and 5F and Figure S7D). Since ETOP-induced DSBs are
usually repaired with fast kinetics by classical NHEJ, and DNA
end resection is known to counteract NHEJ, we speculated
that NHEJ is compromised in CtIP-2A mutant cells (Shibata
et al., 2011). To this end, we monitored the amount of broken
DNA after ETOP treatment in both cell lines in the presence
and absence of a DNA-PKcs inhibitor. Indeed, in both NHEJ-pro-
ficient and -deficient backgrounds, we found that CtIP-2A cells
exhibited more DSBs than did CtIP-wt cells (Figure 5G and Fig-
ure S7E). This suggested that the DSB repair defect in CtIP-2A
mutant cells is caused by hyperresection, thereby channeling
repair into HR, which operates at slower kinetics compared to
NHEJ. To further substantiate these findings, we measured the
frequencies of HR and NHEJ in HEK293 GFP-reporter cells after
transient transfection of CtIP-wt, CtIP-T847A, and CtIP-2A (Fig-
ures S7F–S7H). At first, overexpression of the CtIP-2A mutant
coincided with a decrease in NHEJ, reflecting the fact that end
resection precludes NHEJ usage. In contrast, however, CtIP-
2A-expressing cells were as efficient in HR as cells expressing
CtIP-wt, indicating that hyperresection may also negatively
affect HR by promoting mutagenic types of homology-directed
repair such as single-strand annealing (Bennardo et al., 2008).
In fact, it was recently reported that depletion of DNA2, which
promotes ‘‘long-range’’ resection, leads to increased HR using
the same reporter cells (Karanja et al., 2012). Accordingly, the
anticipated increase in HR due to hyperresection (e.g., in CtIP-
2A cells) could be potentially outweighed by the fact that long-
range resection hinders the restoration of a functional DR-GFP
reporter gene.
Finally, we addressed whether PIN1 restricts CtIP-dependent
DNA end resection particularly in late S/G2 phase when both HR
andNHEJ are operable butmost DSBs preferably undergoNHEJ
(Shibata et al., 2011; Karanam et al., 2012). To this end, we
exposed late S/G2 cells stably expressing either CtIP-wt or
CtIP-2A to IR and measured the extent of DSB resection by
monitoring the levels of hyperphosphorylated RPA2. Consistent
with our previous results, we noted a significant increase in phos-
phorylated RPA2 in CtIP-2Amutant cells, indicative of enhanced
resection (Figure 5H). Taken together, these results suggest that
CtIP isomerization serves as a key regulatory mechanism re-
stricting DSB resection in late S/G2 phase of the cell cycle.
PIN1 Controls CtIP Stability and Promotes Its
Ubiquitylation
Prolyl isomerization by PIN1 was shown to play a crucial role in
regulating the stability of many proteins (Liou et al., 2011). Inter-
estingly, in many of our PIN1 depletion experiments, we have
noticed increased CtIP protein levels (e.g., Figures 1B and 1D).
Moreover, we repeatedly observed a reduction in the amount
of CtIP after transient transfection of cells with PIN1-wt, but
not with PIN1 mutants, particularly in the presence of DSBs (Fig-
ures 1C and 1F and Figure 6A). Thus, we speculated that PIN1
might indeed promote CtIP degradation. To address this idea,
we treated cells expressing either CtIP-wt or CtIP-2A for 8 hr
with MG132. Interestingly, by blocking the ubiquitin-proteasome
pathway, we observed a more substantial increase in the levels
of CtIP-wt (4.7-fold) compared to those of CtIP-2A (1.7-fold),
indicating that PIN1 is at least partially responsible for CtIP
degradation under these conditions (Figure 6B). Next, we
exposed CtIP-wt- and CtIP-2A-expressing cells to ETOP and,
at different time points after the removal of the drug, analyzed
CtIP protein turnover by blocking de novo biosynthesis. Strik-
ingly, CtIP-wt levels rapidly dropped after the recovery from
ETOP, whereas CtIP-2A levels remained stable (Figure 6C and
Figure 4. CtIP-PIN1 Interaction and CtIP-T315 Phosphorylation
Require CDK2 Activity
(A) Extracts from U2OS cells treated for 2 hr with DMSO, R-Roscovitine
(25 mM), or RO-3306 (25 mM) were subjected to GST-PIN1 pull-down assays.
(B) HEK293T cells were treated for 2 hr with DMSO or ROSC, and extracts
were immunoblotted for CtIP before (input) and after immunoprecipitation (IP)
using the anti-CtIP-pT315 antibody.
(C) HEK293 cells expressing GFP-CtIP (wt and 2A) were treated for 3 hr
with either DMSO or ROSC (25 mM). After lysis, whole-cell extracts were
immunoblotted for GFP either directly (input) or after immunoprecipitation (IP)
with anti-pT315 or anti-pS276 antibodies.
(D) Extracts from HEK293T cells transfected with either pcDNA3.1 (!) or
plasmids expressing HA-tagged dominant-negative (dn) mutants of CDK1,
CDK2, and CDK4 for 48 hr were subjected to GST-PIN1 pull-down assays. The
ratios of input versus pull-down (I/P; in A and D) and input versus IP (I/IP; in B
and C) were quantified by densitometry using ImageJ. See also Figure S6.
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Figure S8), further supporting the role of PIN1 in negatively regu-
lating CtIP stability. Since polyubiquitylation is a requirement for
proteasome-mediated protein degradation, we next addressed
whether PIN1 may indeed facilitate CtIP ubiquitylation. To this
end, we transfected His-Ubiquitin into HEK293 cell lines induci-
bly expressing GFP-CtIP and analyzed the level of CtIP poly-
ubiquitylation after Ni-NTA pull-down (Figures 6D and 6E).
Strikingly, CtIP ubiquitylation was largely abolished when PIN1
was efficiently depleted (Figure 6F). Moreover, the CtIP-2A
mutant was less ubiquitylated compared to CtIP-wt (Figure 6G).
Collectively, these results suggest that CtIP isomerization by
PIN1 is a prerequisite for CtIP ubiquitylation and subsequent
proteasomal degradation.
DISCUSSION
The PIN1 isomerase regulates a number of cellular processes
but has so far not been connected to DNA repair (Liou et al.,
2011). Here we report that human PIN1 interacts with key DSB
repair factors and demonstrate that PIN1 is involved in the
regulation of DSB repair. Our results point to a model in which
PIN1 affects DSB repair by restricting DNA end resection
through phosphorylation-dependent CtIP isomerization, which
in turn controls CtIP stability (Figure 7). As a consequence of de-
regulated DNA end resection, we find that cells lacking PIN1
display reduced levels of NHEJ and potentially increased levels
of mutagenic forms of homology-directed repair (e.g., single-
strand annealing), while cells overexpressing PIN1 are compro-
mised in error-free HR and repair DSBs more frequently by
NHEJ. Since PIN1-mediated isomerization of p53 was shown
to potentiate its activity in response to genotoxic stress, and
based on the fact that p53 is a regulator of HR, our findings
that PIN1 controls DSB repair pathway choice may specifically
apply to cancer or immortalized cells that have lost p53 function
(Zacchi et al., 2002; Zheng et al., 2002; Bertrand et al., 2004;
Liou et al., 2011).
Figure 5. CtIP-2A Mutant Promotes Hyperresection of DSBs
(A) U2OS cells stably expressing siRNA-resistant GFP-tagged CtIP-wt and CtIP-2A or the empty vector (!) were transfected with CNTL or CtIP siRNA for 72 hr,
and whole-cell extracts were analyzed by western blotting.
(B) The same cells as in (A) were analyzed by flow cytometry.
(C) The same cells as in (A) were sensitized with BrdU followed by laser microirradiation. After 30min, cells were fixed, coimmunostained for g-H2AX and cyclin A,
and analyzed by fluorescence microscopy (see also Figure S7B).
(D) The same cells as in (A), including the resection-defective CtIP-T847Amutant, were transfected with CtIP siRNA for 72 hr and treated for 1 hr with either DMSO
or low doses of CPT (see also Figure S7C). Survival was determined by colony formation. Data are represented as mean ± SEM (n = 3).
(E) The same cells as in (A) were treated with ETOP (5 mM) for 1 hr, released into drug-free medium for the indicated times, and analyzed by immunoblotting.
(F) The same cells as in (A) were treated with ETOP (5 mM) for 1 hr andwere either immediately fixed or released into drug-freemedium for 2 hr before fixation. After
pre-extraction, cells were coimmunostained for RPA2 and g-H2AX and analyzed by fluorescencemicroscopy (see also Figure S7D). For each condition at least 50
cells were scored. Graph shows the percentage of cells exhibiting more than 10 RPA foci per nuclei. Data are represented as mean ± SEM (nR 2).
(G) The same cells as in (A) were treated with ETOP (10 mM) for 2 hr in the absence or presence of a DNA-PKcs inhibitor (NU7441, 10 mM). Cells were harvested
either directly or at 30 min after the release into drug-free medium. Whole-cell extracts were analyzed by immunoblotting, and genomic DNA was analyzed by
PFGE. DNA breakage in each lanewas quantified using ImageJ and normalized against intact DNA. Relative amount of broken DNA in cells expressingGFP-CtIP-
wt treated with ETOP was set to 100%.
(H) Same cells as in (A) were synchronized by a single thymidine block. Eight hours after the release from thymidine, cells enriched in S/G2were irradiated at 30Gy
and, 2 hr later lysates were analyzed by immunoblotting. In (E), (G), and (H), the asterisk indicates the hyperphosphorylated form of RPA2. See also Figure S7.
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Besides restricting CtIP activity in DNA end resection, it is very
tempting to speculate that PIN1 modulates DSB repair pathway
choice through regulating the fate of other phosphoproteins. For
example, based on our results and previously published data, it
is very likely that PIN1 controls the function of 53BP1 and/or
BRCA1: (1) we have identified both proteins in a proteomic
screen for PIN1 interactors, (2) we find that depleting CtIP
does not completely rescue the NHEJ defect in PIN1-deficient
cells, (3) BRCA1 was shown to displace 53BP1 from DSBs to
enable DNA resection by CtIP (Bunting et al., 2010), (4) PIN1
was very recently identified in a SILAC-based screen for
53BP1 interactors (Di Virgilio et al., 2013), and (5) both proteins
are known to be phosphorylated at multiple S/T-P motifs, mak-
ing them attractive targets for PIN1 (Jowsey et al., 2007; Johnson
et al., 2009).
Regarding the mechanism of CtIP regulation by PIN1, we
identify S276 and T315 as the two crucial S/T-P motifs medi-
ating PIN1-CtIP interaction. Phosphorylated T315 emerges as
the main docking site for PIN1, whereas pS276 is required
for cis/trans isomerization. Furthermore, we find CDK2 to be
the responsible kinase for the phosphorylation of T315. In
contrast, phosphorylation of S276 turns out to be independent
of CDK activity. In addition, we find that DNA damage stabilizes
PIN1-CtIP interaction, but without upregulating T315 phosphor-
ylation, suggesting that it is rather S276 phosphorylation that
is induced by genotoxic stress. Interestingly, the amino acid
sequence surrounding S276 matches the consensus motif
for p38MAPK, a stress kinase reported to be activated by
ATM and ATR in response to various DNA-damaging agents
including DNA topoisomerase inhibitors (Manke et al., 2005;
Reinhardt et al., 2007). Clearly, further investigations are needed
to establish both the role of DNA damage in PIN1-mediated
CtIP isomerization and the kinase responsible for S276
phosphorylation.
Figure 6. PIN1 Destabilizes CtIP by Promoting Its Ubiquitylation
(A) Two days after transfection with the indicated plasmids, HEK293 cells were treated with CPT (1 mM) for 2 hr and whole-cell extracts were analyzed by
immunoblotting. Asterisk indicates hyperphosphorylated form of CtIP.
(B) HEK293T cells were transfectedwith either FLAG-CtIP-wt or FLAG-CtIP-2A. Eight hours after transfection, cells were splitted into two newplates. Twenty-four
hours after plasmid transfection, cells were treated with MG132 (10 mM) for 8 hr and lysed for immunoblot analysis using the indicated antibodies. The signal
intensities of CtIP bands were quantified by densitometric analysis using the ImageJ software and normalized to those of Actin. The values represent the relative
increase in CtIP-wt and CtIP-2A levels upon MG132 treatment.
(C) Three days after transfection with CtIP siRNA, U2OS cells stably expressing siRNA-resistant GFP-CtIP (wt and 2A) were treated with DMSO or ETOP (10 mM).
After 1 hr, cells were released into fresh medium supplemented with 200 mg/ml cycloheximide (CHX) or not for the indicated times, and lysates were analyzed by
immunoblotting (see also Figure S8).
(D) HEK293/Flp-In/T-REx cells containing stably integrated GFP-CtIP constructs (wt and 2A) were cultivated in the absence or presence of doxycycline (Dox;
1 mg/ml) for 24 hr, and lysates were analyzed by immunoblotting.
(E) The same cells as in (D) were treated with Dox for 24 hr. After lysis, whole-cell extracts were analyzed by western blotting either directly (input) or after
immunoprecipitation (IP) with the indicated anti-CtIP phospho-specific antibodies.
(F) Forty-eight hours after transfection with the indicated siRNAs, HEK293/Flp-In/T-REx cells were transfected with His-Ub, and the expression of GFP-CtIP-wt
was simultaneously induced with Dox (except in lane 1). Eight hours after induction, cells were transfected with siRNA for a second time. Seventy-two hours after
the first siRNA transfection, cells were treated with MG132 (20 mM) for 6 hr, followed by lysis in buffer containing guanidium-HCl. Ubiquitin conjugates were
purified using Ni-NTA-agarose beads, eluted, and analyzed by western blotting using anti-GFP antibody.
(G) Thirty hours after transfection with His-Ub, Dox-induced HEK293/Flp-In/T-REx cells expressing either GFP-CtIP-wt or GFP-CtIP-2A were lysed in buffer
containing guanidium-HCl and processed as in (F).
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It also remains to be determined how,mechanistically, isomer-
ization by PIN1 primes CtIP for polyubiquitylation and subse-
quent degradation. Interestingly, a similar regulatory mechanism
involving CDK and PIN1 has recently been reported for hypoxia-
induced PML degradation by a Cullin-3 (CUL3) E3 ubiquitin
ligase. The authors of this study showed that phosphorylation
of PML by CDK1/2 and PIN1-mediated isomerization promotes
the recruitment of a CUL3-KLHL20 ubiquitin ligase to polyubiqui-
tylate PML and trigger its degradation (Yuan et al., 2011). Alterna-
tively, a SKP1-CUL1-F box protein (SCF)-type E3 ligase may be
involved in CtIP ubiquitylation, since most F box proteins bind to
a distinct sequence in their substrates, which typically needs to
be phosphorylated (‘‘phospho-degron’’) (Silverman et al., 2012).
Ultimately, our findings that overexpression of PIN1 sup-
presses HR may have important therapeutic implications. For
example, PIN1 overexpression, which is frequently found in can-
cers, may render those cells hypersensitive to PARP inhibition
based on the concept of synthetic lethality, analogous to the sit-
uation described for BRCA mutant cancers (Bao et al., 2004;
Rouleau et al., 2010; Bouwman and Jonkers, 2012). We antici-
pate that future studies investigating the role of PIN1 in the regu-
lation of other DNA repair factors will provide further important
clues to understand how PIN1 contributes to the maintenance
of genome stability.
EXPERIMENTAL PROCEDURES
Cell Culture, siRNAs, and Plasmids
U2OS, HEK293T, Pin1!/! MEFs, and HEK293T retroviral packaging cells
were grown in DMEM supplemented with 10% FCS, 100 U/ml penicillin, and
100 mg/ml streptomycin. The Flp-In T-REx HEK293 host cell line (Invitrogen)
was maintained in medium supplemented with 10 mg/ml blasticidin and
300 mg/ml zeocin. Maintenance of the DR-GFP and EJ5-GFP HEK293 cell lines
was done as described previously (Bennardo et al., 2008). U2OS clones stably
expressing siRNA-resistant formsGFP-CtIP were generated as described pre-
viously and were cultured in DMEM supplemented with 10% FCS, standard
antibiotics and 500 mg/ml G-418 (Sartori et al., 2007). Retroviral infection of
Pin1!/! MEFs was carried out as described previously (Zacchi et al., 2002).
IR was given using a Faxitron X-ray machine. Laser microirradiation was per-
formed as described previously (Eid et al., 2010). Data for survival curves were
generated by colony formation assays as described previously (Sartori et al.,
2007). Transfection of siRNA oligos was done using Lipofectamine RNAiMAX
(Invitrogen). All siRNA duplexes were purchased from Microsynth except the
ON-TARGETplus SMARTpool for PIN1 (PIN1-SP [L-003291-00-0005] [Mar-
cucci et al., 2011; Krishnan et al., 2012] Dharmacon), and the sequences
(50 to 30) were as follows: luciferase (CNTL; CGUACGCGGAAUACUUCGA)
(Sartori et al., 2007), CtIP (GCUAAAACAGGAACGAAUC) (Sartori et al.,
2007), XRCC4 (AUAUGUUGGUGAACUGAGA) (Sartori et al., 2007), 53BP1
(CAGGACAGTCTTTCCACGAAT) (Meerang et al., 2011), PIN1-30UTR (CCGU
CACACAGUAUUUAUU), and PIN1-2 (GCUACAUCCAGAAGAUCAA) (Phan
et al., 2007). All siRNA transfections were done with 40 nM final concentration
of oligos. Plasmids were transfected by using either the standard calcium
phosphate method or FuGene 6 (Roche) according to manufacturer’s instruc-
tions. The pGEX-4T3 plasmid for bacterial expression of recombinant GST-
tagged PIN1 was a gift from Christopher Nelson (University of Victoria,
Canada). The epitope-tagged expression vectors for human CtIP have been
described previously (Yu et al., 2006; Sartori et al., 2007). The HA-tagged
expression vectors for human PIN1 were described previously (Rustighi
et al., 2009). The HA-tagged expression vectors for HA-CDK1-dn,
HA-CDK4-dn, and HA-CDK2 (wt and dn) were purchased from Addgene
(van den Heuvel and Harlow, 1993). The pcDNA3.1-6xHis-Ubiquitin plasmid
was a gift from Matthias Peter (ETH Zurich, Switzerland). All PIN1 and CtIP
point mutants were introduced by site-directed mutagenesis using Expand
Long Template PCR System (Roche) and confirmed by sequencing.
Statistics
Statistical analyseswere carried out using unpaired, two-tailed t tests. p values
expressed as *p < 0.05, **p < 0.005, and ***p < 0.0005 were considered signif-
icant. ns indicates that the difference between the two groups is not
significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes eight figures, one table, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article at http://dx.doi.org/10.1016/j.molcel.2013.03.023.
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Figure 7. Hypothetical Model: How PIN1-Mediated CtIP Isomeriza-
tion Controls DNA End Resection
During S/G2, CtIP together with other nucleases promotes the resection of
DSBs. Following resection initiation, proline-directed kinases including CDK2
phosphorylate CtIP on T315 and S276, resulting in the binding of PIN1 to CtIP.
PIN1-mediated isomerization of CtIP leads to CtIP ubiquitylation through an
as-yet-unknown E3 ubiquitin ligase and subsequent CtIP degradation by the
proteasome. This mechanism ensures an appropriate usage of DSB end
resection. Consequently, cells with abrogated PIN1 function or inherently low
PIN1 levels display reduced NHEJ and aberrant (error-prone) forms of
homology-directed repair due to enhanced CtIP resection activity (hyper-
resection). In contrast, cells overexpressing PIN1 display reduced HR and
increased NHEJ due to decreased CtIP resection activity (hyporesection).
Therefore, we propose that PIN1 plays an important role in the regulation of
DSB repair, particularly in late S and G2 phases of the cell cycle.
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DNA double-strand breaks (DSBs) are repaired by two major pathways: homologous
recombination (HR) and non-homologous end-joining (NHEJ). The choice between HR
and NHEJ is highly regulated during the cell cycle. DNA-end resection, an evolutionarily
conserved process that generates long stretches of single-stranded DNA, plays a
critical role in pathway choice, as it commits cells to HR, while, at the same
time, suppressing NHEJ. As erroneous DSB repair is a major source of genomic
instability-driven tumorigenesis, DNA-end resection factors, and in particular their
regulation by post-translational modifications, have become the subject of extensive
research over the past few years. Recent work has implicated phosphorylation at S/T-P
motifs by cyclin-dependent kinases (CDKs) as a major regulatory mechanism of DSB
repair. Intriguingly, CDK activity was found to be critically important for the coordinated and
timely execution of DNA-end resection, and key players in this process were subsequently
identified as CDK substrates. In this mini review, we provide an overview of the current
understanding of how the DNA-end resection machinery in yeast and human cells is
controlled by CDK-mediated phosphorylation.
Keywords: DNA double-strand break repair, DNA-end resection, homologous recombination, cyclin-dependent
kinase, phosphorylation, CtIP/Sae2, PIN1
INTRODUCTION
In order to preserve genome integrity, cells employ a com-
plex surveillance network that detects, signals and repairs DNA
lesions. These intricate and highly regulated pathways are col-
lectively termed the DNA damage response (DDR; Zhou and
Elledge, 2000). One major hallmark of the DDR represents the
activation of checkpoints to temporarily delay cell cycle pro-
gression through inhibition of cyclin-dependent kinase (CDK)
activity. In the budding yeast Saccharomyces cerevisiae, a single
CDK, Cdc28 (or Cdk1), drives both G1/S and G2/M transitions,
whereas in metazoan four CDKs are responsible for cell cycle
progression (Morgan, 1997). CDK activity is modulated by asso-
ciation with regulatory subunits known as cyclins, the levels of
which oscillate during the cell cycle (King et al., 1996). G1 phase
is controlled by CDK4 and CDK6 in complex with D-type cyclins,
whereas CDK2-cyclin E is essential for G1/S transition and the
assembly of the DNA replication machinery. CDK2-cyclin A is
required for proper completion of DNA replication and progres-
sion through S phase. Toward the end of interphase, cyclin A
associates with CDK1 to facilitate S/G2 transition before CDK1-
cyclin B complexes drive cells through mitosis (Morgan, 1997;
Malumbres and Barbacid, 2005). CDKs belong to a large family of
proline-directed kinases (which also includes MAPKs and GSK3)
that exclusively phosphorylate serines or threonines immediately
preceding a proline (S/T-P motifs) (Hanks and Hunter, 1995;
Errico et al., 2010). CDK substrate specificity is increased by
direct binding of the cyclin subunit to conserved RxL motifs
present in certain CDK targets (Harper and Adams, 2001). A
recent study showed that 50% of CDK2-cyclin A targets car-
ried at least one RxL motif distal to the phosphorylation site
(Chi et al., 2008).
In accordance with reduced CDK activity as a consequence
of DNA damage-induced checkpoint activation, S/T-P motifs
are largely dephosphorylated in response to DNA double-strand
breaks (DSBs) (Bennetzen et al., 2010; Beli et al., 2012). However,
in apparent contrast to this, CDK activity is strictly required for
accurate processing and repair of DSBs in S/G2 phase, indicating
that at least some DDR factors are primed by CDK phosphoryla-
tion prior to checkpoint activation (Enserink and Kolodner, 2010;
Chapman et al., 2012). DSBs are highly deleterious lesions with
the potential to cause cell death or genomic instability leading to
cancer. DSBs can arise spontaneously as a result of replication
fork collapse or can be induced by exogenous DNA-damaging
agents including ionizing radiation and certain anti-cancer drugs
(Jackson and Bartek, 2009). In order to repair DSBs, all organ-
isms rely on two major pathways: non-homologous end-joining
(NHEJ) and homologous recombination (HR). NHEJ functions
throughout the cell cycle and religates broken ends without the
need of extensive processing (Lieber, 2010). HR, instead, requires
an undamaged template for faithful DSB repair, usually the sis-
ter chromatid, and is therefore restricted to S/G2 phase (Heyer
et al., 2010). HR is initiated by 5′-3′ degradation of the DSB
ends to generate 3′-single-stranded DNA (ssDNA) overhangs.
This evolutionarily conserved process, termed DNA-end resec-
tion, requires the coordinated action of several nucleases and
helicases (Figure 1; Mimitou and Symington, 2009; Blackwood
et al., 2013). Recent work in yeast and human cells has established
that DNA recombination and particularly DNA-end resection
are highly regulated by various kinases including Mec1/ATR,
Tel1/ATM, Rad53/CHK1, Cdc5/PLK1, and, as reviewed here,
CDKs (Longhese et al., 2010; Chapman et al., 2012; Finn et al.,
2012; Krejci et al., 2012).
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FIGURE 1 | CDKs target components of the DNA-end resection
machinery. Upon induction of a DNA double-strand break (DSB), the MRX/N
complex rapidly localizes to the damaged site. During S and G2 phases of the
cell cycle, DSB repair via homologous recombination (HR) is initiated by
DNA-end resection. At first, short-range resection is carried out by the
MRX/N complex and Sae2/CtIP; the two factors collaborate in the initial end
trimming creating short 3′-ssDNA overhangs, which are immediately coated
by replication protein A (RPA). Importantly, processed DSB ends are no
longer suitable substrates for Ku binding and, thus, for the repair by
non-homologous end-joining. Next, long-range resection is catalyzed either
by the 5′-3′ exonuclease Exo1 or the helicase Sgs1/BLM in conjunction with
the endonuclease Dna2. Subsequently, RPA is removed from ssDNA and
replaced by the Rad51 recombinase that is required for strand invasion of the
sister chromatid and further downstream steps in HR (not depicted in the
figure). The dashed box depicts the proposed inhibitory role of PIN1 during
DNA-end resection: PIN1 binds and subsequently isomerizes phosphorylated
CtIP, thereby promoting its degradation by the proteasome and, hence,
counteracting resection and HR. Note that both short- and long-range
resection factors are potentially regulated by CDK phosphorylation
(please refer to the main text for details).
CDK SUBSTRATES IN DNA-END RESECTION
In 2004, two studies in S. cerevisiae described for the first time
that Cdk1 is essential for DSB repair pathway choice by pro-
moting DNA-end resection in G2 phase (Aylon et al., 2004; Ira
et al., 2004). These findings were later confirmed in human cells,
showing that ssDNA-dependent activation of the ATR checkpoint
pathway in response to DSBs is restricted to S/G2 and requires
CDK activity (Jazayeri et al., 2006). Similarly, inhibition of CDK2
in mammalian cells was shown to impair HR and delay DSB sig-
naling (Deans et al., 2006). Based on these key findings, it was
proposed that DNA-end resection is governed by CDK-mediated
phosphorylation (Figure 1) (Ira et al., 2004). However, it was
only until the last few years that components of the resection
machinery were identified as CDK substrates.
MRX/MRN
Genetic studies in S. cerevisiae have long implicated the Mre11-
Rad50-Xrs2 (MRX) complex in the initial processing of DSBs
(Symington and Gautier, 2011). However, as MRX exhibits both
endonuclease and 3′-5′ exonuclease activities in vitro (Paull,
2010), it still remains unclear howMRX catalyzes 5′-3′ nucleolytic
degradation of DNA ends in vivo. New clues came from a recent
study suggesting that DNA-end resection could occur with bidi-
rectional polarity, as opposed to the unidirectional model shown
in Figure 1. Accordingly, Mre11 endonuclease first creates a nick
in the strand to be resected up to 300 nucleotides away from the
DSB that, in a second step, serves as an entry point for resection
byMre11 3′-5′ exonuclease toward the DSB end and by Exo1 5′-3′
exonuclease away from the DSB (Garcia et al., 2011).
None of the MRX subunits have so far been reported as Cdk1
substrates. Moreover, an mre11 mutant in which all six S/T-P
motifs have been mutagenized did not exhibit any major phe-
notypes attributable to a resection defect. The same holds true
for an xrs2 mutant in which both CDK consensus motifs (S/T-
P-x-K/R) were mutated (Ira et al., 2004). Notably, however, three
additional S/T-P motifs in Xrs2 were found to be phosphorylated
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in a proteomic study, raising the possibility of it being indeed a
Cdk1 substrate (Albuquerque et al., 2008). In human cells, akin
to the situation in yeast, only the NBS1 subunit of the MRN com-
plex was found to be phosphorylated in a cell-cycle-dependent
manner (Figure 1; Olsen et al., 2010). Additionally, two groups
reported that CDKs phosphorylate NBS1 at serine 432 in S phase
(Falck et al., 2012; Wohlbold et al., 2012). Surprisingly, while
Falck et al. concluded that NBS1-S432 phosphorylation promotes
DNA-end resection, Wohlbold et al. reported normal resection in
the absence of NBS1-S432 phosphorylation. Although it is rather
difficult to reconcile these contradicting results, they have most
likely emanated from the different NBS1-deficient cells used for
complementation studies. Thus, it remains to be clarifiedwhether
Xrs2/NBS1 phosphorylation by CDKs is a conserved mechanism
to promote DNA-end resection by MRX/N.
Sae2/CtIP
SAE2 (or COM1) was originally identified as being required
to complete meiotic recombination in S. cerevisiae (McKee and
Kleckner, 1997; Prinz et al., 1997). Subsequent genetic and bio-
chemical studies in yeast and mammalian cells have shown
that Sae2 and its human counterpart CtIP cooperates with the
MRX/N nuclease to initiate resection of DSBs (Figure 1; Sartori
et al., 2007; Symington and Gautier, 2011). There are three
potential CDK phosphorylation sites in Sae2 and 12 in CtIP.
Remarkably, phosphorylation of a single S/T-P motif in the C-
terminus of both proteins (Sae2-S267/CtIP-T847) by CDK is
required to promote resection (Huertas et al., 2008; Huertas
and Jackson, 2009). Consistent with a role of Cdk1 in posi-
tively regulating Sae2 function, mutation of a RxL cyclin-binding
motif present upstream of S267 caused comparable DNA damage
hypersensitivity to that of sae2-S267A cells (Huertas et al., 2008).
Moreover, in cells expressing a phospho-mimicking mutant
(Sae2-S267E/CtIP-T847E), resection is permitted even in absence
of Cdk1 activity; however, not to the same extent as in normal
cells. Therefore, it was proposed that additional Cdk1 sites, on
Sae2/CtIP itself or on other proteins, are required for optimal
resection (Huertas, 2010). Despite the fact that the precise mech-
anism of how S267/T847 phosphorylation “activates” Sae2/CtIP
is still unclear, it is of major importance for both meiotic and
mitotic recombination (Manfrini et al., 2010; Nicolette et al.,
2010).
Prior to the identification of CtIP-T847 as a CDK site, phos-
phorylation of S327 was shown to occur exclusively during S/G2
and to be a pre-requisite for CtIP-BRCA1 interaction (Yu and
Chen, 2004; Yu et al., 2006). Furthermore, it was recently shown
that CtIP-S327 phosphorylation is CDK2-dependent and facili-
tated by MRE11, which directly interacts with CDK2 and CtIP,
thereby bringing CDK2 in proximity with its substrate (Buis et al.,
2012). Although evidence for a direct role of CtIP-S327 phospho-
rylation in resection is still missing, the BRCA1-CtIP complex was
recently reported to facilitate the removal of the 53BP1 effector
protein RIF1 from DSBs in S/G2, thereby channeling DSB repair
into HR (Escribano-Díaz et al., 2013). Moreover, it was recently
reported that phosphorylation of a cluster of five additional
S/T-P motifs located in the central region of CtIP is impor-
tant for DNA-end resection (Wang et al., 2013). Mechanistically,
phosphorylation of this cluster is needed for the association of
CtIP with NBS1, which promotes DNA damage-induced CtIP
phosphorylation by ATM (You et al., 2009; Wang et al., 2013).
It is important to note, however, that Wang et al. did not directly
address whether any of these clustered phosphosites in CtIP are
indeed targeted by CDKs in vivo.
KU
When DSBs arise in the cell, Ku—a heterodimer composed
of Ku70 and Ku80—is usually loaded onto duplex DNA ends.
During the repair process, Ku serves as a docking site for many
NHEJ proteins, including DNA-PKcs andDNA ligase IV, to rejoin
the broken ends (Lieber, 2010). It has been shown that DNA-end
resection and HR are constrained during G1 due to both efficient
NHEJ and low CDK activity (Aylon et al., 2004; Jazayeri et al.,
2006). Interestingly, in the absence of Ku, Cdk1 activity is dis-
pensable for the initiation of resection by MRX-Sae2, but is still
needed for long-range resection by Exo1 or Sgs1-Dna2 (Clerici
et al., 2008). Therefore, Ku is thought to antagonize DNA-end
resection and has to be removed from the ends in order to per-
mit HR. These data also indicate that CDK activity promotes
resection by restraining the recruitment of Ku to DSBs, rais-
ing the question whether Ku itself is a potential CDK substrate
(Figure 1). However, removal of all putative Cdk1 phosphoryla-
tion sites on Ku70 and 3 out of 4 sites on Ku80 failed to elicit any
DSB repair phenotype in S. cerevisiae, suggesting that the nega-
tive regulation of Ku by Cdk1 is most likely indirect (Zhang et al.,
2009). Ku binding to DNA ends also attenuates resection and HR
in mammalian cells (Shao et al., 2012; Tomimatsu et al., 2012).
Furthermore, Ku70 was reported as a binding partner and sub-
strate of CDK2-cyclin A, and Ku70-T455 was identified as a CDK
target site by mass spectrometry (Müller-Tidow et al., 2004; Chi
et al., 2008; Olsen et al., 2010); but whether or not Ku phospho-
rylation by CDKs has an impact on DNA-end resection has yet to
be determined.
EXO1
Exonuclease 1 (Exo1) belongs to the RAD2/XPG family of
structure-specific 5′ nucleases and has been implicated in mul-
tiple genome maintenance pathways including DNA repair and
telomere maintenance (Tran et al., 2004). Exo1 is dispensable
for initial resection in yeast and human cells but acts in a sepa-
rate pathway from Sgs1-Dna2/BLM-DNA2 to promote extensive
5′-3′ DSB resection (Figure 1; Symington and Gautier, 2011).
Moreover, Exo1-dependent resection and its recruitment to DSBs
depends on both MRX/N and Sae2/CtIP and is blocked by the
presence of Ku (Eid et al., 2010; Sun et al., 2012; Tomimatsu
et al., 2012). Although DNA damage-induced phosphorylation of
Exo1 has been reported to attenuate its activity in both yeast and
human cells (Morin et al., 2008; Bolderson et al., 2010), proba-
bly by controlling its stability (El-Shemerly et al., 2005), there is
currently no published data available whether Exo1 is a CDK tar-
get. However, several S/T-P sites in human EXO1 were repeatedly
found to be phosphorylated using mass spectrometry analyses
(El-Shemerly et al., 2008; Chen et al., 2009; Shiromizu et al.,
2013). Indeed, some of these sites are phosphorylated by CDKs in
S/G2 phase, thereby stimulating DNA-end resection by EXO1 and
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promoting DSB repair by HR while at the same time suppressing
NHEJ (S. Burma, personal communication).
Sgs1-Dna2/BLM-DNA2
Sgs1 and its human ortholog BLM are members of the RecQ fam-
ily of 3′-5′ DNA helicases and are involved in the suppression
of crossovers by promoting the dissolution of Holliday junc-
tion intermediates (Bernstein et al., 2010). The role for Sgs1 in
conjunction with the Dna2 nuclease in the generation of long
stretches of ssDNA during HR was discovered because of its
redundancy with Exo1 (Figure 1; Gravel et al., 2008; Mimitou
and Symington, 2008; Zhu et al., 2008). Although there is cur-
rently no data available on CDK-mediated phosphorylation of
Sgs1, BLM is phosphorylated at various S/T-P motifs by mitotic
kinases including CDK1 (Beausoleil et al., 2004; Leng et al., 2006;
Dephoure et al., 2008; Olsen et al., 2010). However, these mod-
ifications are more likely to be involved in the regulation of
BLM’s function in the separation of sister chromatids during
mitosis rather than in DNA-end resection (Chan and Hickson,
2011). In contrast, Cdk1-mediated phosphorylation of S. cere-
visiae Dna2 at T4, S17, and S237 stimulates its recruitment to
DSBs and DNA-end resection (Chen et al., 2011). Consistent with
the redundancy observed between Dna2- and Exo1-dependent
resection pathways, dna2-T4A/S17A/S237A cells only resect DSBs
in the presence of functional Exo1. Interestingly, T4 and S17 lie
within a bipartite nuclear localization signal, suggesting a timely
regulated nuclear import of Dna2 upon phosphorylation during
G1/S transition (Kosugi et al., 2009). Remarkably, human DNA2
lacks the entire N-terminal region of yeast Dna2 including all
three S/T-P sites, suggesting that CDK-mediated regulation of
long-range resection in human cells differs from yeast.
RPA
Replication protein A (RPA) is an evolutionarily conserved,
heterotrimeric complex consisting of RPA1, RPA2, and RPA3.
Owing to its high ssDNA binding affinity, RPA is required for
most aspects of DNA metabolism including replication, repair
and recombination (Oakley and Patrick, 2010). Following resec-
tion, RPA wraps around the generated 3′-ssDNA overhangs to
protect the DNA against nuclease degradation and to prevent
hairpin formation that would impede Rad51 filament assembly
(Figure 1; Holloman, 2011). In vitro studies have also impli-
cated RPA in promoting long-range resection through stimula-
tion of both Exo1- and Sgs1-Dna2-dependent pathways (Cejka
et al., 2010; Niu et al., 2010; Nimonkar et al., 2011; Cannavo
et al., 2013). Furthermore, under DNA-damaging conditions,
RPA-coated ssDNA serves to recruit the Mec1/ATR kinase, a
critical event in checkpoint activation (Zou and Elledge, 2003).
RPA2 contains a flexible N-terminal domain that is differentially
phosphorylated at multiple residues during the cell cycle and
in response to genotoxic stress. Two residues within this region,
S23 and S29, are phosphorylated by CDK2-cyclin A and CDK1-
cyclin B at the G1/S boundary and during mitosis, respectively
(Figure 1); however, they are not conserved in yeast (Oakley and
Patrick, 2010). In response to DSBs, ATR-mediated phosphoryla-
tion of RPA2-S33 induces phosphorylation of RPA2-S23/S29, and
both act synergistically to stimulate phosphorylation of additional
residues closer to the N-terminus by DNA-PK (Anantha et al.,
2007; Liaw et al., 2011). Although DNA damage-induced RPA2
hyper-phosphorylation seems critical for Rad51 recruitment and
HR in response to replication stress, it is not essential for HR
as measured by an I-SceI-based reporter assay (Shi et al., 2010;
Serrano et al., 2013). Moreover, dephosphorylation of RPA2 by
the PP4 phosphatase complex has also been reported to facilitate
HR (Lee et al., 2010). However, a direct role of CDK-mediated
RPA phosphorylation in DNA-end resection has not yet been
demonstrated.
CHROMATIN BINDING AND REMODELLING FACTORS
DNA-end resection occurs in the context of chromatin, which
constitutes a natural barrier to all kind of DNA transac-
tions including DSB repair (Price and D’Andrea, 2013; Tsabar
and Haber, 2013). Last year, three groups described a role of
the S. cerevisiae chromatin-remodeling factor Fun30 (and its
human counterpart SMARCAD1) in the repair of DSBs by HR
(Chen et al., 2012; Costelloe et al., 2012; Eapen et al., 2012).
Fun30/SMARCAD1 physically associates with DSB ends and,
by weakening the histone-DNA interactions in nucleosomes,
establishes a DNA conformation that facilitates both Sgs1- and
Exo1-dependent resection. Furthermore, it was shown that Fun30
function in resection becomes less important in cells lacking the
histone-bound Rad9 checkpoint protein, suggesting that Fun30
helps to overcome the inhibitory effect of Rad9 on DNA-end
resection (Chen et al., 2012). Interestingly, both Fun30 and Rad9
were identified as Cdk1 substrates and reported to be phospho-
rylated at multiple S/T-P sites (Ubersax et al., 2003; Albuquerque
et al., 2008). Moreover, loss of Rad9 has been reported to par-
tially bypass the requirement for Cdk1 in resection (Lazzaro
et al., 2008). This inhibitory mechanism is likely to be evolu-
tionarily conserved as 53BP1, the mammalian ortholog of Rad9
(Wang et al., 2002), suppresses resection to promote NHEJ and
immunoglobulin class switching (Bunting et al., 2010; Bothmer
et al., 2011). Accordingly, multiple CDK consensus sites in
SMARCAD1 and 53BP1 were repeatedly found to be phosphory-
lated (Beausoleil et al., 2004; Linding et al., 2007; Bennetzen et al.,
2010; Olsen et al., 2010; Shiromizu et al., 2013). Further exper-
iments are required to establish whether some of the CDK sites
in Fun30/SMARCAD1 and Rad9/53BP1 play a role in the regu-
lation of DNA-end resection and, thus, in DSB repair pathway
choice.
CONCLUDING REMARKS
While the role of CDKs in regulating DNA-end resection is a
given fact, we are only beginning to understand the mechanis-
tic consequences of these phosphorylation events for individual
repair factors, e.g., on protein-protein interactions, intracellular
localization, or protein stability. Another important question to
address in the future is howDNA-end resection is limited in order
to generate confined tracts of ssDNA that are suitable for homol-
ogy search by the Rad51 recombinase leading to productive HR.
In other words, there must be additional regulatory mechanisms
providing a switch between activation and inhibition of DNA-end
resection to coordinate DSB repair pathways in a spatiotemporal
manner.
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Novel insights are provided by a recent study showing that
PIN1, a phosphorylation-specific peptidyl-prolyl cis/trans iso-
merase, counteracts DNA-end resection in human cells (Steger
et al., 2013). PIN1 was previously shown to isomerize phospho-
rylated S/T-P peptide bonds, thereby controlling the function of
a subset of CDK substrates involved in diverse cellular processes
(Liou et al., 2011). In a proteomic screen for PIN1 substrates,
Steger et al. identified several prominent DSB repair proteins
including BRCA1, 53BP1 and CtIP. Interestingly, PIN1-mediated
isomerization of CtIP requires the phosphorylation of CtIP at two
S/T-P sites: CtIP-pT315 (by CDK) serves as the major binding site
for PIN1, whereas CtIP-pS276 (by an unknown proline-directed
kinase) is isomerized by PIN1. Following isomerization, CtIP gets
ubiquitylated and subsequently degraded by the proteasome. In
this way, PIN1 is proposed to limit DNA-end resection, thereby
possibly contributing to fine-tune the coordination of HR and
NHEJ during S andG2 phases of the cell cycle (Figure 1; Karanam
et al., 2012). So far, no direct connection has been made between
PIN1 and the regulation of DSB repair in S. cerevisiae, studies of
which are hampered by the fact that yeast PIN1 (Ess1) is essential
for viability (Siepe and Jentsch, 2009). Future studies will have
to determine whether phosphorylation-dependent regulation by
PIN1 in concert with CDKs applies to other DSB repair proteins
apart from CtIP and, thus, represents a general feature of the
DDR.
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